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SUMMARY
A novel primitive stem cell from the Wharton's jelly of the human umbilical cord
(hWJSCs) has been derived and characterized. Although these hWJSCs share
the same developmental origins as adult human bone marrow mesenchymal
stem cells (BMMSCs) and possess low level expression of embryonic stem cell
markers, they do not induce tumorigenesis in laboratory animals, primates and
humans and do not transform to tumor-associated fibroblasts. There have been
no reports of any toxicity or side effects when hWJSCs were injected into
laboratory animals, non-human primates and in human clinical trials for the
treatment of aplastic anemia, leukemia, type 1 diabetes mellitus, heart failure and
neurological disorders. This suggests that hWJSCs or its extracts have the
potential to be used clinically. Numerous independent reports have confirmed
hWJSCs paradoxical tumoricidal properties both in vitro and in vivo on mammary
adenocarcinoma, ovarian carcinoma, osteosarcoma, cholangiocarcinoma and
bladder carcinoma. Being similar to BMMSCs, hWJSCs could also provide the
structural and physiological support for self renewal, expansion and homing of
hematopoietic stem cells (HSCs). Furthermore, hWJSCs express and secrete a
high level of adhesion molecules and extracellular matrix components like
glycosaminoglycans, osteopontin, MCP-1 and ICAM-1 which are inherent
constituents of the hematopoietic stem cell niche that help regulate the expansion
and maintenance of HSCs. As such, this thesis hypothesize that hWJSCs and/or
its extracts can be used to enhance the treatment of hematological malignancies
and blood disorders. The approach to the hypothesis was to evaluate (1) the
tumoricidal effect of hWJSCs or its extracts on hematological malignancies and
(2) to use hWJSCs or its extracts to enhance the numbers and freeze thaw
survival of hematopoietic stem cells (HSC).
viii
In summary, the tumoricidal effect of hWJSCs or its extracts on lymphoma cancer
cell lines was evaluated in this thesis. The tumoricidal effect of hWJSCs or its
extracts was not restricted to solid tumors but also non-solid tumors. hWJSCs
engulfed lymphoma cell lines when co-cultured while its extracts attenuated cell
growth and induced lymphoma cell death. In addition, the tumoricidal effect was
cancer cell specific as hWJSCs did not engulf control fibroblasts while its extracts
did not induce cellular death in control adult BMMSCs. It has also been
demonstrated that the effective agents in hWJSC-conditioned medium (hWJSC-
CM) were 3kDa and above. In addition, the 3kDa hWJSC-CM concentrate
modulated the activities of key oxidative stress enzymes involved in hydrogen
peroxide metabolism in lymphoma cell lines. Treatment of lymphoma cell lines
with 3kDa hWJSC-CM concentrate increased hydrogen peroxide level, oxidative
stress and lipid peroxidation. The ability of the 3kDa hWJSC-CM concentrate to
induce immunogenic cell death to lymphomas, osteosarcomas and breast
adenocarcinomas was also evaluated in the thesis. All three cancer cell lines
expressed increased danger associated molecular pattern (DAMPs)-ecto-CRT,
ecto-Hsp90, extracellular ATP and HMGB1 which are molecular hallmarks for
immunogenic cell death after exposure to the 3kDa hWJSC-CM concentrate.
Lastly, similar to BMMSCs, hWJSCs or hWJSC-CM could also be used for the
expansion of cord blood CD34+ cells ex vivo. It is also possible to isolate and
expand CD34+ cells using autologous hWJSCs within 24 hours of umbilical cord
and cord blood collection. Moreover, addition of hWJSC-CM into the freezing
media during freezing could enhance the freeze-thaw survival of cord blood
CD34+ cells.
Collectively, the findings in the thesis support the storage of hWJSCs in public
cord blood banks and their use in improving the efficiency in the clinical
management of hematological malignancies and blood disorders.
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1.1.1 Human Umbilical Cord
The human umbilical cord (hUC) that connects the fetus and placenta enables
the transport of blood supply and the removal of biological waste from the
developing fetus during pregnancy. The fertilization of oocytes and embryonic
development up to the early blastocyst stage takes place in the fallopian tubes.
The early blastocyst will then descend down into the uterus and the fully
expanded blastocyst will implant in the uterine endometrium around day 7 to 9
after fertilization. The migration of cells within the expanded blastocyst results in
the formation of two distinct cell layers, a peripheral layer of trophectoderm (TE)
which will become the placenta and a cluster of 30-50 cells known as the inner
cell mass (ICM). The ICM which protrude from the inner wall of the polar TE will
eventually form the entire fetus. In the process of embryonic development, the
ICM becomes delineated into the hypoblast and epiblast. The epiblast cells are
pluripotent in nature and give rise to the three germ layers which later develop
into various organs and extra-embryonic membranes that include the amnion,
chorion, placenta and umbilical cord 1. The umbilical cord which is derived from
the extraembryonic mesoderm and/or embryonic mesoderm during day 26 of
gestation, weighs approximately 40g, is 30-65 cm long and has a mean diameter
of 1.5 cm at birth. The hUC contains three blood vessels (2 arteries and a vein)
which are surrounded by a mucous proteoglycan-rich matrix known as Wharton's
jelly. Wharton's jelly, first described by Thomas Wharton in 1656, is a primitive
connective tissue mainly composed of gelatinous ground substance rich in
sulfated proteoglycans, collagenous fibers (collagen types I and III),
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glycosaminoglycan and extracellular matrix proteins. It serves to protect the hUC
vessels from compression, torsion and strangulation during fetal development.
1.1.2 Human Wharton's Jelly Stem Cells
Ever since the first isolation of fibroblastic-like cells from the Wharton's jelly of
hUC in 1991 was first reported 2, many research groups worldwide (including
ours) have been trying to isolate, characterize and evaluate the cells within the
hUC or Wharton's jelly both in vitro and in vivo for therapeutic and regenerative
use. To date, various mesenchymal stem/stromal cells (MSCs) populations,
namely amniotic, subamniotic, perivascular and Wharton's jelly regions, have
been identified within the hUC 1. In our laboratory, we have derived a method to
isolate MSCs from the Wharton's jelly directly and it has been referred to as
human Wharton's jelly stem cells (hWJSCs). The collected hUC pieces were first
cut open, then inverted (Wharton's jelly portion facing down) into an enzymatic
solution containing collagenase/hyaluronidase to loosen and detach the
Wharton's jelly. The hWJSCs were then separated and collected from the
Wharton's jelly by passing the detached Wharton's jelly through a syringe needle
1,3,4. There are two possible hypotheses on why these hWJSCs reside in the
Wharton's jelly during gestation. First, findings in a study on cells collected from
fetal bone marrow, yolk sac and aorta-gonadal mesonephros (AGM) of whole
aborted human conceptuses postulated that there are two waves of migration of
fetal MSCs where they first migrated from the yolk-sac and AGM to the placenta
via hUC in the first wave and then reverse-migrated from the placenta back to
home in the fetal liver and bone marrow via hUC in the second wave 5. It was
suggested some of the MSCs got trapped and resided in the gelatinous
Wharton's jelly during the migration 5,6. The second hypothesis suggests that
MSCs in the Wharton's jelly are primitive MSCs which originate from
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mesenchyme that is within the hUC matrix 1. Though the role of these hWJSCs
was probably to secrete (1) various glycoproteins, mucopolysaccharides,
glycosaminoglycans and extracellular matrix to maintain the gelatinous nature of
Wharton's jelly to prevent strangulation of hUC 1 and (2) secrete several bioactive
molecules like interferons, growth factors, interleukins and cell adhesion
molecules 7-9 for immunomodulatory and tissue repair mechanism during
gestation but the exact role during fetal development remains to be elucidated .
These hWJSCs meet the minimum criteria of MSCs set by the International
Society for Cellular Therapy 10.  Similar to adult tissue-derived MSCs, hWJSCs (1)
adhere to plastic, (2) express cell surface antigens CD105, CD90, CD73, but not
CD34, CD45, CD14, CD11b, CD19 and HLA class II and (3) differentiate along
the adipogenic, osteogenic and chondrogenic lineages in vitro 3,11-14. hWJSCs
shared the same developmental origins as human bone marrow MSCs
(hBMMSCs) and resemble them in terms of morphology, MSC marker expression,
absence of hematopoietic surface markers, hypoimmunogenecity and
multipotency but both are distinctly different, probably due to the differences in
niche microenvironment 1. As the umbilical cord lies between the embryo and
adult organs on the developmental map (Fig. 1), hWJSCs also express different
levels of pluripotency markers such as Oct4, Sox2, Nanog and Rex2, embryonic
surface marker antigens such as SSEA-4, Tra-1-60 and Tra-1-81 and alkaline
phosphatase 15-18. Given their unique characteristics, hWJSCs appear to have the
best attributes (which will be described in details later) for usage clinically as
compared to stem cells isolated from the embryo and adults (Table 1). The
suitability of these stem cells are also supported by numerous FDA-approved or
local regulatory approved human clinical trials using hWJSCs in treating
neurological, diabetic, liver, cardiovascular, immune and blood disorders
worldwide 19-25 (Table 2).
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Figure 1 Stages of Human Developmental Map and types of stem cells isolated
from each stages. Human Wharton's jelly stem cells also known as umbilical cord matrix
stem cells (red box) and are isolated from birth associated tissues lies between the
embryo and adult organs.
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Table 1. Comparison of hWJSCs with hESCs and adult BM-MSCs
Table 2 List of FDA and Local regulatory approved human clinical trials
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1.1.3 Characteristics and use of Human Wharton's Jelly Stem Cells in
Stem-cell based therapy
1.1.3.1 Plasticity
hWJSCs are multipotent cells. Other than the common adipogenic, chondrogenic
and osteogenic classical lineages expected from MSCs, hWJSCs have been
shown to differentiate into other cell types including neural, islet-like clusters cells,
hepatocyte-like cells, cardiomyoctes, skeletal muscles and endothelial cells in
vitro. As such, they have immense therapeutic potential in the management of
neurological diseases, type 1 diabetes, hepatic, cardiovascular and myogenic
diseases. Many studies using hWJSCs in experimental diseased animal models
have shown improved functional outcomes 26 (Table 3).





Mitchell and colleagues first demonstrated that hWJSCs could be induced into
neuronal lineages 27. Since then hWJSCs have been successfully differentiated
into different neuronal cell types such as dopaminergic neurons 26,28 and
Schwann cells 29-31. Moreover, hWJSCs were also able to produce significant
amounts of trophic factors such as glial-derived neurotrophic factor and
fibroblastic growth factor (FGF)-20, interleukin-6, FGF2, brain-derived
neurotrophic factor 26,32,33. Ding and colleagues previously transplanted one
million hWJSCs into the cortex of stroke rat model and observed improvement in
neurological function and cortical neuronal activity with increased local cortical
blood flow in the ischemic hemisphere 34. Other researchers also observed that
the experimental rat model transplanted with hWJSCs have reduced injury
volume and neurological functional deficits significantly 26. Transplanted hWJSCs
into rat model of spinal cord injury secrete large amounts of human neutrophil-
activatin protein-2, NT-3, FGF2, glucocorticoid induced tumor necrosis factors
receptor, VEGF receptor 3 in host spinal cord and significant improvements in
locomotor function and increased numbers of regenerated axons around the
lesion site were observed 35. In a phase II FDA-approved clinical trial,
spinocerebellar ataxia and multiple system atrophy patients were injected with
hWJSCs intrathecally once every two weeks. Though the disease continued to
progress in some patients, there was significant improvement in the International
Cooperative Ataxia Rating Scale, neural function and better quality of life post-
treatment 36. In another FDA-approved trial, hWJSCs were co-transplanted with
cord blood mononuclear cells in Autism patients and showed significant reduction
in Childhood Autism Rating Scale and Aberrant Behavior Checklist score. There
was also marked improvement in Clinical Global Impression Scale, visual
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responses, emotional responses, intellectual responses, typical displays and
behaviours 37.
Islet-like cell clusters
hWJSCs can differentiate into islet-like cell clusters that contained human C-
peptide, and were able to express insulin and pancreatic beta-cell-related genes
that are capable of releasing human insulin in response to glucose in vitro 38.
Alleviation of hyperglycemia and glucose intolerance were observed after these
hWJSC-derived islet-like cell clusters were transplanted into streptozotocin-
induced diabetic rat model 38. In a recently published FDA-approved human
clinical trial, 15 patients with type 1 diabetes were transfused with hWJSCs where
they showed better glucose control, increased insulin secretion and regeneration
of islet cells than the control group. The usage of insulin was progressively
reduced in the hWJSCs treated patients and in some patients did not require
insulin intervention 20.
Hepatocytes-likes lineages
hWJSCs can differentiate into hepatocytes-like cells after induction with
hepatogenic factors 39-42. hWJSCs exhibited hepatocyte-like morphology,
upregulated hepatic markers such as albumin, human alpha-fetoprotein,
cytokeratin 18, and also demonstrated glycogen storage, lipoprotein uptake and
urea production 40. Human albumin and human alpha-fetoprotein were observed
several weeks after transplantation of undifferentiated hWJSCs into spleen of
SCID mice with partial hepatectomy 40. It was observed that there were
significantly lower levels of serum glutamic oxaloacetic transaminase, glutamic
pyruvate transaminase, alpha-smooth muscle actin and transforming growth
factor beta1 several weeks after transplantation of hWJSCs into livers of carbon
tetrachloride-induced liver fibrosis rat model 43. Though the engrafted hWJSCs
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were not shown to differentiate into hepatocyes after transplantation,
upregulation in expression of hepatocyte growth factor, hepatic mesenchymal
epithelial transition factor-phosphorylated type, tryptophan 2, 3-dioxygenase,
human alpha-fetoprotein, cytokeratin-18, fibroblast secretory protein-1 and alpha
smooth muscle actin were seen. They also secreted a variety of bioactive factors
such as human cutaneous T cell attracting chemokines, leukemia inhibitory factor,
prolactin which contributed to attain functional recovery of liver functions probably
by degradation of fibrous matrix and stimulation of endogenous parenchymal
cells to promote liver regeneration 43. A FDA-approved trial where hWJSCs were
transfused into patients with acute-on-chronic liver failure showed significant
improvement in Model for End-stage Liver Disease scores, liver function and
survival rates as compared to control 44. In another human clinical trial, the
transfusion of hWJSCs improved liver function as determined by (i) increased
serum albumin levels, (ii) decreased  total serum bilirubin level, (iii) decreased in
the sodium model for end-stage liver disease scores and (iv) significant reduction
in the volume of ascites in decompensated liver cirrhosis patients compared to
control 45.
1.1.3.2 Immune-modulating properties
Similar to hBM-MSCs, hWJSCs have been shown to possess hypoimmunogenic
properties and are capable of immune suppression. They do not express MHC
class II (HLDA-DR)  or co-stimulatory molecules such as CD80, CD86, CD40
known to activate the adaptive T and B cells responses 46-48. hWJSCs do express
low levels of MHC class I (HLA ABC) 46; B7-H1,a negative regulator of T-cell
activation and pan-HLA-G which contribute to immune tolerance during
pregnancy 48,49. In addition, they secrete large amounts of anti-inflammatory
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factors such as interleukin-10, indoleamine 2,3-dioxygenase-mediated tryptophan
depletion, TGF-B, LIF, HGF and prostaglandin E2 47,49.
Concanavalin-induced splenocyte proliferation was inhibited by hWJSCs and
there were no stimulation of T cells in either one-way or two way mixed
lymphocyte reaction assay 46. In addition, hWJSCs also inhibited CD4+, CD8+,
CD2+ and CD3+ T cells subset proliferation but stimulated the expansion of
CD4+CD25+Foxp3+ T-regulatory cells (Treg) in hWJSCs/Treg co-cultures 46.
Furthermore, hWJSCs also prevented CD14+ monocytes differentiation into
mature dendritic cells and leading to their arrest as immature dendritic cells 49.
Expression of co-stimulatory ligands were also blocked in hWJSCs/monocytes
co-cultures 49. Given the immuno-modulation properties, Kikuchi-Taura et al.
investigated whether hWJSCs help the suppression of Graft verus Host Disease
(GvHD) in mice model 50. Significant reduction in the frequency of GvHD was
observed at 6 weeks post-transplantation in C57BL/6 mice that underwent
allogeneic bone marrow transplantation with unexpanded hWJSCs at day 0 and
day 6. Those mice that received concomitant treatment with hWJSCs also
showed better survival at 6 weeks and 25 weeks after transplantation as
compared to control. Moreover, in a human clinical trial, no chronic GvHD was
observed when hWJSCs were transfused into human patients with severe
steroid-resistant acute GvHD 25. Similarly, there were lesser incidence or lesser
side effects of GvHD in other human clinical trials which hWJSCs were co-
transplanted with cord blood HSCs or peripheral blood stem cells for the
treatment of leukemia and severe aplastic anemia 19,23.
1.1.3.3 Tumoridicial
Numerous independent studies have reported the tumoricidal properties of
hWJSCs or its extracts both in vitro and in vivo on solid tumors like mammary
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adenocarcinoma, ovarian carcinoma, osteosarcoma, cholangiocarcinoma,
hepatocellular carcinoma, bronchioloalveolar and bladder carcinoma 9,51-61 (Table
4). De Coppi et al. first reported the migration of hWJSCs to metastatic tumor
sites in the lungs after intravenous injection into SCID mice with mammary
adenocarcinomas which suggested their homing abilities 62. Ganta et al. in an
elegant experiment first documented the direct tumoridicial effect of WJSCs
where intravenous or intra-tumoral injection of un-engineered rat WJSCs into rats
with mammary carcinomas led to completely abrogation of cancer growth
compared to control 53. Likewise, Ayuzawa et al demonstrated that hWJSCs
administered intravenously into human mammary adenocarcinoma xenograft rat
model, migrated to metastatic tumor sites in the lungs and attenuated tumor
growth 52. As hWJSCs tended to home into tumor sites, WJSCs were engineered
to express cytotoxic cytokines like interferon-B that effectively homed and
attenuated the growth of human breast adenocarcinoma and bronchioloalveolar
carcinoma cells in xenograft SCID mice 51,54.
The tumoridicial effect of hWJSCs were mediated via cell-to-cell and/or non-
cellular contact mechanism. Several modes of action of the inhibitory effects of
hWJSCs on cancer cells have been demonstrated. Most groups demonstrated an
induction of apoptosis, inhibition of proliferation and cell cycle arrest after
treatment with hWJSCs or its extracts. Time lapse imaging study showed that
hWJSCs inhibited mammary carcinoma cehlls by an entosis mechanism where
the hWJSCs were first engulfed by mammary adenocarcinoma cells, which
underwent disintegration due to apoptosis 56. Another group reported a G2 cell
cycle arrest and inhibition of PI3K/Akt signaling pathway when hWJSCs were co-
cultured with breast cancer cell lines or primary breast cancer cells 60.
Earlier studies from our group as well as others have also demonstrated the
tumoricidal effects of the extracts of hWJSCs like hWJSC-conditioned medium
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(hWJSC-CM); its cell-free lysate (hWJSC-CL) or its microvesicles (MVs). The
extracts of hWJSCs inhibited the growth of mammary carcinoma, osteosarcoma
cells, bladder carcinoma, cholangiocarcinoma both in vitro and in vivo 9,57,59,61.
The tumoridicial effect of hWJSC extracts (hWJSC-CM and hWJSC-CL) on
breast adenocarcinoma, ovarian carcinoma and osteosarcoma cell lines were
evident by their inhibition of growth and morphological changes that ranged from
cell shrinkage, blebbing to vacuolation with resultant cell death either due to
apoptosis or autophagy 9. Intra-tumor injection of hWJSCs or hWJSC-CM on
mammary adenocarcinoma xenograft decreased tumor size 57. Likewise, Liu et al.
also demonstrated that subcutaneous injection of hWJSCs and hWJSC-CM on
xenograft model of cholangiocarcinoma decreased tumor size 59. In vitro
treatment of cholangiocarcinoma cell lines inhibited cell growth via the inhibition
of PI3K/Akt and Wnt/B-catenin signaling pathways 59. Likewise, Wu et al also
demonstrated inhibition of bladder tumor cell line proliferation was mediated
through downregulation of Akt phosphorylation, as well as upregulation of p21,
p53 and cell cycle arrest at G0/G1 phase. In addition, subcutaneous injection of
hWJSCs or its MVs decreased tumor incidence and tumor size in xenograft
model of bladder tumor in BALB/c nude mice 61.
Another possible mechanism of hWJSC-mediated inhibition or death of cancer
cells is through the modulation of immune response to cancer cells. Ganta et al.
observed via immunohistochemistry that T cells formed the majority of infiltrating
lymphocytes in rat WJSCs treated rat mammary carcinomas 53. Rat WJSCs
treatment increased CD8+ T cell infiltration throughout the tumor tissues.
Moreover, the same group later showed that rat WJSCs attenuated orthotopic
Mat B III rat mammary tumor cell growth via the modulation of an endogenous
immune response through the secretion of monocyte chemotactic protein-1
(MCP-1) 58. The attenuation of tumor growth was accompanied by lymphocytes
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infiltration and immunohistochemistry analysis indicate that the rat WJSCs
increased number of CD3+, CD8+ and CD4+ T cells, natural killer cells
throughout tumor tissue while CD68+ monocytes/macrophages and Foxp3+
regulatory T cells were rarely observed compared to control 58.




1.1.4 Advantages in using Human Wharton's Jelly Stem Cells in Stem
Cell Therapy
1.1.4.1 Source and Isolation
Isolation of hWJSCs poses no ethical issues as compared to human embryonic
stem cells (hESCs) and fetal MSCs. hESCs are derived from the inner cell mass
of a blastocysts and its isolation will lead to the destruction of fertilized human
embryo 63,64. As there is no consensus whether these embryos are considered as
human being at this embryonic state, its destruction is of ethical issues. Similarly,
fetal MSCs isolated from aborted fetuses which their uses can be controversial 1.
hWJSCs, derived from commonly discarded umbilical cord pose no such ethical
issues in their isolation and subsequent usage in the clinics 1. In addition, the
isolation of hWJSCs from discarded cord poses no discomfort or risk to the
patients or donors as compared to isolating MSCs from bone marrow or adipose
tissues, which involves an invasive procedures which is painful, posing infection
risks and donor site morbidity to both patients and donors 1,65,66. The ease of
derivation and lack of ethical issues concerning the usage of hWJSCs make
them a better stem cell choice over hESCs/iPSCs, fetal BM-MSCs and adult BM-
MSCs.
1.1.4.2 Cell Numbers and Maintenance
One major drawback of using adult BM-MSCs in the clinics is the limitation in cell
number that can be harvested from the donor bone marrow aspirates and thus an
ex vivo cell expansion is often needed to obtain the required cell numbers.
Moreover, BM-MSCs limited proliferation before reaching senescence and
variation in relation to donor age is a concern 67. In addition, the need to expand
BM-MSCs ex vivo accentuated the risks of having their genotype altered during
the process. It is well documented that in vitro manipulation of cells like
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continuous passaging leads to major and minor chromosomal changes, loss of
stemness properties and poses the risk of contaminations in vitro 1. Likewise,
both hESCs and human induced pluripotent stem cells (iPSCs) can develop
chromosomal deletions or duplications after serial passaging 68 while
chromosomal changes could also be induced during the reprogramming stages
in generating iPSCs 69. On the other hand, our laboratory has successfully
isolated hWJSCs from discarded cords and could consistently harvest about 5
million fresh hWJSCs per centimetre of umbilical cord before culture 3,4. As such,
we could theoretically harvest 2500 millions of fresh hWJSCs per hUC. In
addition, hWJSCs have higher proliferation rates and longer telomere length than
adult BM-MSCs because of its young chronological age. We are able to maintain
the hWJSCs for at least 20 passages with no changes to their stemness markers
and genome 3,4,15,17. Moreover, hWJSCs adhere well onto tissue culture dishes
and hence their derivation and propagation in vitro do not need any feeder cells
or cell attachment matrices. As such, the high cell number and easy maintenance
of hWJSCs make them a better stem cell choice over hESCs/iPSCs and adult
BM-MSCs.
1.1.4.3 Non-tumorigenic behaviour
Though hESCs and human iPSCs are pluripotent, their clinical translation has
been limited as undifferentiated pluripotent cells have been shown to induce
teratomas when injected into normal or immunocompromised mice 70. Likewise,
teratoma formation was also reported when mouse embryonic stem cell derived
insulin producing islets or cardiomyocytes were transplanted in
immunosuppressed mice 71,72, presumably due to the inherent property of rogue
undifferentiated pluripotent cells. The challenges of eliminating all rogue
pluripotent stem cells in the derived population have delayed the use in patients.
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Though hWJSCs also expressed different levels of pluripotent markers such as
Oct4, Sox2, Nanog and Rex2, embryonic surface marker antigens such as
SSEA-4, Tra-1-60 and Tra-1-81 and alkaline phosphatase 15-18, they did not to
form teratomas when injected via subcutaneous; intramuscular ; intraperitoneal
routes even after 20 weeks 73. Similarly, no tumorigenesis has been reported
when hWJSCs or hWJSC-derived tissues were transplanted into primates and
humans 26. In addition, no development of tumors in all injection sites and organs
and no stem cell transplantation-related toxicity were observed when hWJSCs
were injected intravenously every 2 weeks for 6 weeks in non-human primates-
cynomolgus monkeys 74.
The use of adult BM-MSCs in numerous regenerative cell therapies also holds
immense clinical potential. Tthough BM-MSCs do not form teratomas when
injected into mice, fetal and adult MSCs have been shown to produce tumors 75-77.
In addition, it has been reported that BM-MSCs or adipose derived MSCs favor
tumor cell growth in vivo 78,79. Moreover, MSCs can form tumor associated
fibroblasts (TAF) in tumor microenvironment and played an important role in
tumor formation, tumor growth, angiogenesis and metastasis 80-84. BM-MSCs can
also acquire TAF phenotypes after exposure to or systemic recruitment into
xenograft models of breast, pancreatic and ovarian cancers 85. As such, it has
been hypothesized that the precursor cells that form TAFs in solid tumors are the
hBMMSCs 85-87. An alternative MSCs, hWJSCs (though they share the same
developmental origin as BM-MSCs) failed to transform into TAF phenotype after
their growth in the presence of breast and ovarian cancer cell conditioned
medium for 30 days 88. Our group demonstrated that unlike BM-MSCs, hWJSCs
did not express TAF markers like fibroblast specific proteins, fibroblast activated
proteins, cell aggressive markers, tumor growth factors and angiogenic factors 88.
In addition, unlike BM-MSCs, hWJSCs cultured for 30 days in cancer cell
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conditioned medium also failed to stimulate cancer cell growth in vitro in the
same study 88.
As recent report on a 13-year old child developing multiple brain and spinal cord
glioneuronal tumors after receiving fetal stem cells for ataxia telangiectasia 77
highlighted the importance of ensuring the tumourigenic potential of any stem
cells are assessed before using them on human patients. Therefore, hWJSCs
which has been demonstrated to be non-tumorigenic and did not formed TAF
serves as an ideal stem cell source for future clinical applications.
1.1.4.4 Hypoimmunogenicity
Another hurdle that has delayed the translation of stem cells usage in human
clinical trials is the concern of immunorejection of stem-cell derived tissues in an
allogeneic settings 70. Like all tissue/organ transplants, in the use of hESCs cell
therapy, there is a need to circumvent the host immune system rejection or the
need to prevent Graft vs host disease (GvHD) during the treatment. Though the
breakthrough in creating patients' specific iPSCs by nuclear reprogramming of
patients' somatic cells should be immune-tolerated 1, there are now conflicting
reports as to whether these patient specific iPSCs will be immuno-tolerated 89,90.
Zhao et al. reported in 2012 that teratomas of  iPSCs generated from B6 mouse
embryonic fibroblasts were mostly immune-rejected by B6 mice recipients 89, but
Guha et al. on the other hand did not observe an immune response against
iPSCs or iPSCs derived cells in vitro and after transplantation into syngeneic
mouse recipients 90. It was suggested that the low immunogenicity of hWJSCs
protected hWJSCs or hWJSC-derived cells from immune-rejections in immune-
competent rats 91. Swine derived WJSCs multiplied following transplantation into
rat brain without activation of host immune response and swine WJSCs could be
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recovered 6 weeks after transplantation from the brain of rat that did not receive
immune suppression 32,91. Likewise, human hWJSCs did not trigger host immune
response when transplanted into immuno-competent rats 32. The lack of immuno-
rejection or infiltration of host immune cells after hWJSCs or hWJSC-derived cells
transplantation in immuno-competent animal model bodes well for its engraftment
in an allogeneic transplantation setting. In addition, hWJSCs have more robust
immunomodulatory properties than BM-MSCs. Though BM-MSCs inhibited
mitogen-, alloantigen- or specific antigen- driven T cell responses 92,93, hWJSCs
exhibited a robust suppression as compared to BM-MSCs at a very low dose
range 47,94. Moreover, hWJSCs were able to suppress allogeneically stimulated T
cells to a greater extent than BM-MSCs and this regulation is stimuli-independent
47. The kinetics of pro-inflammatory cytokines secretion profiles of hWJSCs or
BM-MSCs co-cultured with PHA-activated lymphocytes indicated that the
threshold and kinetics of IL-2 changes only with BM-MSCs but not with hWJSCs
47. The early activation of negative co-stimulatory ligands on lymphocytes was
more evident with hWJSCs 47. As such, it demonstrated that hWJSCs were less
immunogenic than BM-MSCs making them a more ideal choice for allogeneic
transplantation.
1.1.5 Stem Cell-based Therapy for the Management of Hematological
Malignancies and Blood Disorders.
Currently, hematopoietic stem cells (HSC) transplantation is by far the most
widely performed stem cell based therapy in the clinics since its introduction in
1968. Since then, HSC transplantation has been used to treat blood disorders,
immunodeficiency disorders, hematopoietic malignancies like leukemia, and
lymphoma, as well as in the treatment of diseases like chronic liver failure and
acquired immunodeficiency syndrome (AIDS) 95,96. HSC transplantations in utero
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were successful in the treatments of fetuses diagnosed with severe combined
immunodeficiency disorder 97,98. Data provided by the Center for International
Blood and Marrow Transplant Research shows a rising trend of transplantation
performed worldwide over the last decade. Therefore, large numbers of HSCs
are needed to support the increasing demand of HSC transplantation.
Despite its success, there are two major limitations to a successful HSCT. They
are (i) the identification of tissue-matched HSC sample and (ii) the presence of
adequate numbers of HSCs. The current sources of HSCs come from the bone
marrow (BM), mobilized peripheral blood (mPB) and umbilical cord blood.
Collection of HSCs from the BM or mPB depends mainly on patients’ relatives
and volunteers. In such instance, identification of suitable tissue-matched HSCs
remained a challenge. Even though public cord blood banks have been set up to
help in identifying suitable tissue-matched HSCs, they are still unable to meet the
overwhelming demand. Additionally, harvesting of HSCs from bone marrow is an
invasive procedure and is usually associated with discomfort and risk of infection.
Rare incidents of rupture of the spleen and sickle cell damage have occurred and
the long term safety of the donors following peripheral blood HSCs collection
remains unclear 99-102. With these safety concerns and discomfort surrounding the
donors, the ability to collect HSCs samples from the bone marrow or peripheral
blood are mainly restricted to patients’-related donors or volunteers.
Harvesting of HSCs from umbilical cord blood (UCB) has several advantages
over that of BM or mPB. The advantages are (i) it is easy to collect and store
UCB HSCs in cord blood banks which make them easily available to patients, (ii)
UCB HSCs pose less risk of graft versus host disease (GVHD) due to their
immune naivety, (iii) there is less stringent requirement needed to find a matching
sample between donors’ cells and recipients’ and (iv) UCB HSCs have higher
proliferation rates, and longer telomeres due to their young chronological age 103-
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105. The UCB HSCs are also associated with delayed neutrophil response, slower
platelets recovery and higher incidence of infection-hemorrhage related morbidity
and mortality as compared to BM or mPB HSCs 106-108.
Despite having many advantages, the biggest obstacle in using UCB HSCs is the
limited number of HSCs that can be isolated from a cord blood unit. The number
of UCB HSCs from a single UCB unit that can be harvested typically ranges from
0.4 to 1.0x 107 CD34+ cells but a minimum of 2.0 to 2.5x107 MNCs/kg CD34+
cells are required for a favorable transplantation outcome 109. Thus, HSCs
collected from each cord unit can only be used for one patient and its use is
mainly restricted to children or small sized adults. Most patients therefore
succumb to their illness due to the lack of suitable tissue-matched HSCs units
and also insufficient HSCs number for a successful treatment.
1.1.6 Human Wharton’s Jelly Stem Cells and Hematological Disorder
Management
hWJSCs could provide the structural and physiological support for self renewal,
expansion and homing of HSCs as reported by several groups 110,111. This
supportive role of hWJSCs was demonstrated through long-term culture initiating
cells assays and also when cord blood CD34+ cells that were co-cultured with
hWJSCs for a period of up to 5 weeks could still demonstrate methylcellulose
colony-forming potential 110,111. The mechanism of this supportive role was
attributed to the high expression and secretion of hematopoietic cytokines and
growth factors such as SCF, LIF, VEGF, Flt3-L, TPO, HGF, IL-1a, IL-6, IL-8, IL-
11, GM-CSF, G-CSF, M-CSF, and SDF-1 111,112. Furthermore, hWJSCs express
and secrete high level of adhesion molecules, extracellular matrix components
like glycosaminoglycans, osteopontin, MCP-1 and ICAM-1 which are inherent
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constituents of the hematopoietic stem cell niche that help regulate the expansion
and maintenance of HSCs. Previous studies have indicated that co-
transplantation of human MSCs enhanced the engraftment of UCB HSCs in
NOD/SCID mice model and also in human patients 113-117. The hypoimmunogenic
properties of MSCs were often cited as the main reason for the improved
engraftment which reduced immune-rejection 118. However, the capacity of MSCs
to engraft in the patients’ bone marrow is still debatable 119 because most studies
indicate a lack of engraftment 120. Recent research has shown that these MSCs
homed to the bone marrow eventually 121,122 especially when the stromal niche
was considerably damaged 123. The myeloablative regime used during pre-
transplantation preparation to eliminate malignant cells and/or to
immunosuppress the patients prior to HSC transplantation often also damaged
the bone marrow microenvironment extensively 124-126 and this influenced the
HSCs engraftment kinetics 126. More recent studies indicate that MSCs could
home to the bone marrow microenvironment and help reconstitute and repair the
hematopoietic microenvironment in vitro and in vivo mouse bone marrow-
damaged models 119,127,128. Likewise, co-transplantation of hWJSCs with UCB
CD34+ cells could accelerate hematopoietic recovery in NOD/SCID mice even
when limited numbers of UCB CD34+ cells were infused 112. Though results
showed presence of human CD105+ cells only in some of the bone marrow of
the recipient mice, it is still indicative of engraftment of the transplanted hWJSCs
into the recipient mice 112. Yet, another study observed that hWJSCs could
mitigate chemotherapy-associated tissue injury in pre-clinical mouse model 128.
There were a few human clinical trials that involved hWJSCs transplantation for
the treatment of leukemia, severe aplastic anemia and thrombocytopenia
19,23,24,129.  In one of these trials,  hWJSCs were co-transplanted with cord blood
HSCs in patients with high-risk acute lymphoblastic or acute myeloid leukemia 129.
Chapter 1: Introduction
22
The results indicated that co-transplantation with hWJSCs led to faster
engraftment and faster recovery of absolute neutrophil and platelets counts which
indicated enhanced hematopoiesis after cord blood transplantation as compared
to patients that received cord blood transplantation alone 129.  In addition, higher
survival rates were associated with hWJSCs co-transplantation 129. Similar results
were seen in the another trial where patients with  acute lymphoblastic or acute
myeloid leukemia or severe aplastic anemia and B-thalassemia major were
treated with cord blood co-transplanted with hWJSCs 23. In another clinical trial,
hWJSCs were co-transplanted with peripheral blood stem cells in patients with
severe aplastic anemia  and similarly, accelerated engraftment and higher
survival rates were associated with hWJSCs co-transplantation compared to
control 19. hWJSCs were also transplanted into 2 patients with chronic immune
thrombocytopenia in a human clinical trial where both patients showed no signs
of bleeding and normal peak platelet count after hWJSCs transplantation 24.
1.2 Research hypotheses and aims
The current management of hematological malignancies involved the use of
chemotherapeutic agents, irradiation and hematopoietic stem cells (HSCs)
transplantation. There are 2 challenges with these methods of treatments. Firstly,
the use of aggressive chemotherapeutic agents or radiation-conditioning regimes
prior to HSC transplantation often cause damage to the bone marrow
microenvironment and have a profound influence on HSC engraftment kinetics
and the outcome of patient treatment 126,130-133. As the bone marrow
microenvironment made up of mesenchymal stem cells (MSCs) and extracellular
matrix (ECM) serves as an important hematopoietic niche which influences the
abilities of hematopoietic stem cells (HSCs) or hematopoietic progenitor cells
(HPCs) to home, engraft, self-renew and differentiate via direct cell-cell contact
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and secretion of hematopoietic growth factors 119,134,135. It is therefore important to
explore alternative anti-cancer therapies that will inhibit leukemic or lymphoma
cell growth while at the same time do not damage the bone marrow
microenvironment. Secondly, HSCs from the bone marrow have been
traditionally used in the form of bone marrow transplants for the treatment of
malignant hematopoietic diseases. However, aspiration of HSCs from the bone
marrow is painful and there is the potential risk of infection and morbidity.
Additionally, optimal HSC numbers from the bone marrow are not available for
successful transplantation in many cases. In order to avoid these disadvantages,
HSCs from the human umbilical cord blood (UCB) have been successfully used
for the treatment of malignant and non-malignant blood-related diseases in
infants and children in both autologous and allogeneic settings 136,137. However,
UCB also has its limitations in that the HSC and HPC yields are low and the cell
numbers are usually inadequate for the treatment of blood-related diseases in the
adult. Therefore, to overcome these challenges, this thesis hypothesized that the
dual anti-tumorigenic and MSCs properties hWJSCs and its extract could be
used to manage and improve to the treatment of hematological malignancies and
blood disorders.
Hypothesis:
It was hypothesized that the dual anti-tumorigenic and MSCs properties of
hWJSCs and/or its extract can be used to manage and improve the treatment of
hematological malignancies and blood disorders.
Specific Aims:
The specific aims of the thesis were:
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1.  To evaluate the use of hWJSCs and its extract as an direct anti-tumorigenic
agent for hematological malignancies.
(i) To evaluate the anticancer effects of hWJSCs, its conditioned medium
(hWJSC-CM) and cell-free lysate (hWJSC-CL) on various malignant cell
lines of the hematopoietic system.
(ii) To evaluate the hydrogen peroxide mediated tumoridical effect of
hWJSC-CM on malignant cell lines of the hematopoietic system.
(iii) To evaluate the immunogenic cell death induction of hWJSC-CM on
cancer cell lines of the hematopoietic, osteosarcomas and breast cancer
system.
2.  To evaluate the use of hWJSCs and its extracts for increasing the number
cord blood CD34+ cells
(i) To evaluate the use of hWJSCs and its conditioned medium (hWJSC-
CM) as stromal and non-stromal support systems for the ex vivo expansion
of hematopoietic stem cells (HSCs).
(ii) To comparatively evaluate the use of hWJSC-CM + DMSO freezing
media for the improvement of thaw-survival rates of HSCs so as to
maximize cell numbers for treatment of hematopoietic diseases.
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Chapter 2: Tumoricidal Effect on Lymphoma Cells
2.1 Introduction
Human or murine bone marrow mesenchymal stem cells (hBMMSCs) are known
to home to cancer tissues and have been explored as vehicles for gene or anti-
cancer drug delivery to inhibit cancer growth 138,139. However, their anticancer
effects have been controversial as reports shows an inhibitory and proliferative
effect on cancer cells 140. hBMMSCs were demonstrated to have a potent anti-
cancer effect in numerous in vivo experimental models including Kaposi's
sarcoma, colon carcinoma, Lewis lung carcinoma and melanoma 141-143. However,
it has also been reported that when hBMMSCs is in the vicinity of breast,
pancreatic and ovarian cancer cells, they could transform to tumor associated
fibroblasts (TAFs) which enhance tumor growth in human xenograft animal
models 86,144. Such hBMMSC-derived TAFs also encourages metastasis of the
tumors resulting in systemic spread of the solid tumors 80-83,85. Thus, the use of
hBMMSCs as vehicles for the delivery of anti-cancer agents remains a clinical
hurdle.
Our laboratory have derived a primitive stromal cell from the Wharton's jelly
compartment of the human umbilical cord with high expression of MSC CD
markers and low level expression of human embryonic stem cell (hESC) markers.
These stem cells have similar CD signatures, differentiation capabilities and
share common developmental origins as hBMMSCs 3-5. There are numerous
reports which have confirmed their tumour inhibitory properties both in vitro and
in vivo on solid tumours such as mammary adenocarcinoma, ovarian carcinoma,
osteosarcoma, cholangiocarcinoma and bladder carcinoma 9,51-53,55-57,59-61.
Though extensive studies have been carried out on the tumoricidal effects of
hWJSCs on solid cancer tissues, no studies have evaluated whether non-solid
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tumors such as leukemia and lymphoma cells are susceptible to the tumoricidal
effects of hWJSCs. One study suggested that adult hBMMSCs improved the
overall survival of disseminated non-Hodgkin's lymphoma 145. These workers
showed massive stromal infiltration of hBMMSCs into tumor masses that resulted
in necrosis. In in vitro experiments they suggested that the release of pro-
angiogenic cytokines by hBMMSCs induced endothelial cell migration and
apoptosis thus prevented new blood vessel formation which consequently was
the cause of tumor growth inhibition 145. Umbilical cord MSCs inhibited leukemia
cell growth in vitro possibly by the release of interleukins such as IL-6 and IL-8 146.
Since hWJSCs secrete high levels of various factors not observed with
hBMMSCs, the aim of this chapter was to evaluate the tumoricidal effects of
hWJSCs and its extracts on Burkitt's lymphoma cancer cells and the mechanism
involved.
2.2 Material and Methods
2.2.1 Cell Culture
Human Wharton's jelly stem cells (hWJSCs)
The hWJSCs were derived from human umbilical cords after informed patient
consent and approval from the Institutional Domain Specific Review Board
(DSRB). In all experiments, early passages of hWJSCs (3P to 5P) were used. In
some experiments, green fluorescent protein (GFP)-transduced hWJSCs (GFP-
hWJSCs) that were generated in our laboratory were used. hWJSCs were
maintained in hWJSC medium that comprised of 80% DMEM medium
supplemented with 20% fetal bovine serum (FBS) (Biochrom, Berlin, Germany),
1% non-essential amino acids, 2 mM L-glutamine, 0.1 mM β-mercaptoethanol, 1%
insulin-transferrin-selenium (ITS), antibiotic/antimycotic mixture [penicillin (50IU),
streptomycin (50μg/ml), amphotericin B(0.25μg/ml)] (Invitrogen Life Technologies,
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Carlsbad, CA) and  16 ng/ml basic fibroblast growth factor (Millipore Bioscience
research agents, Temecula, CA).
Human lymphoma cells (Ramos)
Approval for purchase and use of commercial human Burkitt's lymphoma cell line
(Ramos, CRL 1596) (American Type Culture Collection, ATCC, Rockville, MD,
USA) was granted by the National University of Singapore Institutional Review
Board (NUS-IRB). The cell lines were thawed and cultured in lymphoma medium
consisting of RPMI medium (Thermo Scientific) supplemented with 10% heat
inactivated FBS (Biochrom) and 1% antibiotic/antimycotic mixture (Invitrogen).
Human skin fibroblasts (CCD1112sk) and bone marrow mesenchymal stem cells
(hBMMSCs)
Approval for purchase and use of commercial adult hBMMSCs (Lonza, Allendale,
NJ, USA) and human foreskin fibroblasts (CCD-1112sk) (ATCC) (abbreviated as
CCD) was granted by the NUS-IRB. The cells were thawed and cultured in
medium consisting of DMEM-high glucose (Invitrogen) supplemented with 10%
FBS (Biochrom), 1% antibiotic/antimycotic mixture and 2mM L-glutamine
(Invitrogen).
2.2.2 Preparation of hWJSC conditioned medium (hWJSC-CM)
The preparation of hWJSC-CM was carried out as previously described 8,9,57.
Briefly, early passages of hWJSCs (3P to 5P) were first cultured in hWJSC
medium until 70% confluency. The medium was then replaced with basal RPMI
medium (Thermo Scientific) supplemented with 1% antibiotic/antimyotic mixture
(Invitrogen). After 48 h, the medium (hWJSC-CM) was collected, filtered through
a 0.22 M filter (Millipore) and stored at -80oC until use.
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2.2.3 Preparation of hWJSC lysate (hWJSC-CL)
The preparation of hWJSC-CL was carried out as previously described 9,57. Early
passages of hWJSCs (3P to 6P) were cultured in hWJSC medium until 80%
confluency, dissociated with trypsin (TrypLETM Express, Invitrogen) and
centrifuged to obtain a cell pellet. The hWJSC lysate was harvested using a
commercial mammalian cell extraction kit supplemented with protease inhibitor
cocktail and dithiothreitol (BioVision Inc., Mountain View, CA). Briefly, 100 l of
cell lysis buffer containing the protease inhibitor cocktail and dithiothreitol were
added to the hWJSC pellet, mixed and incubated at 4oC for 45 min. The mixture
was then centrifuged at 15,000 x g for 15 min and the supernatant separated and
stored at -80oC until use. The total protein content of the lysate was measured
using a NanodropTM spectrophotometer (Nanodrop Technologies, Wilmington,
DW). hWJSC-CL containing 15 g/mL protein was used for all experiments.
2.2.4 Experimental Design
Co-Culture
Lymphoma (Ramos), skin fibroblasts (CCD) and hBMMSCs were first stained
with CellTrackerTM Red (CTR) (Invitrogen) according to the manufacturer's
instructions. Briefly, the cells were incubated with 10 M of Cell TrackerTM Red in
growth medium for 30 min at 37oC in a 5% CO2 at room temperature and
pressure. The media were then discarded and cells washed with PBS before
incubation for another 30 min with growth media. The cells were then passaged
and equal numbers of GFP-hWJSCs and CTR-lymphoma cells cocultured in a
Lab-Tek(R) Chambered #1.0 Borosilicate coverglass system (Thermo Scientific).
Time lapse imaging and fluorescence in-situ hybridisation (FISH) for Y-
chromosomes
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To find out whether the CTR-lymphoma cells were actually engulfed by the GFP-
hWJSCs as whole cells or in parts or that there was no engulfment, the
interaction of the two cell types was monitored under time lapse imaging and
after 24h of cell interaction z-stack images of cell-to-cell interaction and cell death
was taken using an Olympus FluoView FV1000 laser scanning confocal
microscope (Olympus, Japan).
Since the two cell types were of opposite sex, the Y chromosomes of the
lymphoma cells were probed using FISH to further confirm whether whole
lymphoma cells or their remnants were taken up by the GFP-hWJSCs. GFP-
hWJSCs were not used in this experiment as their green signals which are closer
in color to yellow FISH-Y chromosome signals would interfere with interpretation.
We therefore first stained hWJSCs with Cell TrackerTM Red (CTR) as described
above before co-culturing with unstained lymphoma (Ramos) cells on coverslips
in 24-well plates (Thermo Fisher Scientific, Rochester, NY) for 24h. The cells
were then fixed in cold methanol: acetic acid (3:1) overnight and stored at -80oC
until use. The X-spectrum Orange/ Y-spectrum Green DNA probe (Vysis Ltd,
London, UK) (5mL of 2:3 dilution) was added to the fixed cells and placed in a
hybridization block for 7 min at 71oC and subsequently for 4h at 37oC in a
humidified chamber. The cells were then washed with 0.4X salted sodium citrate
(SSC) for 2 min at 71oC followed by further washing with 2X SSC for 2 min at
room temperature. After air-dying, the cells were then stained with DAPI and
mounted with FluoroshieldTM (Sigma, St. Louis, MO). The cells were observed
and Y chromosome FISH signals photographed with an Olympus FluoView
FV1000 laser scanning confocal microscope.
Exposure of lymphoma cells to hWJSCs, hWJSC-CM and hWJSC-CL
Lymphoma (Ramos) cells (0.5 to 10 x 104 cells) were separately exposed to
hWJSCs (0.5 to10 x104 cells in lymphoma medium), hWJSC-CM (supplemented
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with 10% heat inactivated FBS (Biochrom) and 1% antibiotic/antimycotic mixture;
0.5 to 2 ml)  and hWJSC-CL (15 g/mL in lymphoma medium; 0.5 to 2 ml) for 48h
in 24-well plates or T25 culture flasks at 370C in a 5% CO2 atmosphere. The
lymphoma cells were then evaluated for morphology (phase contrast inverted
optics), viability and proliferation rate (MTT, BrdU and Ki67), cell survival
(Annexin V-FITC and live/dead analysis) and cell cycle analysis.
Exposure of hWJSC-CM and hWJSC-CL to hBMMSCs
To evaluate whether hWJSCs or its extracts would harm the bone marrow,
hBMMSCs were exposed to the chemotherapeutic agents VP-16 (100 M)
(control), hWJSC-CM (100%) and hWJSC-CL (15 g/mL) for 6 days with change
of respective medium after 72 h. The cells were then evaluated for cell
morphology, cell viability (MTT) and cell survival (percentage of PI+ cells).
2.2.5 Experimental Analysis Test
Cell viability (MTT assay)
The lymphoma (Ramos) cells were collected, washed once with PBS (-),
centrifuged at 300 x g and then re-suspended in 100 L growth media. 10 µl [3-
(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide] (MTT, 0.5 mg/ml)
(Duchefa Biochemie B.V., Haarlem, Netherlands) was added to the medium for
each sample and the tubes were incubated overnight at 37oC in 5% CO2. The cell
suspension was then centrifuged at 1,500 x g for 5 min, medium decanted and
100 µl of DMSO reagent (Sinopharm Chemical Reagent Co.Ltd) added to the cell
pellet. The cells were dispensed into 96-well assay plates (NUNC, Rochester, NY)
and incubated in the dark at 37oC for 10 min. Absorbance at 570 nm against a
reference wavelength of 630 nm was measured using a spectrophotometer
microplate reader (mQuant; BioTek, Winooski, VT, USA).




The bromodeoxyuridine (BrdU) assay was carried out on the lymphoma cells
using a commercial kit according to the manufacturer's instructions (Cell
Signaling Technology, Danvers, MA). Briefly, the lymphoma cells were first
separately exposed to hWJSCs, hWJSC-CM and hWJSC-CL for 48 h in medium
containing 1X BrdU. The cell suspension was collected, washed once with PBS (-)
before resuspending the cell pellet in 100 L of the fixation/denaturing solution for
30 min at room temperature and centrifuged at 300 x g. After removing the
solution, 100 µL of 1X BrdU detection antibody solution was added and incubated
at room temperature for 1h. The cells were then washed with 1X wash buffer
before the addition of 100 µL of 1X HRP-conjugated secondary antibody solution
for 30 min at room temperature. The cells were washed again with 1X wash
buffer before addition of 100 L of TMB substrate for 30 min at room temperature.
Finally, 100 µL of STOP solution was added to the cells and BrdU levels
measured using a spectrophotometer microplate reader (mQuant; BioTek) at
450nm wavelength.
Ki67+ analysis
The lymphoma cells were collected, washed once with PBS (-), centrifuged at
300 x g for 5 min and then fixed in cold 70% ethanol at -20oC overnight. The cells
were then washed and blocked with 10% normal goat serum (NGS) (Invitrogen)
for 10 min at room temperature. The cells were incubated with primary anti-
human Ki67 antibodies (1:100) (Biolegends, San Diego, USA) for 30 min at room
temperature. The cells were then incubated with anti-mouse IgG (H+L) Alexa
Fluor® 488 secondary antibody (1:750) (Invitrogen) for 30 min at room
temperature in the dark. The cells were centrifuged, cell pellet resuspended in 10%
Chapter 2: Tumoricidal Effect on Lymphoma Cells
32
NGS and filtered using a 40 m nylon strainer to remove any cell clumps before
analysis using CyAn ADP Analyser (Beckman Coulter).
Cell Death Analysis
Morphology
Changes in cell morphology of the lymphoma cells were monitored using inverted
phase contrast optics (Nikon Instruments, Tokyo, Japan).
Annexin V/PI assay
The lymphoma cells were collected, washed once with PBS (-), centrifuged and
then resuspended with 500 L of 1X Annexin V binding buffer (BioVision, Inc.,
Mountain View, CA). The cells were then stained with 1 L of Annexin V- FITC
(BioVision) and counterstained with 1L of propidium iodide (PI, Invitrogen), at
room temperature for 15 min, filtered with a 40 m nylon strainer and analyzed
using a CyAnTM ADP analyzer (Beckman Coulter, Fullerton, CA, USA).
Live/Dead cell assay
The live/dead cell assay was performed on the lymphoma cells using the
Live/Dead® Viability/Cytotoxicity Kit for mammalian cells (Invitrogen). A working
solution of component A (included in the kit) was first made by adding 1 l of
component A into 79 l of DMSO (Sinopharm Chemical Reagent Co.Ltd). 1 µL of
component A working solution and 2 µL of component B (supplied in the kit) were
added to 500 µl of PBS (-) to make the staining solution.
The cells were later collected, washed once with PBS (-), centrifuged and
resuspended in 500 µl of staining solution and then incubated for 15 min in the
dark. The cell suspension was filtered with a 40 µm nylon strainer and analyzed
using a CyAnTM ADP analyzer (Beckman).
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Cell cycle analysis
The lymphoma cells were collected, washed once with PBS (-), then fixed in cold
70% ethanol at -20oC overnight. The cells were later washed with PBS (-) once
before adding 20 g/mL PI, 100 µg/mL RNase A (AppliChem GmbH, Garmstadt,
Germany) to each sample and then incubated for 15 min at 37oC in 5% CO2. The
cell suspension was then filtered using a 40 µm nylon strainer to remove any cell
clumps before analysis using a CyAnTM ADP analyser (Beckman).
2.2.6 Statistical Analysis
All results were expressed as mean ± SEM and statistical signiﬁcance between
the groups was calculated using the two-tailed Student’s t-test (SPSS Statistic v
17.0 software package) (SPSS, Inc, IL).  The p-value of <0.05 was considered as
statistically significant.
2.3 Results
2.3.1 Co-culture of hWJSCs with lymphoma cells
In the beginining of the co-culture, both GFP-hWJSCs and red-labelled
lymphoma cells were separated [Fig. 2A (i)]. Sections of Z-stack images of the
Lab-Tek(R) Chambered #1.0 Borosilicate coverglass co-culture system after 24 h
of cell seeding showed that the red-labelled lymphoma cells were engulfed by the
green-labelled GFP-hWJSCs and were located in the cytoplasm [Fig. 2A (ii)]
compared to red-labelled CCD cells (controls) that were not engulfed by GFP-
hWJSCs (Fig. 2B). When sections of Z-stack images of female red-labelled
hWJSCs were examined after FISH, green Y-chromosome signals of male
lymphoma nuclei were observed in
the hWJSC cytoplasm (Fig. 2C).
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2.3.2 Cell Viability and Proliferation
Lymphoma cells showed significant decreases in cell viability after 48h exposure
to hWJSCs, hWJSC-CM and hWJSC-CL compared to controls. The cell viability
rates reduced to 0.91 ± 0.01, 0.65 ± 0.02 and 0.68 ± 0.04 for the hWJSCs,
hWJSC-CM and hWJSC-CL respectively (Fig. 3A). Lymphoma cells showed
significant decreases in cell proliferation after 48h exposure to hWJSCs, hWJSC-
CM (not significant) and hWJSC-CL compared to controls. The cell proliferation
rate using the BrdU assay decreased to 2.74 ± 0.07, 2.47 ± 0.09 and 2.48 ± 0.12
for the hWJSC, hWJSC-CM and hWJSC-CL respectively (Fig. 3B). The cell
Figure 2 Confocal images of hWJSCs co-cultured with Ramos cells
(A) (i) Image of GFP-tagged hWJSC and CellTrackerTM Red-labelled Ramos at zero time
point. (ii) Z-stack confocal images of GFP-hWJSCs co-cultured with CellTrackerTM Red-
labelled Ramos lymphoma cells. In horizontal and cross-sectional images. Note that
parts of lymphoma cells were localized within the cytoplasm of GFP-hWJSCs after 48h
(white arrows) (Magnification: 600X; Scale Bar: 15 µM). (B) Confocal image of GFP-
hWJSCs cocultured with CellTrackerTM Red-labelled skin fibroblasts. Note that both GFP-
hWJSCs and skin fibroblasts grow side by side (Magnification: 200X; Scale Bar: 20 µM).
(C) Horizontal and cross-sectional z-stack confocal images of female CellTrackerTM Red-
labelled hWJSCs showing Y-chromosome FISH signals (arrows) of male lymphoma cells
in hWJSC cytoplasm (Magnification: 1200X; Scale Bar: 10 µM).
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proliferation rate using the Ki67+ assay showed significant decreases in Ki67+
cells when exposed to hWJSC-CM or hWJSC-CL for 48h. The percentage of
Ki67+ cells were 71.28 ± 3.51% and 83.91 ± 2.3% for the hWJSC-CM and
hWJSC-CL arms respectively (Fig. 3C).
Figure 3 Cell viability and cell proliferation assay of Ramos lymphoma cells
(A) Cell viability (MTT assay) of Ramos lymphoma cells exposed to hWJSCs, hWJSC-
CM and hWJSC-CL. Note significant decrease in cell viability (normalized to control)
when lymphoma cells were exposed to hWJSCs, hWJSC-CM and hWJSC-CL for 48h.
(B) Cell proliferation (BrdU assay) of lymphoma cells exposed to hWJSCs, hWJSC-CM
and hWJSC-CL.  Note significant decrease in cell proliferation when lymphoma cells
were exposed to hWJSCs and hWJSC-CL for 48h. (C) Cell proliferation (Ki67 assay) of
lymphoma cells exposed to hWJSCs, hWJSC-CM and hWJSC-CL. Note significant
decrease in the percentages of Ki67+ lymphoma cells when exposed to hWJSC-CM and
hWJSC-CL for 48h. All values in (A-C) are expressed as mean ± SEM of 3 different
experiments. Asterisk (*) indicates statistical significance of p<0.05.
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2.3.3 Cell Death Analysis
The lymphoma cells after 48h exposure to hWJSCs, hWJSC-CM or hWJSC-CL
showed morphological changes like degeneration and shrinkage indicating cell
death (Fig. 4A).
The Annexin V/PI assay of lymphoma cells exposed to hWJSCs showed no
significant differences in the percentage of late apoptotic cells (AV+PI+ cells) but
there were significant increases in the percentages of AV+PI+ lymphoma cells
when exposed to hWJSC-CM or hWJSCs-CL for 48 h. The percentage of late
apoptotic cells after 48 h of treatment were 4.8 ± 0.30%, 7.31 ± 0.02% and 13.8 ±
1.76% for the hWJSCs, hWJSC-CM and hWJSC-CL arms respectively (Fig. 4B).
The live/dead assay of lymphoma cells exposed to hWJSCs showed no
significant differences in the percentage of dead cells but significant increases in
the percentages of dead lymphoma cells were observed when they were
exposed to hWJSC-CM or hWJSCs-CL for 48h. The percentages of dead cells
after treatment were 5.6 ± 0.28% and 8.4 ± 1.18% for hWJSC-CM and hWJSC-
CL respectively (Fig. 4C).
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Figure 4 Cell death assays of Ramos lymphoma cells
(A) Phase contrast images of Ramos lymphoma cells exposed to hWJSCs, hWJSC-CM
and hWJSC-CL. (a) Low magnification and (b) Inset enlarged: Lymphoma cells show
typical spherical morphology in controls. (c, e, g) Low magnification and (d, f, h) Inset
enlarged: Increased cell death (black arrows) were observed when lymphoma cells were
exposed hWJSCs, hWJSC-CM and hWJSC-CL for 48h (Magnification 100X; Scale Bar:
100µM) (B) Annexin V/PI assay of lymphoma cells exposed to hWJSCs, hWJSC-CM and
hWJSC-CL. No significant differences in percentages of late apoptotic AV+PI+ lymphoma
cells were observed between hWJSC and control arms. However, significant increases in
AV+PI+ lymphoma cells were observed when exposed to hWJSC-CM and hWJSC-CL.
(C) Viability (Live/Dead assay) of lymphoma cells exposed to hWJSCs, hWJSC-CM and
hWJSC-CL. No significant differences in the percentages of dead cells between hWJSC
and control arms were observed but significant increases in the percentages of dead cells
were observed in lymphoma cells exposed to hWJSC-CM and hWJSC-CL for 48h. All
values in (B-C) are expressed as mean ± SEM of 3 different experiments. Asterisk (*)
indicates statistical significance of p<0.05.
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2.3.4 Cell Cycle Analysis
Evaluation of the cell cycle of lymphoma cells showed increases in the sub-G1
and S phases when exposed to hWJSCs, hWJSC-CM or hWJSC-CL. The rates
of increase in sub-G1 cells compared to controls were hWJSCs: 1.41 ± 0.24,
hWJSC-CM: 4.77 ± 0.77 and hWJSC-CL: 6.87 ± 1.45. However, only the
increase observed for the hWJSC-CM arm was statistically significant (Fig. 5A).
The rates of increase in S phase cells compared to controls were hWJSCs: 1.10
± 0.04, hWJSC-CM: 1.19 ± 0.02 and hWJSC-CL: 1.14 ± 0.01. The increases
observed with hWJSC-CM and hWJSC-CL were statistically significant (Fig. 5B).
There was also a significant decrease in G2/M phase lymphoma cells when
exposed to hWJSCs, hWJSC-CM or hWJSC-CL.  The rates of decrease in G2/M
phase cells compared to controls were hWJSCs: 0.73 ± 0.07, hWJSC-CM: 0.61 ±
0.03 and hWJSC-CL: 0.57 ± 0.04 (Fig. 5C).
Figure 5 Cell cycle analysis of Ramos lymphoma cells
(A-C) Cell Cycle analysis of Ramos lymphoma cells exposed to hWJSCs, hWJSC-CM
and hWJSC-CL. Increased percentages (normalized to control) of lymphoma cells were
observed at Sub-G1 (A) and S phases (B) when they were exposed to hWJSCs,
hWJSC-CM and hWJSC-CL. Lower percentages of lymphoma cells were observed in
G2/M phase (C) when they were exposed to hWJSCs, hWJSC-CM and hWJSC-CL. All
values are expressed as mean ± SEM of 3 different experiments. Asterisk (*) indicates
statistical significance of p<0.05.
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2.3.5 Effect on adult BMMSCs
When green GFP-hWJSCs were co-cultured with red CTR-stained hBMMSCs no
engulfment or inhibition of the hBMMSCs by hWJSCs were observed. The GFP-
hWJSCs and CTR-stained hBMMSCs were seen to grow side by side in the
tissue culture plates when observed under fluorescent confocal microscopy (Fig.
6A). Additionally, treatment of hBMMSCs for 6 days with hWJSC-CM and
hWJSC-CL showed no cell death unlike the exposure to the chemotherapeutic
agent etoposide (VP-16) (Fig. 6B). The MTT assay on the hBMMSCs showed
significant decreases in cell viability after 6 days when exposed to hWJSC-CL
(15 g/mL) and VP-16. However, cell viability was not significantly decreased in
hBMMSCs exposed to hWJSC-CM (Fig. 6C). hBMMSCs showed significantly
increased percentages of PI+ cells after 6 days of culture in VP-16 compared to
hWJSC-CM and hWJSC-CL. The percentages of PI+ cells were 2.76 ± 0.15,
21.74 ± 0.24, 4.44 ± 0.41 and 4.33 ± 0.13 for controls, VP-16, hWJSC-CM and
hWJSC-CL respectively (Fig. 6D).
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Figure 6 Effects of hWJSCs and its extract on adult BM-MSCs
(A) Confocal images of GFP-hWJSCs cocultured with CellTrackerTM Red-labelled human
bone marrow MSCs (hBMMSCs). Both GFP-hWJSCs and red labeled hBMMSCs grew
side by side with no inhibition or engulfment of either cell type (Magnification: 200X;
Scale Bar: 20 µm). (B) Phase contrast images of hBMMSCs exposed to VP-16,
hWJSC-CM and hWJSC-CL for 6 days. No hBMMSC cell death was observed in (a)
controls, (c) hWJSC-CM and (d) hWJSC-CL dishes but increased cell death was
observed in (b) VP-16 positive controls (black arrows) (Magnification: 400X; Scale Bar:
200 µm) (C) Cell viability (MTT assay) of hBMMSCs exposed to VP-16, hWJSC-CM and
hWJSC-CL. Significantly high cell viability (normalized to controls) measured in delta OD
(differences in absorbance reading at 570 nm with reference wavelength 630 nm) were
observed when lymphoma cells were exposed to hWJSC-CM or hWJSC-CL compared
to VP-16 exposure. (D) Cell death analysis (PI) of hBMMSCs exposed to VP-16,
hWJSC-CM and hWJSC-CL for 6 days.  Significant decreases in the percentages of
dead PI+ hBMMSCs were observed when exposed to hWJSC-CM or hWJSC-CL as
compared to VP-16 exposure. All values in (C-D) are expressed as mean ± SEM of 3
different experiments. Asterisk (*) indicates statistical significance of p<0.05.
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2.4 Discussion
Human Wharton jelly stem cells (hWJSCs) are a homogeneous population of
primitive mesenchymal-like stem cells that have been trapped in the gelatinous
connective tissue matrix of the Wharton’s jelly following their migration to and
from the placenta during early embryogenesis 5. However, the actual role of
these hWJSCs during embryonic and foetal development is not clear. Yang and
Chao 147 recently postulated that their paradoxical tumoricidal properties
suggested that they are a natural defence mechanism against the migration of
metastasizing cancer cells from the mother via the umbilical cord since the
incidence of malignant cancer cells in the fetus was significantly low in pregnant
mothers suffering from  ovarian carcinoma, mammary carcinoma, sacromas or
chorocarcinomas of the placenta 147-152.
The results of this chapter confirmed that hWJSCs have tumoricidal effects not
only on solid tumours but also on hematological malignancies. The mechanisms
whereby the hWJSCs attenuate the growth of the lymphoma cells appeared to be
both by direct cell-to-cell engulfment and apoptosis as well as by non-cellular
contact via secretions from the hWJSCs because the hWJSC extracts
(conditioned medium and lysate) were also able to inhibit lymphoma cell growth.
The former engulfing mechanism observed under time lapse imaging appears to
be different from an engulfing mechanism reported recently by another group
where they reported that mammary carcinoma cells engulfed hWJSCs via an
entosis mechanism and then undergo disintegration 56. These inconsistencies
may be related to the differences in size of lymphoma and mammary carcinoma
cells. Lymphoma cells being small (about 5-12 µm) would be unable to engulf the
larger hWJSCs (about 15-20 µm). In addition, this engulfment-like mechansim do
mimic that of macrophages and it have been shown that macrophages
phagocytosed tumor cells and later act as a antigen presenting cells to bridge the
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innate and adaptive immune response 153,154. It would be interesting to see
whether hWJSCs could also act as a antigen presenting cells after engulfment
lymphoma to stimulate host immune system too. With respect to the latter non-
contact mechanism the higher percentages of cells in the sub-G1 and lower
percentages in G2/M phases in the cell cycle analysis suggested that certain
components released by hWJSCs arrest cell division of lymphoma cells in the S
phase.
Most chemotherapy or radiation treatment regimens administered to lymphoma
patients often result in damage to the bone marrow, gastrointestinal tract, heart,
brain and kidney 128,155-157. The bone marrow microenvironment made up of
mesenchymal stem cells (MSCs) and extracellular matrix (ECM) served as an
important hematopoietic niche which influenced the abilities of hematopoietic
stem cells (HSCs) or hematopoietic progenitor cells (HPCs) to home, engraft,
self-renew and differentiate via direct cell-cell contact and secretion of
hematopoietic growth factors 119,127,134,135. The use of aggressive
chemotherapeutic agents or radiation-conditioning regimes prior to HSC
transplantation often cause damage to the bone marrow microenvironment and
have a profound influence on HSC engraftment kinetics and the outcome of
patient treatment 126,130-133. The non-specific inhibition of growth of normal cells by
conventional regimes is an unwanted side effect. Also, previous studies indicated
that aggressive chemotherapeutic or radiation conditioning regimens prior to
HSC transplantation often caused irreversible damage to the stromal cells in the
hematopoietic microenvironment ultimately affecting HSC engraftment and
reconstitution after transplantation 127,158-161. Co-transplantation of HSCs together
with hBMMSCs or MSCs from other sources which repaired or reconstituted the
bone marrow microenvironment often improved the functional outcome of
transplantation both in animal models and human clinical trials 23,112,117,129,162. The
Chapter 2: Tumoricidal Effect on Lymphoma Cells
43
results of the present study showed that hWJSCs, hWJSC-CM inhibited
lymphoma cells but not hBMMSCs. Therefore, they would be safe options for not
only targeting cancerous cells but also reconstitution of the bone marrow
hematopoietic niche during co-transplantaion with HSCs in patients with
hematological malignancies.
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Chapter 3: H2O2 mediated Tumoricidal Effects on Lymphoma Cells
3.1 Introduction
Human Wharton jelly stem cells (hWJSCs) which share the same developmental
origin as adult bone marrow MSCs get trapped in the gelatinous connective
tissue matrix of the WJ during migration to and from the placenta during early
embryogenesis 5. It has been reported that hWJSC extracts inhibited the growth
of mammary carcinoma, osteosarcoma, cholangiocarcinoma and bladder cancer
in vitro or in vivo 9,57-59,61. These studies have suggested that the tumoricidal
effects of hWJSCs or its extracts may be mediated by a variety of mechanisms
with probably each cancer cell type being inhibited by a separate mechanism.
Kawabata et al. 58 reported that rat WJSCs secreted monocyte chemotactic
protein-1 (MCP-1) that modulated the endogenous immune response to
attenuate mammary carcinoma growth. It was reported that hWJSC-CM or its
microvesicles attenuated cholangiocarcinoma or bladder cancer growth via the
inhibition of phosphoinositide 3-kinase, Akt and Wnt/ B-catenin signalling
pathways 59,61.
Increasing evidence has suggested that the concentration of intracellular H2O2
plays a crucial dual role in cancer cell development 163,164. At low concentrations,
H2O2 played a physiological role in cell signaling, and a constitutive increase in
H2O2 has been associated with malignant transformation by exerting increased
proliferation 165, DNA damage 166, genetic instability 167, apoptosis resistance 168,
angiogenesis 169 and metastasis in cancer cells 165. There is also compelling
evidence that high H2O2 concentration could efficiently and specifically induce
cancer cell death after treatment with H2O2-generating drugs 164,170,171. As the
cellular level of H2O2 in animal cells are carefully regulated by key antioxidant
enzymes such as Mn+2- dependent superoxide dismutase (SOD), glutathione
peroxidase (GPx), catalase and thioredoxin peroxidase (TPx), new cancer
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therapies targeting these H2O2-regulating enzymes to increase intracellular H2O2
level selectively in cancer cells will be an attractive clinical approach. We recently
postulated that hWJSC-CM modulated changes in key oxidative stress enzyme
activities involved in maintaining hydrogen peroxide (H2O2) levels as a
mechanism to attenuate Burkitt lymphoma growth 172.
As such, the aim of this chapter is to investigate the tumoricidal effect of a 3kDa
MWCO concentrate of hWJSC-CM on two B-cell lymphoma cell lines (Ramos
and Toledo) for cell viability, cell death, mitochondria health, apoptosis, oxidative
stress enzyme and reactive oxidative species (ROS) levels to explore whether
the tumoricidal effects are H2O2 mediated.
3.2 Material and Methods
3.2.1 Cell Culture
Human Wharton's jelly stem cells (hWJSCs)
After informed patient consent and approval from the Institutional Domain
Specific Review Board (DSRB), hWJSC lines were derived from human umbilical
cords. hWJSCs were cultured in hWJSC medium comprising of 80% DMEM, 20%
fetal bovine serum (FBS) (Biochrom, Berlin, Germany),  1% non-essential amino
acids, 2 mM L-glutamine, 0.1 mM β-mercaptoethanol, 1% insulin-transferrin-
selenium, antibiotic/antimycotic mixture (Invitrogen Life Technologies, Carlsbad,
CA) and 16 ng/ml basic fibroblast growth factor (Millipore Bioscience, Temecula,
CA).
Human lymphoma cells (Ramos and Toledo)
Approval for purchase and use of commercial human Burkitt's lymphoma cell
lines (Ramos, CRL 1596) and diffuse large B cell lines (Toledo, CRL-2631)
(American Type Culture Collection, ATCC, Rockville, MD, USA) was granted by
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the National University of Singapore Institutional Review Board (NUS-IRB). The
cell lines were thawed and initially cultured in lymphoma medium consisting of
RPMI medium (Thermo Scientific) supplemented with 10% heat inactivated FBS
(Biochrom) and 1% antibiotic/antimycotic mixture (Invitrogen).
Bone marrow mesenchymal stem cells (hBMMSCs)
Approval for purchase and use of commercial adult hBMMSCs (Lonza, Allendale,
NJ, USA) was granted by the NUS-IRB. The cells were thawed and cultured in
medium consisting of DMEM-high glucose (Invitrogen) supplemented with 10%
FBS (Biochrom), 1% antibiotic/antimycotic mixture and 2 mM L-glutamine
(Invitrogen).
3.2.2 Preparation of hWJSC conditioned medium (hWJSC-CM)
The preparation of hWJSC-CM was carried out as previously described 8,9,57,172.
Briefly, early passages of hWJSCs (3P to 5P) were first cultured in hWJSC
medium until 70% confluency. The medium was then replaced with basal RPMI
medium (Thermo Scientific) supplemented with 1% antibiotic/antimyotic mixture
(Invitrogen). After 48 h, the medium (hWJSC-CM) was collected, filtered through
a 0.22 M filter (Millipore) and stored at -80oC until use.
3.2.3 Preparation of hWJSC-CM concentrate
Twenty ml aliquots of the 48h hWJSC-CM were concentrated by centrifuged by
placing them in 100kDa, 50kDa, 30kDa, 10kDa, 5kDa and 3kDa MWCO Vivaspin
20 tubes (Sartorius, Goettingen, Germany) and centrifugation at 3,000 x g for 1-2
h. The concentrates which were retained at the collection column were collected
and stored at -20oC. The protein concentration of concentrated hWJSC-CM was
estimated using the Bradford assay (Biorad, USA).
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3.2.4 Exposure of Ramos and cells to 3kDa to 100kDa hWJSC-CM
concentrates
Ramos cells (1 x 105) were exposed to different hWJSC-CM MWCO
concentrates (equal volumes) supplemented with 10% heat inactivated FBS, 1%
antibiotic/antimycotic mixture and 20 mM L-glutamine (Invitrogen) for 48 h in 12-
well plates at 370C in a 5% CO2. The cells were then evaluated for cell viability
(MTT).
3.2.5 Exposure of Ramos cells to 3kDa MWCO hWJSC-CM
concentrate and flow-through fractions
Ramos cells (1 x 105) were exposed to equal volume of 3kDa MWCO
concentrate and flow-through supplemented with 10% heat inactivated FBS, 1%
antibiotic/antimycotic mixture and 20mM L-glutamine for 48 h in 12-well plates at
370C in a 5% CO2. The cells were then evaluated for cell viability (MTT).
3.2.6 Exposure of Ramos and cells to 3kDa hWJSC-CM concentrate
and heat-inactivated 3kDa hWJSC-CM concentrate
Equal volume of 3kDa concentrates were heat inactivated at 56oC and 80oC for
30 mins. Ramos cells (1 x 105) were then exposed to equal volume of 3kDa
concentrates, 3kDa concentrates that were heat-inactivated at  56oC (HI-56) and
3kDa concentrates that were heat-inactivated at 80oC (HI-80) supplemented with
10% heat inactivated FBS, 1% antibiotic/antimycotic mixture and 20mM L-
glutamine for 48 h in 12-well plates at 370C in a 5% CO2. The cells were then
evaluated for cell viability (MTT).
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3.2.7 Experimental Design
Exposure of Ramos, Toledo and hBMMSCs to 3kDa MWCO hWJSC-CM
concentrates
Ramos and Toledo cells, (1 x 105 each) were exposed to 3kDa MWCO hWJSC-
CM concentrates (3kDa hWJSC-CM concentrates, 500 g/mL) for 48h at 370C in
a 5% CO2. The lymphoma cells were then evaluated for viability (MTT assay),
cell death analysis (PI+ and mitochondrial membrane potential), apoptosis
(caspases 3, 8, 9), functional activity of key oxidative stress enzymes [superoxide
dismutase, glutathione peroxidase, catalase and thioredoxin peroxidase],
intracellular and extracellular hydrogen peroxide levels and oxidative stress
analysis (mitochondrial superoxides, hydroxyl/peroxynitrile radicals, lipid
peroxidation). Similar experiments were also carried out with hBMMSCs.
3.2.8 Experimental Analysis Test
Cell viability (MTT assay)
For cell viability, the treated Ramos, Toledo, hBMMSC cells and controls were
collected and then re-suspended in 100 L lymphoma media with 10 µl [3-(4, 5-
dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide] (MTT, 0.5 mg/ml) (Duchefa
Biochemie B.V., Haarlem, Netherlands) and incubated for at least 4h at 37oC in a
5% CO2. The cell suspension was then centrifuged at 1,500 x g for 5 min and cell
pellet resuspended in 100 µl of DMSO reagent (Sinopharm Chemical Reagent
Co.Ltd) and dispensed into 96-well plates (NUNC, Rochester, NY). The plates
were incubated in the dark at 37oC for 10 min. Absorbance at 570 nm against a
reference wavelength of 630 nm was measured using a spectrophotometer
microplate reader (mQuant; BioTek, Winooski, VT, USA).
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Cell Death Analysis
Propidium Iodide (PI+ Assay)
The treated and control cells were analyzed for PI positive cells using the
propidium iodide molecular probe (Invitrogen). Briefly, the cells were collected
and then resuspended with 500 L of culture medium containing 1 µL of PI (1.0
mg /mL, Invitrogen) at 37oC for 30 min. The cells were filtered with a 40 m
strainer and analyzed with CyAnTM ADP analyzer (Beckman Coulter, Fullerton,
CA, USA).
Mitochondrial membrane potential assay ()
The mitochondrial membrane potential () of the treated and control cells were
analyzed using MitoTracker(R) Red CMXRos (Invitrogen). Briefly, the cells were
collected and then incubated with 500 L of culture medium containing 1 µL of 1
mM MitoTracker(R) Red CMXRos stock solution (Invitrogen) at 37oC for 30 min.
The cells were filtered with a 40 m strainer and analyzed with CyAnTM ADP
analyzer (Beckman Coulter).
Apoptosis analysis
The treated and control cells were analyzed for caspase 3, 8, 9 activities using
the CellEventTM Caspase-3/7 Green Detection Reagent (Invitrogen), Vybrant(R)
FAM Caspase-8 Assay Kit (Invitrogen) and Caspase 9 (active) FITC Staining Kit
(Abcam, Cambridge, UK). Briefly, for caspase 3, the cells were collected and
then incubated with 500 L of culture medium with 0.125 L of the 2.0 mM
CellEventTM Caspase-3/7 Green Detection Reagent at 37oC for 30 min. For
caspase 8, the cells were collected and then resuspended with 300 L of culture
medium with 10 L of 30X FLICA at 37oC for 60 min. For caspase 9, cells were
collected and then incubated with 300 L of culture medium with 1 L of 30X
FITC-LEHD-FMK at 370C for 60 min. The cells were then washed, filtered with a
40 m strainer and analyzed with a CyAnTM ADP analyzer (Beckman Coulter).
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Oxidative stress enzyme analysis
The treated and control cells were collected and lysed using a mammalian cell
extraction kit without protease cocktail and dithiothreitol (BioVision).  Briefly, the
cell pellet was incubated with 1000 L of cell lysis buffer at 4oC for 45 min. The
mixture was then centrifuged at 15, 000 x g for 15 min. The supernatant was
collected and stored at -80oC until further analysis. Protein concentration of cell
lysates were estimated using the conventional Bradford protein assay (Biorad).
These cellular lysates were used for the analysis of superoxide dismutase,
glutathione peroxidase (Sigma), catalase (Invitrogen) and thioredoxin peroxidase
(Redoxica) activites using commercial kits.
Superoxide dismutase (SOD)
Briefly, for the SOD assay, 80 µL of the cell lysate was added to 200 µL of WST
and 20 µL of enzyme working solutions and incubated at 37oC for 30 min. Cell
lysis buffer was used as a blank reference. Absorbance at 450 nm was measured
using a micro plate ELISA reader (mQuant, BioTek).
Glutathione peroxidase (GPx)
Briefly for the GPx assay, 50L of the cell lysate was mixed with 890 L of GPx
assay buffer, 50 L NADPH assay reagents and 10 L t-Bu-OOH in 24-well
plates and changes in absorbance at 340 nm were measured
spectrophotometrically using a kinetic program (interval of 50 seconds, 6
readings) using a microplate ELISA reader (mQuant, BioTek). Cell lysis buffer
was used as a blank reference.
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Catalase
Briefly for catalase activity assay, 25 l of cellular lysate was mixed with 25 l of
40 M H2O2 in 96-well microreader plates and incubated at room temperature for
30 min. 50 l of HRP/Amplex Red reaction mixture reagent was then added into
each sample and incubated at 37oC for 30 min or longer. Cell lysis buffer was
used as a blank reference. Absorbance at 560 nm was measured using a
microplate ELISA reader (mQuant, BioTek).
Thioredoxin peroxidase (TPx)
Briefly, TPx activity was analyzed using the 2-Cys-Peroxiredoxin Activity Assay
Kit (Redoxica, Arkansas, USA). The treated and control cells were collected and
sonicated with a microtip sonicator on ice for 1 min with 10-15 seconds pulse in
the supplied assay buffer. The samples were then centrifuged at 12,000 x g at
40C for 20 min. The cell lysates (supernatant) were collected, quantified using the
Bradford assay and stored at -80oC. Briefly, for peroxiredoxin activity assay, 25
µL of the cell lysate was mixed with 91 µL of reaction buffer, 5 µL of thioredoxin,
25 µL NADPH, 2 µL thioredoxin reductase and 2 µL of substrate in 96-well plates
and changes in absorbance at 340 nm were measured spectrophotometrically
using a kinetic program (interval of 50 seconds, 6 readings) using a microplate
ELISA reader (mQuant, BioTek). Similar plates without the addition of thioredoxin
were used as reaction blanks. The 2-Cys-peroxiredoxin activity was then
calculated using the formula dA (Total-Reaction Blank)/0.0062 where dA=change
in absorbance (Reaction-Reaction Blank).
Hydrogen peroxide assay
The culture media from the treated and control arms were collected and stored at
-80oC. The treated and control cells were then collected and lysed as described
above.
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Briefly, for hydrogen peroxide assay, 50 l of cell lysate or 50 l of supernatant
was mixed with 50 l of HRP/Amplex Red reaction (Invitrogen) in a 96-well plate
and incubated at 37oC for 30 min or longer. Fluorescence readings using
excitation 560 nm and emission detection at 590 nm were measured using a




The treated and control cells were analyzed for mitochondrial superoxide using
the MitoSOXTM Red mitochondrial superoxide indicator (Invitrogen). Briefly, the
cells were collected and incubated with 100 L of culture medium containing 0.1
L of 5mM MitoSOXTM working solution at 37oC for 30 min. The cells were then
washed, filtered with a 40 m strainer and analyzed with CyAnTM ADP analyzer
(Beckman Coulter).
Hydroxyl radical and peroxynitrile anion
The treated and control cells were analyzed for highly reactive oxygen species
(hydroxyl radical and peroxynitrile anions) using 3'-(p-hydroxyphenyl) fluorescein
(HPF, Invitrogen). Briefly, the cells were collected and incubated with 100 L of
culture medium containing 0.2 L of 5 mM HPF at 37oC for 30 min. The cells
were then washed, filtered with a 40 m strainer and analyzed with CyAnTM ADP
analyzer (Beckman Coulter).
Lipid peroxidation
The treated and control cells were collected and stained using the Image-iT(R)
Lipid Peroxidation Kit based on the manufacturer's instructions (Invitrogen).
Briefly, the cells were collected and incubated with 100 L of culture medium
containing 1 L of 10 mM Image-iT(R) Lipid Peroxidation Sensor (Component A)
for 30 min at 37oC. The cells were then washed, filtered with a 40 m strainer
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before analysis using BD LSRFortessaTM (BD Bioscience, Heideberg, Germany)
with excitation/emission 581/591 nm and 488/510 nm.
3.2.9 Statistical Analysis
All results were expressed as mean (fold change) ± SEM and statistical
signiﬁcance between the groups was calculated using the one way ANOVA or
two-tailed Student’s t-test (SPSS Statistic v 17.0 software package) (SPSS, Inc,
IL).  The p-value of <0.05 was considered as statistically significant.
3.3 Results
3.3.1 Evaluation of the best MWCO of hWJSC-CM that inhibit
lymphoma cell growth
The results showed that there were significant reductions in cell viability of
Ramos cells after 48 h across all MWCO concentrates compared to controls.
Additionally, the 3kDa MWCO concentrate had the greatest inhibition of cell
viability.  The fold changes for cell viability normalized to controls were 0.86 ±
0.001, 0.84 ± 0.016, 0.71 ± 0.005, 0.82 ± 0.014, 0.67 ± 0.018, 0.58 ± 0.019 for
100kDa, 50kDa, 30kDa, 10kDa, 5kDa and 3kDa concentrates respectively (Fig.
7).
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3.3.2 Evaluation of 3kDa hWJSC-CM concentrate and flow-through
factions on lymphoma cells
The concentrated hWJSC-CM fraction and flow-through (FT) fractions were
collected as shown in Fig. 8A (Fig. 8A). There was significant decreases cell
viability after 48h exposure to 3kDa hWJSC-CM concentrates compared to the
FT fractions and controls. The cell viability rates for the concentrated hWJSC-CM
were 0.60 ± 0.05, compared to 1.14 ± 0.02 for FT and controls (Fig. 8B).
Figure 7 MWCO Cell viability of Ramos lymphoma cells
Cell viability (MTT assay) of Ramos lymphoma cells exposed to different MWCOs’
concentrates of hWJSC-CM for 48 h. Note significant decreases fold changes of cell
viability (normalized to control) in the Ramos cells exposed to the different MWCO
concentrates. Values are expressed as mean ± SEM of 3 different experiments.
Asterisk (*) indicates statistical significance of p<0.05.
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3.3.3 Evaluation of 3kDa hWJSC-CM concentrate and heat-inactivated
3kDa hWJSC-CM concentrate on lymphoma cells
The 3kDa concentrated hWJSC-CM fraction were heat-inactivated at 56oC (HI-56)
and 80oC (HI-80). The lymphoma cells had significant decreased in cell viability
after 48h exposure to concentrated hWJSC-CM (hWJSC-CM) and heat-
inactivated 3kDa hWJSC-CM concentrates (HI-56/HI-80) compared to control.
There were no significant difference in cell viability between the concentrated
hWJSC-CM and 3kDa hWJSC-CM concentrates heat-activated at both 56oC (HI-
56) and 80oC (HI-80). The fold change in cell viability rates normalised to control
for hWJSC-CM, HI-56 and HI-80 were 0.86 ± 0.009), 0.90 ± 0.01 and 0.84 ± 0.02
respectively (Fig. 9).
Figure 8 Cell viability of Ramos lymphoma cells exposed to CM and FT
(A) Schematic diagram showing VIVASPIN centrifugation of hWJSC-CM to separate
concentrated (CM) and flow-through (FT) fractions. (B) Cell viability (MTT assay) of
Ramos lymphoma cells exposed to CM and FT fractions for 48h. Significant decreases in
cell viability of lymphoma cells when exposed to CM compared to FT and controls. The
values are expressed as mean ± SEM of 3 different experiments. Asterisk (*) indicates
statistical significance of p<0.05.
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3.3.4 Evaluation of 3kDa hWJSC-CM concentrate on cell viability,
mitochondrial membrane potential and cell death in lymphoma cells
Both Ramos and Toledo lymphoma cells had significant reductions in cell viability,
significant increases in the percentage of cells positive for PI and significant
reductions in mitochondrial membrane potential but there were no significant
changes to hBMMSCs.
The fold changes for cell viability normalized to their respective controls were
Ramos cells (0.70 ± 0.05), Toledo cells (0.84 ± 0.03) and hBMMSCs (1.0 ± 0.03)
(Fig. 10A).
The fold changes for the percentages of PI+ cells normalized to their respective
controls were Ramos (1.50 ± 0.11), Toledo (1.76 ± 0.03) and hBMMSCs (1.07 ±
0.04) (Fig. 10B).
Figure 9 Cell viability of Ramos lymphoma cells exposed to heat-inactivated 3kDa
hWJSC-CM concentrates
Cell viability (MTT assay) of Ramos lymphoma cells exposed to heat-inactivated 3kDa
concentrates of hWJSC-CM for 48 h. No significant decreases fold changes of cell
viability (normalized to control) in the Ramos cells exposed to hWJSC-CM concentrates
and heat-inactivated hWJSC-CM concentrates. Note no significant difference (N.S) in
cell viability between hWJSC-CM concentrates compared to heat-inactivated hWJSC-
CM concetrates Values are expressed as mean ± SEM of 3 different experiments.
Asterisk (*) indicates statistical significance of p<0.05.
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The fold changes for  normalized to their respective controls were Ramos
(0.86 ± 0.015), Toledo (0.95 ± 0.003) and hBMMSCs (1.00 ± 0.002) (Fig. 10C).
Figure 10 Cell viability, cell death and mitochondria membrane potential of
Ramos, Toledo and hBM-MSCs
(A) Cell viability fold changes (MTT assay) of Ramos, Toledo and hBMMSCs exposed to
500 µg/ml of the 3kDa MWCO concentrate for 48 h. Note significant decreases in cell
viability (normalized to control) when Ramos and Toledo cells were exposed to the 3kDa
MWCO concentrate with no significant changes in hBMMSCs. (B) (i) Representative
flow cytometry histogram for cell death analysis. (ii) Cell death (PI+ assay) fold changes
of Ramos, Toledo and BMMSCs exposed to 500 µg/ml of the 3kDa MWCO concentrate
for 48 h. Note significant increases in cell death (normalized to control) of Ramos and
Toledo cells exposed to the 3kDa MWCO concentrate with no significant changes in
hBMMSCs. (C) (i) Representative flow cytometry histogram for mitochondria membrane
potential analysis. (ii) Mitochondrial membrane potential fold changes of Ramos, Toledo
and hBMMSCs exposed to 500 µg/ml of the 3kDa MWCO concentrate for 48 h. Note
significant decreases in mitochondrial membrane potential (normalized to control) in the
Ramos and Toledo cells exposed to the 3kDa MWCO concentrate with no significant
changes in hBMMSCs. All values in (A-C) are expressed as mean ± SEM of 3 different
experiments. Asterisk (*) indicates statistical significance of p<0.05.
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3.3.5 Evaluation of 3kDa hWJSC-CM concentrate on apoptosis in
lymphoma cells
Both Ramos and Toledo cells had significant increases in activated caspase 3,
caspase 8 and caspase 9 after 48 h of exposure to the 3kDa MWCO concentrate
but there were no significant changes to the hBMMSCs. The fold changes in
activated caspase 3 normalized to their respective controls were Ramos (1.70 ±
0.01), Toledo (1.53 ± 0.12) and hBMMSCs (0.98 ± 0.10) (Fig. 11A). The fold
changes in activated caspase 8 normalized to their respective controls were
Ramos (1.80 ± 0.02), Toledo (1.50 ± 0.09) and hBMMSCs (0.77 ± 0.2) (Fig.
11B).The fold changes in activated caspase 9 normalized to their respective
controls were Ramos (3.00 ± 0.15), Toledo (1.62 ± 0.08) and hBMMSCs (1.25 ±
0.05) (Fig. 11C).
Figure 11 Apoptotic analysis of Ramos, Toledo and hBM-MSCs
(A-C) Apoptosis analysis fold changes of Ramos, Toledo and hBMMSC cells exposed to
500 µg/ml of the 3kDa MWCO concentrate for 48 h. Note significant increases
(normalized to control)  in activated caspase 3 (A) and activated caspase 8 (B) when
Ramos and Toledo cells were exposed to the 3kDa MWCO concentrate with no
significant changes in hBMMSCs. Note significant increases (normalized to control) of
activated caspase 9 (C) in Ramos, Toledo and hBMMSCs.  All values in (A-C) are
expressed as mean ± SEM of 3 different experiments. Asterisk (*) indicates statistical
significance of p<0.05.
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3.3.6 Evaluation of 3kDa hWJSC-CM concentrate on oxidative stress
enzyme in lymphoma cells
The Ramos, Toledo and hBMMSC cells had significant increases in SOD
functional activity after 48 h of exposure to 500 g/ml of the 3kDa MWCO
concentrate. The fold changes in SOD functional activity normalized to its
respective controls were Ramos (1.43 ± 0.04), Toledo (1.28 ± 0.05) and
hBMMSCs (1.19 ± 0.02) (Fig. 12A).
The Ramos, Toledo and hBMMSC cells had significant decreases in GPx and
catalase functional activity after 48 h exposure to the 3kDa MWCO concentrate.
The fold changes in GPx functional activity normalized to its respective controls
were for Ramos (0.68 ± 0.06), Toledo (0.88 ± 0.01) and hBMMSCs (0.95 ± 0.02)
(Fig. 12B).
The fold changes in catalase functional activity normalized to their respective
controls were Ramos (0.61 ± 0.06), Toledo (0.98 ± 0.003) and hBMMSCs (0.48 ±
0.03) (Fig. 12C).
Both Ramos and Toledo cells had decreased (not significant for Toledo) TPx
functional activity after 48 h of exposure to 500 g/ml of the 3kDa MWCO
concentrate with no significant changes to hBMMSC TPx functional activity. The
fold changes in TPx functional activity normalized to their respective controls
were Ramos (0.78 ± 0.07), Toledo (0.87 ± 0.003) and hBMMSCs (1.03 ± 0.10)
(Fig. 12D).
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3.3.7 Evaluation of 3kDa hWJSC-CM concentrate on hydrogen
peroxide levels in lymphoma cells
The Ramos, Toledo and hBMMSC cells had increased (not significant for Toledo
and hBMMSCs) intracellular and significant increased in extracellular H2O2 after
48 h exposure to 500g/ml of the 3kDa MWCO concentrate. The fold changes of
intracellular H2O2 normalized to their respective controls were Ramos (1.21 ±
0.03), Toledo (1.07 ± 0.03) and hBMMSCs (1.33 ± 0.06) (Fig. 13A). The fold
Figure 12 Oxidative stress enzymes functional activities analysis
(A) SOD functional activity fold changes of Ramos, Toledo and hBMMSC cells exposed
to 500 µg/ml of the 3kDa MWCO concentrate for 48h. Note significantly greater SOD
functional activity (normalized to control) was observed in Ramos, Toledo and hBMMSCs
when exposed to the 3kDa MWCO concentrate (B) GPx functional activity fold changes of
Ramos, Toledo and hBMMSC cells exposed to 500 µg/ml of the 3kDa MWCO
concentrate for 48h. Note significantly lower GPx activity (normalized to control) was
observed in the Ramos, Toledo and hBMMSC cells exposed to the 3kDa MWCO
concentrate (C) Catalase functional activity fold changes of Ramos, Toledo and
hBMMSCs exposed to 500 µg/ml of the 3kDa MWCO concentrate for 48h.  Note
significantly lower catalase activity (normalized to control) was observed in the Ramos,
Toledo and hBMMSC cells exposed to the 3kDa MWCO concentrate. (D) TPx functional
activity fold changes of Ramos, Toledo and hBMMSC cells exposed to 500 µg/ml of the
3kDa MWCO concentrate for 48h.  Note significantly lower TPx activity (normalized to
control) was observed in the Ramos and Toledo cells exposed to the 3kDa MWCO
concentrate with no significant changes in hBMMSCs. All values are expressed as mean± SEM of 3 different experiments. Asterisk (*) indicates statistical significance of p<0.05.
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changes of extracellular H2O2 normalized to their respective controls were Ramos
(3.42 ± 0.34), Toledo (1.57 ± 0.19) and hBMMSCs (1.23 ± 0.02) (Fig. 13B).
3.3.8 Evaluation of 3kDa hWJSC-CM concentrate on mitochondrial
superoxide, hydroxyl radical/peroxynitrile anion and lipid
peroxidation levels in lymphoma cells
The Ramos, Toledo and hBMMSCs had increases (not significant for Toledo) in
mitochondrial superoxide (.O2-) after 48 h exposure to 500 g/ml of the 3kDa
MWCO concentrate with no significant changes to the hBMMSCs. The fold
changes of mitochondrial superoxide (.O2-) normalized to their respective controls
were Ramos (4.30 ± 0.17), Toledo (1.28 ± 0.05) and hBMMSCs (1.08 ± 0.16) (Fig.
14A).
Both Ramos and Toledo cells had significant increases in hydroxyl
radical/peroxynitrile anion (.OH-/.OONO-) after 48 h exposure to the 3kDa MWCO
concentrate with no significant changes to the hBMMSCs. The fold changes
of .OH-/.OONO- (normalized to their respective controls were Ramos (4.64 ± 0.57),
Toledo (1.77 ± 0.13) and hBMMSCs (1.05 ± 0.03) (Fig. 14B).
Figure 13 Hydrogen peroxide analysis of Ramos, Toledo and hBM-MSCs
(A) Hydrogen peroxide fold changes in Ramos, Toledo and hBMMSC cells exposed to
500 µg/ml of the 3kDa MWCO concentrate for 48 h. There were significantly higher
intracellular hydrogen peroxide levels (normalized to control) in cell lysates (A) and
supernatants (B) of Ramos cells exposed to the 3kDa MWCO concentrate. All values
are expressed as mean ± SEM of 3 different experiments. Asterisk (*) indicates
statistical significance of p<0.05.
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Ramos, Toledo and hBMMSC cells had significant increases in lipid peroxidation
after 48 h exposure to the 3kDa MWCO concentrate. The fold changes of lipid
peroxidation normalized to their respective controls were Ramos (2.07 ± 0.12),
Toledo (1.45 ± 0.12) and hBMMSCs (1.10 ± 0.03) (Fig. 14C).
3.4 Discussion
In this study we first reported that exposing lymphoma cells to a 3kDa molecular
weight cut-off (MWCO) concentrate of hWJSC-CM induced the cell death in the
cancer cells compared to other molecular weight cut-offs. Further analysis
suggested that the bioactive molecules were larger than 3kDa as lymphoma cell
Figure 14 Oxidative stress analysis of Ramos, Toledo and hBM-MSCs
(A) Mitochondria superoxide fold changes in Ramos, Toledo and hBMMSC cells exposed
to 500 µg/ml of the 3kDa MWCO concentrate for 48 h. Note significant increases in
mitochondria superoxide levels (normalized to control) when Ramos cells were exposed
to the 3kDa MWCO concentrate with no significant changes in Toledo and hBMMSC
cells. (B) Hydroxyl radical and peroxynitrile anion fold changes (HPF assay) of Ramos,
Toledo and hBMMSCs exposed to 500 µg/ml of the 3kDa MWCO concentrate for 48 h.
Significant increases in hydroxyl radical and peroxynitrile anions (normalized to control)
in Ramos and Toledo cells exposed to the 3kDa MWCO concentrate with no significant
changes in hBMMSCs. (C) Lipid peroxidation fold changes of Ramos, Toledo and
hBMMSC cells exposed to 500 µg/ml of the 3kDa MWCO concentrate for 48 h. Note
significant increases in lipid peroxidation levels (normalized to control) when Ramos,
Toledo and hBMMSC cells were exposed to the 3kDa MWCO concentrate. All values in
(A-C) are expressed as mean ± SEM of 3 different experiments. Asterisk (*) indicates
statistical significance of p<0.05.
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viability significant decreases with the 3kDa hWJSC-CM concentrates fraction
and not with the flow through (FT) fraction. Subsequent experiments using the
3kDa MWCO concentrate showed greater reductions in cell viability, disruption of
mitochondrial membrane potential and increased caspase 3, 8 and 9 apoptosis
and cell death in both types of B cell lymphomas but not in adult bone marrow
MSCs. Current anti-cancer chemotherapy and radiation treatments in lymphoma
patients frequently induce non-specific damage to the bone marrow, stromal cells,
gastrointestional tract, heart, brain and kidney that impede survival outcome
128,155,156,159-161. Since the adult hBMMSCs in the present study were minimally
affected by the 3kDa MWCO concentrate, the use of hWJSC-CM as a potential
therapy for lymphoma patients may be a safe option in the future as the
hematopoietic niche may not be affected. It was observed in the present study
increased functional activity of H2O2-generating SOD enzymes and concomitant
decreases in functional activity of all three H2O2-catabolic antioxidative enzymes
(GPx, catalase and TPx) in both lymphoma cell types, the mechanism of the
tumoricidal effects of hWJSC-CM may be via disruption of these pathways. Under
normal physiological conditions, cells remove reactive oxidative stress by
converting reactive oxygen species to H2O2 via SOD enzymes and the presence
of efficient enzymes such as GPx, catalase and TPx kept H2O2 levels low in the
cells by further breaking them down into water 163. Many types of cancer cells,
including hematological malignancies, were shown to keep H2O2 levels low by
having lowered SOD, GPx and catalase activities 173-175. Numerous previous
studies aimed at manipulating these specific enzymes have all shown promising
results in inhibition of cancer cell growth. For example, extracts of the Creosote
bush (Larrea divaricate) activated Mn2+-SOD and decreased glutathione
peroxidase activity subsequently suppressed lymphoma proliferation and induced
apoptosis 164. Likewise, overexpression of Mn2+-SOD in other cancer cell types
such as human melanoma, fibrosarcoma, human glioma, breast cancer cells, oral
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squamous carcinoma, prostatic carcinoma have resulted in inhibition of their
proliferation in vitro or in vivo 173,176,177. Moreover, since these anticancer effects
were abolished by overexpression of H2O2-removing enzymes (catalase and
peroxidase) it suggested that the anticancer effect may be mediated by the
increased H2O2 177,178.
We also observed increases in H2O2 levels in both lymphoma cell lines after
treatment with the 3kDa MWCO concentrate confirming that the level of H2O2
plays a decisive role in deciding whether cancer cells proliferate or undergoes
apoptosis. Numerous studies have suggested that the high level of intracellular
H2O2 induces cancer cell death 164,170,171. However, direct administration of H2O2
to cancer patients has been controversial over the years as evidence on both
safety and effectiveness were yet to be confirmed 179-181. As such, direct
treatment with H2O2 was never seen as an appropriate therapeutic strategy 181.
On the other hand, more and more convincing evidence now suggests that
increasing cellular H2O2 using a H2O2-generating system is an efficient way of
inducing cancer cell death 164. In fact, many current chemotherapeutic agents
such as paclitaxel, cisplatin, arsenic trioxide, etoposide and doxorubicin exert
their anti-cancer effects by increasing the level of H2O2 in the cancer cells 164.
Likewise, Chen et al 182 observed that treatment with pharmacologic ascorbic
acid selectively induced cell death in several cancer cell lines by increasing H2O2
levels. Their data indicates that the induction of cancer cell death is dependent
on ascorbate radical intermediate-mediated extracellular H2O2 formation. The
increased extracellular H2O2 then target cancer cell membrane lipids or diffuse
across the membranes to target intracellular DNA, DNA repair proteins or the
mitochondria, resulting in oxidative stress. Moreover, recent data using high-dose
intravenous vitamin C therapy in patients generated high H2O2 that were shown to
kill cancer cells 182,183. On the other hand, reports have shown that intercellular
H2O2-generating drugs when used together with certain chemotherapeutic agents
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such as dexamethasone enhanced cancer cell sensitivity to chemotherapy 184,185.
Consequently, the increase in cellular H2O2 level favors the formation of other
reactive oxygen species like the superoxides, hydroxyl radical and peroxynitrile
anions which leads to higher oxidative stress and lipid peroxidation 164,186 that
drive cancer cell death which is consistent with the findings in our present study.
However, it is still relatively unclear as to what levels of H2O2 exert
chemopreventive, carcinogenic and chemotherapeutic effects and more studies
are required in this area. A delicate balance in the cell’s redox system and H2O2
level is paramount to effectively regulate its chemopreventive and
chemotherapeutic effects and yet avoid carcinogenic effects when using H2O2-
generating systems as anti-cancer therapeutics.
The specific active agents present in hWJSC-CM that are responsible for its
tumoricidal effects are still not known. Our previous comparative microarray
transcriptome profile studies of hWJSCs showed upregulation of several pro-
apoptotic and tumor-suppressor genes such as TGF beta-R2, ATM and PTEN in
these cells compared to hBMMSCs and embryonic stem cells 15. Also, our
unpublished data on miRNA-profiling indicated that hWJSCs expressed high
levels of various tumor suppressor miRNAs such as miRNA-146a and miRNA-
126 compared to normal adult hBMMSCs and skin fibroblasts. Furthermore,
previous proteomic cytokine arrays indicated that hWJSC-CM contains various
cytokines expressed at high levels such as MCP-1, IL-6, IL-8 and IL-12 which are
known to regulate cancer cell growth and death 8,58. It would be interesting to test
the tumoricidal effects of these specific molecules in the 3kDa MWCO
concentrate by knocking, blocking or neutralizing the mRNA, miRNA or proteins
in future studies.
Chapter 3: H2O2 mediated Tumoricidal Effects on Lymphoma Cells
67
Chapter 3: H2O2 mediated Tumoricidal Effects on Lymphoma Cells
68
Chapter 4: Immunogenic Cancer Cell Death Induced by hWJSC-CM
69
Chapter 4: Immunogenic Cancer Cell Death induced by hWJSC-CM
4.1 Introduction
In recent years, there are growing evidence indicating that the patient’s immune
competence is crucial in determining the efficacy in chemotherapeutic and radio-
therapeutic treatment 187. However, in many cases, the tumors have already
developed some immune tolerance and therefore the patients' undergoing
treatment have an immunosuppressive tumor microenvironment and affects the
efficacy of chemotherapy and radiotherapy 187.
Recent discover ies of  chemotherapeut ic and radio thereuptic treatment
strategies that induce immunogenic cell death in tumors have resulted in many
long-term successful therapeutic options for tumor eradication 188,189.
Immunogenic cell death (ICD), both directly or indirectly, has resulted in the
emission of specific signals that render the dying cells visible to the immune
system that reinitiate a very potent antitumor immunity response 188,190.
The molecular hallmark of ICD relies on at least 3 independent events: (1) the
early surface exposure of calreticulin (ecto-CRT) on dying cells, (2) secretion of
ATP and (3) release of high mobility group box-1 (HMGB1) and heat shock
proteins (HSPs) by dying cancer cells 187. These sequences of events presented
the "eat-me", 'find-me" signals to facilitate recruitment, phagocytosis, antigen
cross-presentation and polarization of immune cells (antigen-presenting cells-
dendritic cells), cytotoxic natural killer and T cells in re-activating the immune
system for launching a potent anti-tumor immunity response 189. However,
promising as it seems, there are only a few tumor-specific chemotherapeutic
drugs that induce ICD in cancer cells available in the market. Hence it is
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important to explore for novel agents that can elicit ICD response which can be
used alone or as part of an combinational therapy 188.
In chapter 2 and 3, we have previously isolated a primitive population of MSCs
from the Wharton's jelly of discarded umbilical cord. These hWJSCs have been
shown to exhibit anti-tumorigenic properties on many cancer cell types both in
vitro and in vivo animal models. As earlier studies reported that hWJSCs secrete
large varieties of cytokines and factors like IL-6, IL-8, MCP-1 8 that have been
known to play a role in releasing DAMPs and modulating the innate immune
response 58. In addition, treatment of mammary carcinoma xenograft rat model
with rat WJSCs increases CD8+ T cell infiltration in the tumor tissue 53. However,
there are currently no studies evaluating whether these hWJSCs and or its
extract could induce ICD and release signals indicating of immunogenic cell
death.
It has previously been shown that hWJSCs do not induce tumorigenesis in
laboratory animals, primates and in humans 22,23,73,74 and unlike adult BM-MScs,
they do not transform to tumor-associated fibroblasts (TAFs) 88. Additionally,
there have been no reports of any toxicity or side effects when hWJSCs were
injected into laboratory animals 26, non-human primates 74 and in human clinical
trials for the treatment of aplastic anemia 19, leukemia 23, type 1 diabetes mellitus
20, heart failure 22 and neurological disorders 21. All these studies point to the
safety of using hWJSCs or hWJSC-derived products as future cancer
therapeutics. Therefore, the aim of this chapter is to evaluate the immunogenic
cell death effects of 3kDa MWCO hWJSC-CM in vitro assays.
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4.2 Material and Methods
4.2.1 Cell Culture
Human Wharton's jelly stem cells (hWJSCs)
After informed patient consent and approval from the Institutional Domain
Specific Review Board (DSRB), hWJSC lines were developed from human
umbilical cords. hWJSCs were cultured in hWJSC medium comprising of 80%
DMEM, 20% fetal bovine serum (FBS) (Biochrom, Berlin, Germany), 1% non-
essential amino acids, 2 mM L-glutamine, 0.1 mM β-mercaptoethanol, 1%
insulin-transferrin-selenium, antibiotic/antimycotic mixture (Invitrogen Life
Technologies, Carlsbad, CA) and 16 ng/ml basic fibroblast growth factor
(Millipore Bioscience, Temecula, CA).
Human lymphoma cells (Ramos)
Then approval for purchase and use of commercial human Burkitt's lymphoma
cell lines (Ramos, CRL 1596, ATCC) was granted by the National University of
Singapore Institutional Review Board (NUS-IRB). The cell lines were thawed and
initially cultured in lymphoma medium consisting of RPMI medium (Thermo
Scientific) supplemented with 10% heat inactivated FBS (Thermo Scientific
Hyclone) and 1% antibiotic/antimycotic mixture (Invitrogen).
Human Osteosarcoma (MG63)
The approval for purchase and use of commercial human osteosarcoma cell lines
(MG63, CRL-1427, ATCC) was granted by the NUS-IRB. The cells were thawed
and cultured in medium consisting of RPMI (Biowest, Nuaille, France)
supplemented with 10% FBS (Thermo Scientific Hyclone), 1%
antibiotic/antimycotic mixture and 2 mM L-glutamine (Invitrogen Life
Technologies).
Chapter 4: Immunogenic Cancer Cell Death Induced by hWJSC-CM
72
Human Mammary Adenocarcinoma (MDA-MB-231)
The approval for purchase and use of commercial human mammary
adenocarcinoma (MDA-MB-231, ATCC HTB-26) was granted by the NUS-IRB.
The cells were thawed and cultured in medium consisting of RPMI (Biowest,
Nuaille, France) supplemented with 10% FBS (Thermo Scientific Hyclone), 1%
antibiotic/antimycotic mixture and 2 mM L-glutamine (Invitrogen Life
Technologies).
4.2.2 Preparation of hWJSC conditioned medium (hWJSC-CM)
The preparation of hWJSC-CM was carried out as previously described 8,9,57,172.
Briefly, early passages of hWJSCs (3P to 5P) were first cultured in hWJSC
medium until 70% confluency. The medium was then replaced with basal RPMI
medium (Biowest) supplemented with 1% antibiotic/antimyotic mixture
(Invitrogen). After 48h, the medium (hWJSC-CM) was collected, filtered through a
0.22M filter (Millipore) and stored at -80oC until use.
4.2.3 Preparation of 3kDa MWCO hWJSC-CM concentrate
Twenty ml aliquots of the 48h hWJSC-CM was concentrated by centrifugation by
placing them in 3kDa MWCO Vivaspin 20 tubes (Sartorius, Goettingen, Germany)
and centrifuged at 3,000 x g for 1-2h. The concentrates which were retained at
the collection column were collected and stored at -20oC. The protein
concentration of concentrated hWJSC-CM was estimated using the NanodropTM
spectrophotometer (Nanodrop Technologies, Wilmington, DW).
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4.2.4 Experimental Design
Exposure of Ramos, MG63 and MDA-MB-231 to 3kDa MWCO hWJSC-CM
concentrates
Ramos (1 x 105 cells), MG63 (5 x 104 cells) and MDA-MB-231(5 x 104 cells), were
exposed to 3kDa MWCO hWJSC-CM concentrates (hWJSC-CM, 500 g/mL) in
their respective growth media for 48h at 370C in a 5% CO2. The cells were then
evaluated for cell morphology, viability (MTT assay), cell death analysis,
apoptosis, autophagy, mitochondria stress, endoplasmic reticulcum stress and
danger-associated molecular patterns (DAMPs).
4.2.5 Experimental Analysis Test
Cell Morphology
Changes in cell morphology of the cancer cells were monitored using inverted
phase contrast optics (Nikon Instruments, Tokyo, Japan).
Cell viability (MTT assay)
To determine cell viability, the treated Ramos, MG63 and MDA-MB 231 cells and
controls were collected and then re-suspended in 100 L growth media with 10
µl [3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide] (MTT, 0.5 mg/ml)
(Duchefa Biochemie B.V., Haarlem, Netherlands) added and incubated for at
least 4h at 37oC in a 5% CO2. The cell suspension was then centrifuged at 1,500
x g for 5 min and cell pellet resuspended in 100 µl of DMSO reagent (Sinopharm
Chemical Reagent Co.Ltd) and dispensed into 96-well plates (NUNC, Rochester,
NY). The plates were incubated in the dark at 37oC for 10 min. Absorbance at
570 nm against a reference wavelength of 630 nm was measured using a
spectrophotometer microplate reader (mQuant; BioTek, Winooski, VT, USA).
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Propidium Iodide (PI+ Assay)
The treated and control cells were analyzed for PI positive cells using the
propidium iodide molecular probe (Invitrogen). Briefly, the cells were collected
and then resuspended with 500 L of culture medium containing 1 µL of PI (1.0
mg /mL, Invitrogen) at 37oC for 30 min. The cells were filtered with a 40 m
strainer and analyzed with CyAnTM ADP analyzer (Beckman Coulter, Fullerton,
CA, USA).
Apoptosis analysis
The treated and control cells were analyzed for caspase 3 using the CellEventTM
Caspase-3/7 Green Detection Reagent (Invitrogen Life Technologies). Briefly, for
caspase 3, the cells were collected and then incubated with 500 L of culture
medium with 0.125 L of the 2.0 mM CellEventTM Caspase-3/7 Green Detection
Reagent at 37oC for 30 min. The cells were then washed, filtered with a 40 m
strainer and analyzed with a CyAnTM ADP analyzer (Beckman Coulter).
Autophagy analysis
The treated and control cells were analyzed for autophagy using the Autophagy
Detection Kit (Abcam). Briefly, the cells were collected and then incubated in 250
L of indicator free growth media with 250 L of diluted Green stain solution (1
L Green Detection Reagent to 1000 L indicator free growth medium) at 37oC
for 30 min. The cells were then washed, filtered with a 40 m strainer and
analyzed with a CyAnTM ADP analyzer (Beckman Coulter).
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Mitochondria Stress
Mitochondrial membrane potential assay ()
The mitochondrial membrane potential () of the treated and control cells were
analyzed using MitoTracker(R) Red CMXRos (Invitrogen). Briefly, the cells were
collected and then incubated with 500 L of culture medium containing 1 µL of 1
mM MitoTracker(R) Red CMXRos stock solution (Invitrogen) at 37oC for 30 min.
The cells were filtered with a 40 m strainer and analyzed with CyAnTM ADP
analyzer (Beckman Coulter).
Mitochondria transition pore (MTP) Assay
The mitochondrial transition pore assay (MTP) of the treated and control cells
were analyzed using MitoProbeTM Transition Pore Assay Kit (Invitrogen Life
Technologies). Briefly, the cells were collected and then incubated with 500 L of
culture medium containing 1 µL of 1 mM calcein and 80 mM CoCL2 working
solution at 37oC for 30 min. The cells were filtered with a 40 m strainer and
analyzed with CyAnTM ADP analyzer (Beckman Coulter).
Endoplasmic Reticulcum (ER) Stress
Immunocytochemistry for ER stress marker eIF2a and XBP-1
For non-adherent Ramos lymphoma cells, the control and treated cells in culture
were collected, washed once with PBS (-) and fixed in 4% paraformaldehyde for
10 min, permeabilized with 0.1% Triton-X100 for 10 min and then washed with
PBS. Non-specific blocking were done with 10% normal goat serum for 10 min.
The cells were then incubated with primary antibodies against phosphorylated
eIF2a (Cell Signaling Technologies, Danvers, MA, USA) XBP-1 (Abcam,
Cambridge, UK) overnight at 4oC. The cells were then incubated with by
secondary goat anti-mouse IgG (H+L) Alexa Fluor 568 antibodies (1:500)
Chapter 4: Immunogenic Cancer Cell Death Induced by hWJSC-CM
76
(Invitrogen Life Technologies) for 30 min on ice in the dark. The cells were
subsequently washed and mounted with FluoroshieldTM (Sigma, St. Louis, MO),
observed and imaged photographed with an Olympus FluoView FV1000 laser
scanning confocal microscope (Olympus). For adherent cancer cell lines, MG63
and MDA-MB-231, the cells were grown in Lab-Tek(R) Chambered #1.0
Borosilicate coverglass system (Thermo Scientific), treated with hWJSC-CM and
subsequently stained and imaged for ER stress as described above.
Oxidative Stress assay
Mitochondrial superoxide assay
The treated and control cells were analyzed for mitochondrial superoxide using
the MitoSOXTM Red mitochondrial superoxide indicator (Invitrogen). Briefly, the
cells were collected and incubated with 100 L of culture medium containing 0.1
L of 5mM MitoSOXTM working solution at 37oC for 30 min. The cells were then
washed, filtered with a 40 m strainer and analyzed with CyAnTM ADP analyzer
(Beckman Coulter).
Hydrogen peroxide assay
The culture media from the treated and control arms were collected and stored at
-80oC. Briefly, for hydrogen peroxide assay, 50 l of cell lysate or 50 l of
supernatant was mixed with 50 l of HRP/Amplex Red reaction (Invitrogen) in a
96-well plate and incubated at 37oC for 30 min or longer. Fluorescence readings
using excitation 560 nm and emission detection at 590 nm were measured using
a Tecan Infinite M1000 microplate reader (Tecan Group Ltd, Mannedorf,
Switzerland).
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Hydroxyl radical and peroxynitrile anion
The treated and control cells were analyzed for highly reactive oxygen species
(hydroxyl radical and peroxynitrile anions) using 3'-(p-hydroxyphenyl) fluorescein
(HPF, Invitrogen). Briefly, the cells were collected and incubated with 100 L of
culture medium containing 0.2 L of 5 mM HPF at 37oC for 30 min. The cells
were then washed, filtered with a 40 m strainer and analyzed with CyAnTM ADP
analyzer (Beckman Coulter).
Lipid peroxidation
The treated and control cells were collected and stained using the Image-iT(R)
Lipid Peroxidation Kit based on the manufacturer's instructions (Invitrogen).
Briefly, the cells were stained with 10 mM Image-iT(R) Lipid Peroxidation Sensor
(Component A) for 30 min at 37oC. The cells were then washed, filtered with a 40
m strainer before analysis using BD LSRFortessaTM (BD Bioscience, Heideberg,
Germany) with excitation/emission 581/591 nm and 488/510 nm.
Danger associated molecular patterns (DAMPs)
Surface exposed CRT (ecto-CRT)
For FACS analysis of ecto-CRT, the treated and control cells were collected,
blocked with 10% NGS on ice for 10 min. The cells were then incubated with
primary anti human CRT antibodies (1:500) (Abcam) for 30 min on ice followed
by secondary goat anti-mouse IgG (H+L) Alexa Fluor 488 antibodies (1:500)
(Invitrogen Life Technologies) for 30 min on ice in the dark. The cells were
washed with PBS, resuspended in cold 10% NGS, filtered with a 40 m strainer
and analyzed with CyAnTM ADP analyzer (Beckman Coulter, Fullerton, CA, USA).
To visualise the ecto-CRT, the treated and control cells were collected, fixed in
cold 4% paraformaldehyde for 10 min, blocked with cold 10% NGS for 10 min
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and then incubated with primary anti human CRT antibodies (1:500) (Abcam)
overnight in 4oC. The cells were then incubated with by secondary goat anti-
mouse IgG (H+L) Alexa Fluor 488 antibodies (1:500) (Invitrogen Life
Technologies) for 30 min on ice in the dark. The cells were subsequently with
mounted with FluoroshieldTM (Sigma, St. Louis, MO), observed and imaged with
an Olympus FluoView FV1000 laser scanning confocal microscope (Olympus).
Surface exposed Hsp90 (ecto-Hsp90)
For FACS analysis of ecto-Hsp90, the treated and control cells were collected,
fixed in 0.25% paraformaldehyde for 5 min, washed with cold PBS and then
incubated with primary anti human Hsp90 antibodies (1:500) (Abcam) for 30 min
on ice in blocking buffer followed by secondary goat anti-rabbit IgG (H+L) Alexa
Fluor 568 antibodies (1:500) (Invitrogen Life Technologies) for 30 min on ice in
the dark. The cells were washed with PBS, resuspended in cold 10% NGS,
filtered with a 40 m strainer and analyzed with BD LSRFortessaTM (BD
Bioscience).
To visualise ecto-Hsp90, the treated and control cells were collected, fixed in cold
4% paraformaldehyde for 10 min, blocked with cold 10% NGS for 10 min and
then incubated with primary anti-human Hsp90 antibodies (1:500) (Abcam)
overnight in 4oC. The cells were then incubated with by secondary goat anti-
mouse IgG (H+L) Alexa Fluor 568 antibodies (1:500) (Invitrogen Life
Technologies) for 30 min on ice in the dark. The cells were subsequently
mounted with FluoroshieldTM (Sigma, St. Louis, MO), observed and imaged with
an Olympus FluoView FV1000 laser scanning confocal microscope (Olympus).
Extracellular ATP concentration
The culture media from the treated and control arms were collected and stored at
-80oC. The extracellular ATP concentration were determined using an ATP assay
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kit (Abcam) based on manufacturer's instructions. Briefly, 50 l of supernatant
from the control or treated arms were added with 50 l of ATP reaction mix
containing 45.8 l ATP Assay Buffer, 0.2 l ATP Probe, 2 l ATP Converter and
2 l Developer Mix. The mixtures were incubated at room temperature for 30 min
in the dark. Fluorescence readings using excitation 535 nm and emission
detection at 587 nm were then measured using a Tecan Infinite M1000
microplate reader (Tecan Group Ltd).
Extracellular HMGB1 concentration
The culture media from the treated and control arms were collected and stored at
-80oC. The extracellular HMGB1 concentration were determined using an ELISA
assay kit (Uscn Life Science Inc., Wuhan, China) based on manufacturer's
instructions. Briefly, 100 L of supernatant from the control or treated arms,
diluted standard and blank were added into the pre-coated 96 well strip plate for
2h at 37oC. After removal of the liquid, 100 L of Detection Reagent A was added
into each well and incubated for 1 h at 37oC. The wells were then washed with
350 L of 1x Wash Solution 3 times and blotted dry on absorbent paper. 100 L
of Detection Reagent B was then added and incubated 30 min at 37oC. The wells
were then washed with 350 L of 1x Wash Solution 5 times and blotted dry on
absorbent paper. 90 L of Substrate Solution was then added and incubated 20
min at 37oC in the dark. Lastly, 50 L of Stop Solution was added into each well
and HMBG1 level were measured at 450 nm using a spectrophotometer
microplate reader (mQuant; BioTek, Winooski, VT, USA).
4.2.5 Statistical Analysis
All results were expressed as mean (fold change) ± SEM and statistical
signiﬁcance between the groups was calculated using two-tailed Student’s t-test
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(SPSS Statistic v 17.0 software package) (SPSS, Inc, IL).  The p-value of <0.05
was considered as statistically significant.
4.3 Results
4.3.1 Cell Morphology of Cancer cells after 3kDa MWCO hWJSC-CM
concentrate treatment
Phase contrast inverted optics of Ramos cells after 48h exposure to 3kDa
MWCO hWJSC-CM concentrates showed morphologically an increased in the
number of dead cells. These morphological changes included degeneration and
shrinkage (Fig. 15A-B). The morphology of MG63 changes from epithelial-like (in
control) to fibroblastic-like cells after treatment with hWJSC-CM. Lesser number
of MG63 cells were observed after 48h treatment of hWJSC-CM as compared to
the control (Fig. 15C-D). However, there is no distinct morphological change
observed in MDA-231 cells after 48h of treatment with hWJSC-CM concentrate
as compared to control (Fig. 15E-F).
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4.3.2 Evaluation of 3kDa MWCO hWJSC-CM concentrate on cell
viability, and cell death in Ramos, MG63 and MDA-MB-231 cancer
cells
Ramos, MG63 and MDA-MB-231 cancer cells showed significant reductions in
cell viability and significant increases in percentage of cells stained positive for
cell death marker PI after 3kDa MWCO hWJSC-CM concentrates treatment. The
fold changes for cell viability normalized to their respective controls were Ramos
Figure 15 Phase contrast images of Ramos, MG63 and MDA231
Phase contrast images of Ramos, MG63, and MDA231 after exposure to 3kDa hWJSC-
CM concentrate. (A) Ramos cells show typical spherical morphology in controls. (B)
Increased cell death was observed when Ramos cells were exposed hWJSC-CM
concentrate for 48h (Magnification 100X; Scale Bar: 50µM). (C) MG63 cells show typical
epithelial-like morphology in controls. (D) MG63 cells show a more fibroblastic-like
morphology when MG63 cells were exposed to hWJWC-CM concentrate for 48h
(Magnification 40X; Scale Bar: 200µM). (E-F) No distinct morphological changes
observed for MDA231 cells in control and hWJSC-CM concentrate treatment arms
(Magnification 40X; Scale Bar: 200µM).
Chapter 4: Immunogenic Cancer Cell Death Induced by hWJSC-CM
82
cells (0.82 ± 0.04), MG63 cells (0.66 ± 0.01) and MDA-MB-231 (0.76 ± 0.01) (Fig.
16A). The fold changes for the percentages of PI+ cells normalized to their
respective controls were Ramos (3.37 ± 0.36), MG63 (5.12 ± 0.31) and MDA-MB-
231 (2.34 ± 0.24) (Fig. 16B).
4.3.3 Evaluation of 3kDa MWCO hWJSC-CM concentrate on
apoptosis, and autophagy in Ramos, MG63 and MDA-MB-231 cancer
cells
Ramos, MG63 and MDA-MB-231 cancer cells showed a significant increases in
cell apoptosis after 3kDa MWCO hWJSC-CM concentrates treatment. The fold
changes for activated caspase 3 activities normalized to their respective controls
were Ramos cells (2.11 ± 0.12), MG63 cells (4.07 ± 0.31) and MDA-MB-231
(2.41 ± 0.23) (Fig. 17A). Only MG63 and MDA-MB-231 cancer cells showed a
significant increase in cell autophagy. The fold changes for the autophagic cells
normalized to their respective controls were Ramos (1.02 ± 0.02), MG63 (1.38 ±
0.01) and MDA-MB-231 (1.5 ± 0.04) (Fig. 17B).
Figure 16 Cell viability and cell death analysis
(A) Cell viability fold changes (MTT assay) of Ramos, MG63 and MDA231 exposed to
500 µg/ml of the 3kDa MWCO concentrate for 48 h. Note significant decreases in cell
viability (normalized to control) when Ramos , MG63, MDA231 were exposed to the
3kDa MWCO concentrate. (B) Cell death (PI+ assay) fold changes of Ramos, MG63 and
MDA231 exposed to 500 µg/ml of the 3kDa MWCO concentrate for 48 h. Note significant
increases in cell death (normalized to control) of Ramos, MG63 and MDA231 cells
exposed to the 3kDa MWCO concentrate. All values are expressed as mean ± SEM of 3
different experiments. Asterisk (*) indicates statistical significance of p<0.05.
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4.3.4 Evaluation of 3kDa MWCO hWJSC-CM concentrate on
mitochondria stress in Ramos, MG63 and MDA-MB-231 cancer cells
Ramos cells showed a significant reduction in mitochondria membrane potential
while Ramos, MG63 and MDA-MB231 all showed significant increases in
mitochondria porosity after 3kDa MWCO hWJSC-CM concentrates treatment.
The fold changes for mitochondria membrane potential normalized to their
respective controls were Ramos cells (0.63 ± 0.05), MG63 cells (0.97 ± 0.01) and
MDA-MB-231 (0.97 ± 0.01) (Fig. 18A). The fold changes for increased
mitochondria porosity in cells normalized to their respective controls were Ramos
(3.87 ± 0.75), MG63 (1.95 ± 0.41) and MDA-MB-231 (2.81 ± 0.4) (Fig. 18B).
Figure 17 Apoptosis and autophagy analysis
(A) Apoptosis fold changes (activated caspase 3) of Ramos, MG63 and MDA231
exposed to 500 µg/ml of the 3kDa MWCO concentrate for 48 h. Note significant increases
in cell apoptosis (normalized to control) when Ramos , MG63, MDA231 were exposed to
the 3kDa MWCO concentrate. (B) Cell autophagy fold changes of Ramos, MG63 and
MDA231 exposed to 500 µg/ml of the 3kDa MWCO concentrate for 48 h. Note significant
increases in cell autophagy (normalized to control) of MG63 and MDA231 cells exposed
to the 3kDa MWCO concentrate. All values in are expressed as mean ± SEM of 3
different experiments. Asterisk (*) indicates statistical significance of p<0.05.
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4.3.5 Evaluation of 3kDa MWCO hWJSC-CM concentrate on
endoplasmic reticulum (ER) stress in Ramos, MG63 and MDA-MB-231
cancer cells
The cancer cells were evaluated for ER stress marker after 48 h 3kDa MWCO
hWJSC-CM concentrates treatment using immunocytochemistry and viewed
under confocal microscopy. All 3 cancer cell lines were stained positive for ER
stress markers- eLF2a and XBP-1 after hWJSC-CM treatment. These markers
were not stained positive in untreated control cancer cell lines (Fig. 19).
Figure 18 Mitochondria stress analysis
(A) Cell mitochindria membrane potential fold changes (CMXRos) of Ramos, MG63 and
MDA231 exposed to 500 µg/ml of the 3kDa MWCO concentrate for 48 h. Note decrease in
cell mitochondria membrane potential (normalized to control) when Ramos (significant) ,
MG63, MDA231 were exposed to the 3kDa MWCO concentrate. (B) Cell mitochondria
porosity (mitochondria transition pore) fold changes of Ramos, MG63 and MDA231
exposed to 500 µg/ml of the 3kDa MWCO concentrate for 48 h. Note significant increases
in cell mitochondria porosity (normalized to control) of Ramos, MG63 and MDA231 cells
exposed to the 3kDa MWCO concentrate. All values in are expressed as mean ± SEM of
3 different experiments. Asterisk (*) indicates statistical significance of p<0.05.
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4.3.6 Evaluation of 3kDa MWCO hWJSC-CM concentrate on oxidative
stress in Ramos, MG63 and MDA-MB-231 cancer cells
Ramos, MG63 and MDA-MB-231 all showed significant increases in mitochondria
superoxide level after 3kDa MWCO hWJSC-CM concentrates treatment. The
fold changes for percentage of cells positive for mitochondria superoxide level
normalized to their respective controls were Ramos cells (0.49 ± 0.4), MG63 cells
(1.94 ± 0.4) and MDA-MB-231 (1.35 ± 0.07) (Fig .20A).
All 3 cancer cell lines showed significant increases in hydroxyl radical and
peroxynitrile anions levels after 3kDa MWCO hWJSC-CM concentrates treatment.
The fold changes in percentage of cells with HPF normalized to their respective
Figure 19 ER stress marker analysis
Immunocytochemistry analysis for ER stress markers. All 3 cancer cell lines were
stained postive for ER stress markers eLF2a and XBP-1 after 48 h exposure to 500 µg/ml
of the 3kDa MWCO concentrate. Magnification 600X ; Scale Bar: 30µM
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controls were Ramos (1.22 ± 0.02), MG63 (1.28 ± 0.06) and MDA-MB-231 (1.1 ±
0.01) (Fig. 20B).
Ramos, MG63 and MDA-MB-231 all showed an increased (only significant for
Ramos) in extracellular hydrogen peroxide and lipid peroxidation level after 3kDa
MWCO hWJSC-CM concentrates treatment. The fold changes in hydrogen
peroxide level normalized to their respective controls were Ramos (1.35 ± 0.04),
MG63 (2.32 ± 0.52) and MDA-MB-231 (1.51 ± 0.19) (Fig.20C). The fold changes
in lipid peroxidation normalized to their respective controls were Ramos (1.1 ±
0.01), MG63 (1.19 ± 0.1) and MDA-MB-231 (1.28 ± 0.08) (Fig. 20D).
Figure 20 Oxidative stress analysis
(A) Cell mitochondria superoxide fold changes (MitoSox) of Ramos, MG63 and MDA231
exposed to 500 µg/ml of the 3kDa MWCO concentrate for 48 h. Note significant increases
in cell mitochondria superoxde level (normalized to control) when Ramos , MG63,
MDA231 were exposed to the 3kDa MWCO concentrate. (B) Cell hydroxyl
radical/peroxynitrile anion fold changes of Ramos, MG63 and MDA231 exposed to 500
µg/ml of the 3kDa MWCO concentrate for 48 h. Note significant increases in cell hydroxyl
radical/peroxynitrile anion level (normalized to control) of Ramos, MG63 and MDA231
cells exposed to the 3kDa MWCO concentrate. (C) Extracellular hydrogen peroxide level
fold changes of Ramos, MG63 and MDA231 exposed to 500 µg/ml of the 3kDa MWCO
concentrate for 48 h. Note increases in hydrogen peroxide level (normalized to control) of
Ramos (significant), MG63 and MDA231 cells exposed to the 3kDa MWCO concentrate.
(D) Lipid peroxidation level fold changes of Ramos, MG63 and MDA231 exposed to 500
µg/ml of the 3kDa MWCO concentrate for 48 h. Note increases in lipid peroxidation level
(normalized to control) of Ramos (significant), MG63 and MDA231 cells exposed to the
3kDa MWCO concentrate. All values in are expressed as mean ± SEM of 3 different
experiments. Asterisk (*) indicates statistical significance of p<0.05.
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4.3.7 Evaluation of 3kDa MWCO hWJSC-CM concentrate on surface
bound CRT (ecto-CRT) and Hsp90 (ecto-Hsp90) in Ramos, MG63 and
MDA-MB-231 cancer cells
Ramos, MG63 and MDA-MB-231 all showed significant increases in cells with
ecto-CRT after 3kDa MWCO hWJSC-CM concentrates treatment. The fold
changes in median fluorescence level for ecto-CRT normalized to their respective
controls were Ramos (1.21 ± 0.0004), MG63 (2.02 ± 0.24) and MDA-MB-231
(1.29 ± 0.09) (Fig. 21A). Confocal images of the cancer cells after 48 h hWJSC-
CM treatment indicated more CRT staining on the cells plasma membrane as
compared to control (Fig. 21B).
Ramos, MG63 and MDA-MB-231 all showed significant increases in cells with
ecto-Hsp90 after 3kDa MWCO hWJSC-CM concentrates treatment. The fold
changes in median fluorescence level for ecto-Hsp90 normalized to their
respective controls were Ramos (1.54 ± 0.15), MG63 (26 ± 4.84) and MDA-MB-
231 (16.6 ± 0.06) (Fig. 22A). Confocal images of the cancer cells after 48 h
hWJSC-CM treatment indicated more Hsp90 and plasma membrane co-
localization compared to control (Fig. 22B).
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Figure 21 Ecto-CRT analysis
(A) ecto-CRT fold changes of Ramos, MG63 and MDA231 exposed to 500 µg/ml of the
3kDa MWCO concentrate for 48 h. Note significant increases in cell ecto-CRT level
(normalized to control) when Ramos , MG63, MDA231 were exposed to the 3kDa
MWCO concentrate. (B) CRT localization confocal images of Ramos, MG63 and
MDA231 exposed to 500 µg/ml of the 3kDa MWCO concentrate for 48 h. Note higher
level of ecto-CRT in Ramos, MG63 and MDA231 cells (white arrows) exposed to the
3kDa MWCO concentrate. Scale bar: 5m. All values in are expressed as mean ± SEM
of 3 different experiments. Asterisk (*) indicates statistical significance of p<0.05.
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4.3.8 Evaluation of 3kDa MWCO hWJSC-CM concentrate on
extracellular ATP and HMGB1 concentration in Ramos, MG63 and
MDA-MB-231 cancer cells
Ramos, MG63 and MDA-MB-231 all showed significant increases in extracellular
ATP level after 3kDa MWCO hWJSC-CM concentrates treatment. The fold
changes in extracelluar ATP level normalized to their respective controls were
Ramos (4.25 ± 0.35), MG63 (4.97 ± 0.73) and MDA-MB-231 (4.23 ± 0.59) (Fig.
23A). Ramos, MG63 and MDA-MB-231 all showed significant increases in ATP
level in their respective medium after hWJSC-CM treatment. The ATP level
measured spectrophotofluorometrically before treatment and after treatment for
Ramos, MG63, MDA-MB-231 were 2990 ± 153, 11575 ± 671, 15783 ± 1054 and
15295 ± 601 respectively [Fig. 23(B-D)].
Figure 22 ecto-Hsp90 analysis
(A) ecto-Hsp90 fold changes of Ramos, MG63 and MDA231 exposed to 500 µg/ml of the
3kDa MWCO concentrate for 48h. Note significant increases in ecto-Hsp90 level
(normalized to control) of Ramos, MG63 and MDA231 cells exposed to the 3kDa MWCO
concentrate. (B) Hsp90 localization confocal images of Ramos, MG63 and MDA231
exposed to 500 µg/ml of the 3kDa MWCO concentrate for 48h. Note higher level of ecto-
Hsp90 in Ramos, MG63 and MDA231 cells (white arrows) exposed to the 3kDa MWCO
concentrate. Scale bar: 5m. All values in are expressed as mean ± SEM of 3 different
experiments. Asterisk (*) indicates statistical significance of p<0.05.
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Ramos, MG63 and MDA-MB-231 all showed significant increases in extracellular
HMGB1 level after hWJSC-CM treatment. The fold changes in extracelluar
HMGB1 level normalized to their respective controls were Ramos (1.12 ± 0.01),
MG63 (1.33 ± 0.003) and MDA-MB-231 (1.1 ± 0.03) (Fig. 24A). Ramos, MG63
and MDA-MB-231 all showed significant increases in HMGB1 level in their
respective medium after hWJSC-CM treatment. The HMGB1 level measured
spectrophotometrically before treatment and after treatment for Ramos, MG63,
MDA-MB-231 were 0.103 ± 0.003, 0.124 ± 0.004, 0.169 ± 0.008 and 0.149 ±
0.009 respectively [Fig. 24(B-D)].
Figure 23 Extracellular ATP analysis
(A) Extracellular ATP level fold changes of Ramos, MG63 and MDA231 exposed to 500
µg/ml of the 3kDa MWCO concentrate for 48 h. Note significant increases in
extracellular ATP level (normalized to control) when Ramos , MG63, MDA231 were
exposed to the 3kDa MWCO concentrate. (B-D) ATP level in respective medium before
and after exposure to 500 µg/ml of the 3kDa MWCO concentrate for 48 h. Note
significant increases in ATP level in medium when Ramos (B), MG63 (C) and MDA231
(D) when exposed to 3kDa MWCO concentrate. All values in are expressed as mean ±
SEM of 3 different experiments. Asterisk (*) indicates statistical significance of p<0.05.
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4.4 Discussion
The current standard anti-cancer management is generally assumed to act
through the selective killing of tumor cells or induction of their senescence 187.
However, increasing evidence has led to the hypothesis of the possible
contribution of the host immune system in the therapeutic process of
chemotherapy and radiotherapy. Several studies have indicated that several
chemotherapeutic drugs were more efficient in eliminating tumors implanted in
immunocompetent than immunocompromised hosts 191. In addition, immune
competence is crucially required for chemotherapy efficacy 187 and improved
survival outcome in cancer patients have been consistently observed to be
correlated to the presence of tumor infiltrating lymphoctye 192-195, However,
current standard of chemoradiotherapy used in cancer management is generally
Figure 24 Extracellular HMGB1 ELISA analysis
(A) Extracellular HMGB1 fold changes of Ramos, MG63 and MDA231 exposed to 500
µg/ml of the 3kDa MWCO concentrate for 48 h. Note significant increases in extracellular
HMGB1 (normalized to control) of Ramos, MG63 and MDA231 cells exposed to the
3kDa MWCO concentrate. (B-D) HMGB1 level in respective medium before and after
exposure to 500 µg/ml of the 3kDa MWCO concentrate for 48 h. Note significant
increases in HMGB1 level in medium when Ramos (B), MG63 (C) and MDA231 (D)
when exposed to 3kDa MWCO concentrate. All values in are expressed as mean ±
SEM of 3 different experiments. Asterisk (*) indicates statistical significance of p<0.05.
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thought to be immunosuppressive and the systemic immunity in patients is often
severely impaired after chemoradiotherapy 196. Most chemoradiotherapeutic
regimes mediate their cytotoxic effects by apoptosis which is generally
noninflammatory and nonimmunogenic 197,198. As such, the aim of this study is to
evaluate whether the treatment of cancer cells with 3kDa hWJSC-CM
concentrate could elicit an immunogenic cell death (ICD) response.
ICD is characterize by a series of molecular hallmarks that are released by dying
tumor cells and are recognized by antigen presenting cells which ultimately re-
initiate a tumor-specific adaptive immunity response 190. Both Burkitt lymphoma
(Ramos) and osteosarcomas (MG63) showed distinct morphological changes
after 48 hours exposure to 3kDa hWJSC-CM concentrate. Nevertheless, all 3
cancer cell lines of Ramos, MG63 and breast adenocarcinomas (MDA-231)
showed a significant decreased in cell viability and significant increased in cell
death after 3kDa hWJSC-CM concentrate exposure. Similarly, all 3 cancer cells
lines showed significant increase in apoptosis after exposure to hWJSC-CM
concentrate while both MG63 and MDA231 showed a significant increased in
autophagy after hWJSC-CM treatment.
Tumor cells undergoing ICD start to express and secrete several immunogenic
factors, namely the danger associated molecular patterns (DAMPs). DAMPs are
the markers of ICD which were recently identified as indispensable in activating
the immune response. They includes the pre-apoptotic exposure of calreticulin
(ecto-CRT) and heat shock protein 90 (Hsp90), the release of ATP from dying
cells and the postmortem release of high-mobility group box 1 (HMBG1) into the
extracellular space 187,190. Ecto-CRT, ATP and HMGB1 secretion are
indispensable for ICD and absence of any of these DAMPs abolishes the efficacy
of anthracycline- or OXA-induced immunogenicity in mouse models 189,199. The
expression of ecto-CRT stimulate the engulfment of dying tumor cells by DCs 200-
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202 while both ATP and HMGB1 regulate DC-mediated tumor antigen cross-
presentation and T-cell polarization 187.
The results in this study demonstrated a significant increased in mitochondria
stress (reduced mitochondria membrane potential and increased mitochondria
porosity), ER stress markers- eIF2a and XBP-1 and ROS stress (increased in
mitochondria superoxide, hydroxyl radical/peroxynitrile anions, hydrogen
peroxide and lipid peroxidation) in all three cancer cell lines after exposure to
3kDa hWJSC-CM concentrate. The ability of anti-cancer agents to induce ICD
was initially demonstrated using agent capable in inducing ER stress and
reactive oxygen species (ROS) stress 188,190. ER homeostasis ensures the
accuracy of protein folding and secretion while oxidative modification of protein
and lipids represents an important pathway in efficient presentation of DAMPs 190.
Silenced ER stress induced by ICD inducers showed a reduction of DAMPs like
ecto-CRT or ATP secretion in the dying cancer cells and reduces their in vivo
immunogenicity 190. This suggests that robust ER stress response accompanied
or induced by ROS is essential for the activation of ICD 190.
The induction of ecto-CRT or ecto-Hsp90 depends on the properties of
mitochondria stress, ER stress and reactive oxygen species production 188 that
were significantly upregulated in this study. All 3 cancer cell lines expressed
significantly more ecto-CRT and ecto-Hsp90 after treatment with hWJSC-CM
concentrate. Ecto-CRT is an important DAMPs that serves as an 'eat-me' signal
which promotes the phagotocytosis of dying cancer cells by antigen-presenting
cells such as dendritic cells (DCs). Consequently this facilitates their tumor
antigen presentation and induces tumor-associated antigen specific cytotoxic T
cells 188,200,203. Previous studies in both rodent and human patients models have
indicated that ecto-CRT can predict the ability of the dying cancer cells to mount
a protective anti-tumorigenic immune response 203-205. During the initiation of ICD,
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the dying cells will translocate CRT and Hsp90 from the endoplasmic reticulum
(ER) to the cell surface 206. Depletion or blockage of CRT was shown to abolish
the immunogenicity of anthracycline-induced cancer cell death 200,206. Likewise,
previous studies showed that using bortezomib enhances the expression of
Hsp90 of myeloma cells and was crucial for the activation of both human and
murine DCs 206-208. In addition, the fact that the immunogenicity of myeloma cells
was abolished after specific blockage of Hsp90 suggest that cell surface
expression of Hsp90 critical for ICD 207. Other studies showed that treatment with
5-fluorouracils and doxorubicin upregulated Hsp expression and promoted the
engulfment of apoptotic bodies by human DCs and subsequent cross
presentation of tumor antigens to T cells 209,210.
The results in this study demonstrated all three cancer cell lines had significantly
increased ATP secretion following exposure to 3kDa hWJSC-CM concentrates.
While ecto-CRT/ecto-Hsp90 is the 'eat-me' signal, other DAMPs such as
extracellular ATP from apoptotic cells constituted a 'find-me' signal for the
recruitment of DCs and their precursors 189,211. The secreted ATP binds to both
ionotropic (P2X) and metabotropic (P2Y) purinergic receptors which stimulate
DCs maturation 190. During ICD, it have been shown that ATP binds mainly to the
P2RX7 receptors and activates NOD-like receptor family, pyrin domain containing
3 inflammasome within DCs or macrophages 212,213 and the release of IL-1b 188
which is a crucial cytokine for propagation of an anti-tumor immune responses 214.
In addition, ATP was shown to mediate the recruitment and differentiation of
myeloid DCs to the tumor site after anthracycline treatment in vivo 211. After
treatment with chemotherapeutic agents, the secretion of ATP by cancer cells is
important for effective antitumor immune responses and small interfering RNA-
mediated inhibition that prevented ATP secretion from dying cancer cells and
mitigated the antitumor response 215. Moreover, it has been shown that
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autophagy deficient tumors with impaired ATP secretion were less radiosensitive
than control tumors in immunocompetent mice and induction of the protective
immune response could subsequently be restored by the injection of ecto-
ATPases that increases extracellular ATP concentration artificially 216,217.
Lastly, results also demonstrated a significant increased in HMGB1 secretion by
all three cancer cell lines after exposure to 3kDa hWJSC-CM concentrates.
HMGB1 is a endokine that is a chromatin-binding protein that acts as an
intracellular transcription factor and a proinflammatory cytokine when released
extracellularly 190,196. It has been reported that HMGB1 is also associated with
late apoptosis and autophagy 218. Anticancer treatments such as irradiation,
anthracyclines and oxaliplatin could induce HMGB1 released by the dying tumor
cells which then binds to its receptor TLR4 on DCs 196. After the binding to TLR4,
HMGB1 promotes activation of DCs and triggers its migration in vitro 196. In
addition, signaling through TLR4 and its adaptor MyD88 regulates the starting
phase of cognate immune responses by regulating phagocytosis and cross-
presentation of tumor antigens by DCs 191. As such, the released of HMGB1 from
tumor cells after chemotherapy has been shown to enhance the engulfment of
antigenic component by DCs and mediates cross-presentation of tumor antigens
into CD4 and CD8 T cells in murine in vivo models 196. Similarly, significant
upregulation of HMGB1 within the tumor environment of human cancer patients
after preoperative chemoradiotherapy and the increased in local HMGB1 levels
was correlated to higher patient survival 219. The inhibition of HMBG1 in cancer
undergoing immunogenic apoptosis in a prophylactic vaccination model mitigate
their ability to stimulate an antitumor immunity response 191. Furthermore, breast
cancer patients having a mutation in the TLR4 receptor gene were reported to
have early relapse after chemotherapy and radiotherapy treatment 191. These
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observations suggest that HMGB1-related immune response after
chemoradiotherapy plays an important role in clinical cancer treatment.
In summary, the results of this chapter indicated for the first time, that all three
molecular hallmarks for ICD ecto-CRT/Hsp90, extracellular ATP and HMGB1
were significantly increased in all cancer cell lines after exposure to 3kDa
hWJSC-CM concentrates. Moreover, earlier studies reported that hWJSCs
secrete large varieties of cytokines and factors like IL-6, IL-8, MCP-1 8 that have
been known to play a role in modulating the innate immune response 58 while the
treatment of mammary carcinomas xenograft rat model with rat WJSCs increased
CD8+ T cell infiltration in the tumor tissue 53. This supported the hypothesis that
anti-tumorigenic treatment with hWJSCs or its conditioned medium could mount
an immunogenic cell death mechanism which consequently could stimulate
additional anti-tumor immune response. However, the specific active agents
within the 3kDa hWJSC-CM responsible for the induction of immunogenic cell
death is still unknown. Future studies should focus on narrowing down and
determining the specific molecules or targets that are involved in order to further
elucidate the mechanism and their use as a therapeutic drug in the clinics.
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Chapter 5: Ex Vivo Expansion of Cord Blood CD34+ Cells Using
hWJSCs and hWJSC-CM
5.1 Introduction
Hematopoietic stem cells (HSCs) transplantation has been used for the treatment
of malignant and non-malignant hematopoietic diseases such as leukemia,
lymphoma and thalassemia. The current sources of HSCs come from the bone
marrow (BM), mobilized peripheral blood (mPB) and umbilical cord blood.
However, the aspiration of HSCs from the bone marrow is painful with the
potential risk of infection and morbidity and rare incidents of rupture of the spleen
and sickle cell damage have occurred and the long term safety of the donors
following peripheral blood HSCs collection remains unclear 99-102.
To overcome these challenges, HSCs from the human umbilical cord blood (UCB)
have been successfully used for the treatment of hematopoietic diseases in
children in autologous and allogeneic settings 136,137. The usage of HSCs from
UCB holds many advantages over HSCs isolated from bone marrow or peripheral
blood. These advantages includes (i) the ability to collect and store the cord
blood HSCs in a repository banks for faster availability to the patients, (ii) the
immaturity of the immune cells which the patients now bear lesser risk of graft vs
host disease (GVHD), (iii) the less stringent requirement of finding a ‘perfect
match“ sample between donors’ cells and recipients’ and (iv) the higher
proliferation rate, autocrine production of hematopoietic factors and longer
telomeres due to their young chronological age 103-105.
However, one major challenge associated with the use of UCB-HSCs for
transplantation is the relatively low cell dose available. This has contributed to
slower engraftment and increased risk of engraftment failure 220. It has been
reported that the HSC and HPC yielded in UCB was adequate for the treatment
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of hematopoietic diseases in children but not adults. It was estimated that for
successful engraftment, at least 2.5 x 106 CD34+ cells per kg of patient body
weight was required 221,222 but a good UCB harvest from a single umbilical cord
can generate a total of only about 10 x 106 CD34+ cells which is adequate only
for a 4 kg child 109.
Ex vivo expansion of hematopoietic stem cells/ its progenitor cells (HSC) would
break the obstacle of less cell number and widen its application. Hence
optimizing the culture condition for the maintenance and expansion of primitive
HSC is important. However, any expansion protocol must attempt to stimulate in
vivo hematopoiesis while maintaining the stemness properties of HSCs. Human
mesenchymal stem cells (MSCs) have been successfully used in vitro as a
scaffold for stromal support and expansion of HSCs via cell-to-cell contact. This
concept was developed on the understanding that the MSCs within the bone
marrow in vivo act as a natural scaffold on which HSCs interact and proliferate 220.
It is not known whether the mechanisms underlying behind the HSC-MSC
interaction that results in HSC proliferation is mediated by diffusible factors
released after cell-to-cell contact or through constitutive secretions by MSCs into
the immediate microenvironment. To avoid immunological complications,
autologous MSCs from the same patient’s bone marrow or UCB have been used
as a scaffold in vitro for expansion of her own HSCs with successful results
109,223,224. The use of MSCs from UCB for stromal support of autologous HSCs
has its own limitations in that the numbers of MSCs in UCB are extremely low
and their presence in UCB has been debated 225,226. In fact Musina et al 227
reported very low counts of UCB MSCs per volume of UCB and showed that
such MSCs had low proliferation rates.
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These challenges have prompted interest in the study and evaluation of MSCs
from other sources such as birth-associated tissues. Large numbers of MSCs
with high proliferation rates and low population doubling times have been
reported in the Wharton’s jelly (hWJSCs) of discarded human umbilical cord
3,4,11,12. At least 4.6 x 106 fresh live hWJSCs per cm of cord without expansion can
be obtained and its stemness properties of can last for at least 10 passages in
vitro 4. Moreover, they are hypoimmunogenic and are able to be used in both
autologous and allogeneic settings without the concerns of graft versus host
disease 46 (Weiss et al 2008). Freeze-thaw-survival rates of these hWJSCs after
cryopreservation even at the first passage were greater than 90% 4. Hence, given
their abundance we hypothesized that the same patient’s hWJSCs can serve as
an ideal autologous genetic match for stromal co-culture support for the
expansion of her own HSCs. In addition, since the conditioned medium of
cultured hWJSCs (hWJSC-CM) has a variety of beneficial growth factors
interleukins (IL-6, IL-8), granulocyte macrophage colony stimulating factor (GM-
CSF) and granulocyte colony stimulating factor (G-CSF) 49,110 it is possible that
the hWJSC-CM can support the expansion of HSCs. Therefore, the aim of this
chapter is to evaluate the use of allogeneic and autologous hWJSCs and
hWJSC-CM for the ex vivo expansion of UCB CD34+ cells.
5.2 Material and Methods
5.2.1 Cell Culture
Human Wharton's jelly stem cells (hWJSCs)
After informed patient consent and approval from the Institutional Domain
Specific Review Board (DSRB), hWJSC lines were developed from human
umbilical cords. hWJSCs that were previously banked were cultured in hWJSC
medium comprising of 80% DMEM, 20% fetal bovine serum (FBS) (Biochrom,
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Berlin, Germany),  1% non-essential amino acids, 2 mM L-glutamine, 0.1 mM β-
mercaptoethanol, 1% insulin-transferrin-selenium, antibiotic/antimycotic mixture
(Invitrogen Life Technologies, Carlsbad, CA) and 16 ng/ml basic fibroblast growth
factor (Millipore Bioscience, Temecula, CA).
Commercial Cord Blood CD34+ cells
Approval for purchase and use of commercial cord blood CD34+ cells (HSCs)
(StemCell Technologies Vancouver, BC, Canada) was granted by the National
University of Singapore Institutional Review Board (NUS-IRB). The cells were
thawed as per suppliers' instructions. Briefly, the cells were thawed in 37oC and
quickly transferred to 15 ml of Iscove's MDM containing 10% FBS and
centrifudged at 200 x g for 15 min at room temperature. The supernatant was
decanted and cell pellet seeded separately for experiments.
Isolation of Autologous hWJSCs and CD34+ HSCs
Approval for use of autologous hWJSCs and HSCs was granted by Institutional
Domain Specific Review Board (DSRB).
For isolation of hWJSCs, 15-30 cm long of human umbilical cords were collected,
cut into pieces and was washed in Hank's balanced salt solution (Invitrogen Life
Technologies). Each small piece was slit open with sterile forceps and curved
scissors and the Wharton's jelly were inverted face down into a Petri dish
containing enzymatic solution comprised of collagenase type I, collagenase type
IV and 100IU of hydrluronidase (all Sigma Chemical Co, USA) for 45 min in 37oC,
5% CO2. The detached Wharton's jelly and remaining attached Wharton;s jelly
was then separated using blunt surface of a curved forceps and transferred to
new Petri dish with fresh DMEM. The gelatinous Wharton's jelly was syringed
through an 18G needle to release the hWJSCs. Lastly the solution was
centrifuged at 300 x g for 10 min and cell pellets were use for experiments.
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For the isolation of autologous CD34+ cells, 100mL of UCB was aspirated from
umbilical blood vessels using 50 ml syringes and large bore needles. The UCB
CD34+ cells were isolated using Ficoll-Paque (StemCell Technologies) density
gradient centrifugation as described by Jaatinen and Laine. Briefly, the UCB was
first diluted in PBS/EDTA in the ratio of 1:4 and carefully layered on Ficoll-Paque
soultion and centrifuged for 40 min. The buffy coat was then collected, washed
and CD34+ cells were enriched by immunomagnetic positive selection using
MidiMACSTM system (Mitenyi Biotec, auburn, CA) according to manufacturer's
instructions. Briefly, the buffy coat cells were incubated with CD34 microbeads
and FcR blocking solution (Mitenyi Biotec) for 30 min at 4oC, washed and added
into a MACS LD column attached to a MidiMACSTM magnetic separator. The LD
column was then removed from the separator and CD34+ cells were eluted with
a plunger. The collected cells were then centrifuged 200 x g and cell pellets used
for experiment.
Bone marrow mesenchymal stem cells (hBMMSCs)
Approval for purchase and use of commercial adult hBMMSCs (Lonza, Allendale,
NJ, USA) was given by the NUS-IRB. The cells were thawed and cultured in
medium consisting of DMEM-high glucose (Invitrogen) supplemented with 10%
FBS (Biochrom), 1% antibiotic/antimycotic mixture and 2 mM L-glutamine
(Invitrogen).
5.2.2 Preparation of hWJSC conditioned medium (hWJSC-CM)
The preparation of hWJSC-CM was carried out as previously described 8,9,57.
Briefly, early passages of hWJSCs (3P to 5P) were first cultured in hWJSC
medium until 70% confluency. The medium was then replaced with basal
Stemspan SFEM medium (StemCell Technologies) supplemented with 1%
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antibiotic/antimyotic mixture (Invitrogen). After 24h, the hWJSC-CM and was
collected, filtered through a 0.22M filter (Millipore) and stored at -80oC until use.
5.2.3 Immunohistochemistry
hWJSCs and adult BM-MSCs were cultured in a Lab-Tek(R) Chambered #1.0
Borosilicate coverglass system (Thermo Scientific) till confluency. The cells were
then fixed in 4% paraformaldehyde for 10 min, permeabilized with 0.1% Triton-
X100 for 10 min and then washed with PBS. Non-specific blocking were done
with 10% normal goat serum for 10 min. The cells were incubated with primary
antibodies CD29, CD44, CD146, VCAM-1, MMP-2, MMP-9, SDF-1a, Laminin and
Stro-1 (Biolegends, San Diego, USA) at 4oC overnight. The cells were then
incubated with appropriate secondary antibodes (Invitrogen Life Technologies)
for 30 min at room temperature in presence of 1mg/mL Hoechst 33342, mounted
onto slides with appropriate mounting medium. Images were taken using an
Olympus FluoView FV1000 laser scanning confocal microscope (Olympus,
Japan).
5.2.4 Cytokine Analysis of hWJSC-CM using the Multiplex Luminex(R)
Beads Assay
Differential cytokine analysis of hWJSC-CM and controls was carried out using
the Bio-Rad Express assay kit for human group I and II cytokines array (Bio-Rad
Laboratories Singapore Pte Ltd, Singapore) based on manufacturers' instruction.
The 96 wells plates in the kit were first wetted with 100 l of wash buffer and 50
l of beads were added into each well. 50 l of hWJSC-CM were diulted in equal
voulmes of assay diluent and 50 l of the diluted sample and standards was
added to the beads in each well. The plates were then incubated for 1 h at room
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temperature in the dark with shaking. After incubation the plates were washed
twice in buffer and incubated with 100 l of secondary biotinylated antibodies
(1:10) for 1h in the dark. After washing twice with buffer, 100 l of streptavindin-
PE were then added and incubated for 30 min at room temperature in the dark.
Lastly, the wells were washed thrice, loaded with 100 l of wash buffer and
incubated for 2-3 min at room temperature in the dark. The plates were then read
on a Bio-plex array reader and data subsequently analyzed using Bio-plex
manager software version 3.
5.2.5 Experimental Design
Co-culture of Commercial UCB CD34+ cells with Allogeneic hWJSCs or
hWJSC-CM
For co-culture of donor allogeneic hWJSCs with UCB CD34+ cells, hWJSC
monolayers (80% confluent) were first inactivated by exposure to 20 µg/mL of
mitomycin- C (MMC, NUH Pharmacy, Singapore) and incubated at 37°C for 2.5 h.
After incubation the cells were washed thoroughly and then dissociated with
TrypLETM Express (Invitrogen). 25,000 of MMC-treated hWJSCs were seeded
per well in 2 different 24-well plates (Nalge Nunc International, Rochester, NY).
The next day, 25,000 CD34+ cells were seeded in each well containing the
hWJSCs. The two cell types were co-cultured for 9 days at 37 0 C in 5% CO2 in
air in hWJSC-Basal medium (hWJSC-BM) [(Stemspan SFEM medium containing
bovine serum albumin, recombinant human insulin, human transferrin, 2-
mercaptoethanol, Iscove’s MDM medium (IMDM) and supplements) (Stem Cell
Technologies)
For culture of UCB CD34+ cells in hWJSC-CM, 25,000 CD34+ cells were seeded
in each well of 24 well plates and grown separately in 500 l of hWJSC-CM for 9
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days at 37 0 C in 5% CO2 in air with topping up with 250 l of hWJSC-CM every
48 h.
Co-culture of Autologous UCB CD34+ cells with autologous hWJSCs
For co-culture of donor autologous hWJSCs with UCB CD34+ cells, autologous
hWJSC monolayers (80% confluent) were first inactivated by exposure to 20
µg/mL of mitomycin- C (MMC, NUH Pharmacy, Singapore) and incubated at
37°C for 2.5h. After incubation the cells were washed thoroughly and then
dissociated with TrypLETM Express (Invitrogen). 25,000 of MMC-treated hWJSCs
were seeded per well in 24-well plates (Nalge Nunc International, Rochester, NY).
The next day, 25,000 autologous CD34+ cells were seeded in each well
containing the hWJSCs. The two cell types were co-cultured for 9 days at 37 0 C
in 5% CO2.
5.2.6 Experimental Analysis Test
Phase Contrast and Scanning Electron Microscopy
The interaction of commercial and autologous UCB CD34+ cells with hWJSCs
and hWJSC-CM were observed using phase contrast optics and conventional
scanning electron microscopy (SEM) during 9 days of culture. Images of the
behavior of the cells were captured using Olympus IX70 microscope (Olympus,
Japan). For SEM, the cells were first fixed in 3% glutaraldehyde for 3h at room
temperature dehydrated through a series of graded alcohol solutions and dried in
hexamethyldisilazane overnight. The dried samples were then sputter coated
with gold (JEOL JFC-1600 Auto Fine Coaster, Japan) and observed using Field
Emission Scanning Electron Microscope  (FEI-QUANTA 200 F, Czech Republic)
at an accelerating voltage of 10 kV.
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Cell viability (MTT assay)
10 µl [3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide] (MTT, 0.5
mg/ml) (Duchefa Biochemie B.V., Haarlem, Netherlands) was added to the
medium for each sample and the tubes were incubated for 4 h at 37oC in 5% CO2.
The cell suspension was then centrifuged at 300 x g for 5 min, medium decanted
and 100 µl of DMSO reagent (Sinopharm Chemical Reagent Co.Ltd) added to
the cell pellet. The cells were dispensed into 96-well assay plates (NUNC,
Rochester, NY) and incubated in the dark at 37oC for 120 min. Absorbance at
570 nm against a reference wavelength of 630 nm was measured using a
spectrophotometer microplate reader (mQuant; BioTek, Winooski, VT, USA).
Trypan Blue Vital Cell Counts
Aliquots of the cultured UCB CD34+ cells in all control and experimental arms
were taken and stained with 0.4% Trypan Blue (Sigma Chemical Co) for 1 min at
room temperature. The number of live cells were counted using a hemocytometer.
CD34+ cells
The cells pellet from Experimental and Control groups were collected and
blocked with 10% normal goat serum (NGS) to prevent non-specific binding. The
cells were then incubated with primary anti human CD34 antibodies (1:100)
(Biolegends, San Diego, USA) for 30 min followed by secondary goat anti-mouse
IgG (H+L) Alexa Fluor 488 antibodies (1:750) (Invitrogen Life Technologies) for
30 min in the dark. The cells were washed with PBS, resuspended in 10% NGS,
filtered with a 40 m strainer and analyzed with CyAnTM ADP analyzer (Beckman
Coulter, Fullerton, CA, USA).
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Colony Forming Unit (CFU)
The cultured CD34+ cells from all control and experimental arms were separated,
centrifuged at 300 x g for 5 min. The cell pellets were then seeded into 24 well-
plates (Nalge Nunc International) containing 0.5 ml of semisolid methylcellulose
in Methocult H4435 medium (StemCell Technologies). The 24-wells plates were
incubated at 37oC in a 5% CO2 in air atmosphere for 14 days. Colonies (CFU)
that were formed after 14 days were counted and classified based on
morphology as described by the Atlas of Hematopoietic Colonies from Cord
Blood. The CFU colonies were imaged using a Inverted phase contrast
microscope (Nikon Instruments, Tokyo, Japan). Colony forming unit numbers
were then calculated by dividing the number of colonies at day 14 by the number
of cells plated and multiplying this value by 10,000 which reflected the colony
forming ability of 10,000 cells.
5.2.7 Statistical Analysis
All results were expressed as mean ± SEM and statistical signiﬁcance between
the groups was calculated using the one way ANOVA or two-tailed Student’s t-
test (SPSS Statistic v 17.0 software package) (SPSS, Inc, IL).  The p-value of
<0.05 was considered as statistically significant.





hWJSCs were stained positive for markers like CD29, CD44, CD146, VCAM-1,
MMP-2, MMP-9, SDF-1a, laminin and Stro-1 that was shown to help with HSCs
homing and migration [Fig. 25 (A-C)].
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5.3.2 Proteomic profiles in hWJSC-CM
There were significantly higher level of certain members of interleukins cytokines
like IL-1a, IL-6, IL-7 and IL-8, hepatocyte growth factor (HGF), stem cell
factor(SCF) , monocyte chemotactic protein-1 (MCP-1) and intercellular adhesion
molecule 1 (ICAM-1) in hJWSC-CM compared to basal control media (Fig. 26).
Of these factors, the levels of IL-6, IL-8, HGF, SCF and ICAM-1 were extremely
high compared to controls. The mean ± SEM  concentration level in pg/ml were
IL-1a: 4.34 ± 0.02 vs  1.71 ± 0.21; IL-6: 203.82 ± 6.78 vs  0.16 ± 0.01; IL-7: 1.52 ±
0.12 vs  0.635 ± 0.115; IL-8: 1875.94 ± 74.33 vs  4.72 ± 0.14; HGF: 2272.81 ±
5.65 vs  409.05 ± 29.06; SCF: 16390.19 ± 0.15 vs  4.74 ± 0.02; MCP-1: 493.25 ±
27.26 vs 1.695 ± 0.045 and ICAM-1: 118.86 ± 2.09 vs  0 or less than detectable
range.
Figure 26 Proteomic analysis of hWJSC-CM
Proteomic analysis of hWJSC-CM. hWJSC-CM showed significantly higherr concentration
(pg/ml) of IL-1a, IL-6, IL-7, IL-8, HGF, SCF, MCP-1 and ICAM-1 compared to controls.
Asterisk (*) indicates statistical significance of p<0.05.
Figure 25 Immunocytochemistry of BM-MSCs, hWJSCs.
(A-C) Immunocytochemistry of BM-MSCs, hWJSCs. hWJSCs were stained positive for
CD29, CD44, CD146, VCAM-1, MMP-2, MMP-9, laminin and Stro-1. Magnification 40X;
Scale Bar: 100µM




Most of the UCB CD34+ cells changed from a circular to an enlogated
morphology, put out psedopodia-like outgrowths and migrated towards the
bodies of the hWJSCs, loosely attached and undergoing mitosis [Fig. 27(A-B)].
They also became active and showed similar enlongated morphology with
pseudopodia-like outgrowths when were exposed to hWJSC-CM (Fig. 27C).
Such behavior were not observed in the controls (Fig. 26D). Scanning electron
micrographs confirmed the mitotic activity of UCB CD34+ cells on hWJSCs and
showed most of the cells attached on the upper surface of the hWJSCs with very
few cells migrating beneath [Fig. 27(E-F)].
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5.3.4 Cell Viability, Cell Proliferation and CD34+ Analysis
The results showed that there were significant increase in cell viability of UCB
CD34+ cells after 9 days of culture with hWJSCs or hWJSC-CM compared to
control. The cell viability were 0.03 ± 0.01 (Control), 0.092 ± 0.01 (hWJSCs) and
0.12 ± 0.01 (hWJSC-CM) (Fig. 28A).
Figure 27 Phase constrast images of UCB   CD34+ cells cultured with hWJSC or
hWJSC-CM.
(A) UCB CD34+ cells put out pseudopodia-like outgrowths when cultured in hWJSCs
(200x). (B) UCB CD34+ cells migrate towards the upper surfaces of hWJSCs, attaching
and undergoing multiplication (200x) (C) UCB CD34+ cells putting out pseudopodia-like
outgrowths (arrows) in hWJSC-CM which is not seen in control (D). (E) Scanning electron
microscopic images indicate the cells attached loosely on the upper surfaces of hWJSCs
at low magnification. (F) Scanning electron micrograph showing UCN CD34+ cells
undergoing mitosis on surface of hWJSCs.
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There were significant increase in cell proliferation of UCB CD34+ cells after 9
days of culture with hWJSCs or hWJSC-CM compared to control. The fold
change on the number of cells (by trypan blue counting) normalized to initial
starting number of cells were 0.76 ± 0.04 (Control), 1.8 ± 0.2 (hWJSCs) and 7.6 ±
0.4 (hWJSC-CM) (Fig. 28B).
CD34+ analysis showed that when UCB CD34+ cells were cultured in hWJSCs
or hWJSC-CM yield higher percentage of CD34+ cells compared to control. The
percentage of CD34+ cells after 9 days of culture were 86.68% (Control), 93.91%
(hWJSCs) and 96.91% (hWJSC-CM) (Fig. 28C).
Figure 28 Cell viability, proliferation and percentage CD34+ analysis
Cell viability, proliferation and percentage of CD34+ cells after 9 days of culture
with hWJSCs or hWJSC-CM compared to control. (A) Higher mean± SEM of UCB
CD34+ cells' cell viability in the presence of allogeneic hWJSCs and hWJSC-CM
compared to contol. (B) Higher mean ± SEM of UCB CD34+ cells' cell proliferation in
the presence of allogeneic hWJSCs and hWJSC-CM compared to contol. (C) Contour
maps of FACS analysis of UCB CD34+ cells when cultured in the presence of
allogeneic hWJSCs and hWJSC-CM. Each contour map represents the percentage of
FITC+ CD34 cells against unstained controls. Asterisk (*) indicates statistical
significance of p<0.05.
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5.3.5 Colony Forming Unit Analysis
CFU assay showed that there were an increase in CFU colonies when culturing
UCB CD34+ cells with hWJSCs or hWJSC-CM than controls (Fig. 29A). The
mean ± SEM CFU unit per 10,000 cells were 304 ± 34 (Control), 688 ± 125
(hWJSCs) and 846 ± 272 (hWJSC-CM) (Fig. 29B). There was an significant
increase in CFU-GEMM unit when when culturing UCB CD34+ cells with
hWJSCs or hWJSC-CM than controls. The mean ± SEM CFU-GEMM unit per
10,000 cells were 48 ± 11 (Control), 192 ± 23 (hWJSCs) and 208 ± 11 (hWJSC-
CM) (Fig. 29C). All six types of colony morphology for normal hematopoiesis
were observed in hWJSCs and hWJSC-CM compared to control (Fig. 28D).
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5.3.6 Culture of UCB CD34+ cells with Autologous hWJSCs
When fresh unfrozen autologous UCB CD34+ cells cultured in the presence of its
own inactivated umbilical cord for 9 days, significant higher cell viability and
higher percentage of CD34+ cells were also observed. The mean ± SEM cell
Figure 29 Colony forming unit (CFU) analysis
CFU analysis after 9 days of culture with hWJSCs or hWJSC-CM compared to
control. (A) More CFU colonies observed in hWJSCs and hWJSC-CM wells as
compared to control (B) Higher mean ± SEM CFU unit in the presence of allogeneic
hWJSCs and hWJSC-CM compared to control. (C) Higher mean ± SEM GEMM
colonies in the presence of allogeneic hWJSCs and hWJSC-CM compared to control.
(D) Six different types of colony morphology observed with UCB CD34+ cells cultured in
presence of allogeneic hWJSCs and hWJSC-CM. Asterisk (*) indicates statistical
significance of p<0.05.
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viability were 0.87 ± 0.01 (Control), 1.04 ± 0.03 (hWJSCs) (Fig. 30A). The mean
± SEM percentage CD34+ cells were 17.2 ± 1.4% (Control), 65.4 ± 0.6%
(hWJSCs) (Fig. 30B).
5.4 Discussion
Hematopoietic stem cells from the umbilical cord blood can differentiate into the
full spectrum of mature blood lineages and they have been used for the clinical
treatment of malignant and non-malignant hematopoietic disorders. However, the
low numbers of HSCs present in the UCB together with their low self renewal in
vitro has limited their use to only small children. One of the therapeutic strategy
to help increase UCB HSCs number is to develop reliable ex vivo UCB HSCs
expansion methods 220.
A variety of stromal cells have been studied as matrices for ex vivo expansion of
HSCs and these include derived primary monolayers of cells 228, genetically
modified cytokine-releasing cells 229, bone marrow MSCs (BM-MSCs) 114 and
immortalized BM-MSCs 230. The mechanism of action of the feeder cell matrices
Figure 30 Cell viability and percentage of CD34+ cells of UCB 34+ cells cultured
in autologous hWJSCs
(A) Higher mean ± SEM cell viability in the presence of autologous hWJSCs
compared to control. (B) Higher mean ± SEM percentage CD34 in the presence of
autologous hWJSCs to control. Dashed line indicate percentage of CD34+ cells before
culture. Asterisk (*) indicates statistical significance of p<0.05.
Chapter 5: Ex vivo Expansion of Cord Blood CD34+ Cells Using hWJSCs
and hWJSC-CM
116
was to enable a sustained release of molecules to promote HSCs self renewal
and proliferation 109. Fresh patient-aspirated or commercial BM-MSCs have been
the cell of choice for stromal support of HSCs as BM-MSCs are the normal
resident cells in the bone marrow that provide a natural scaffold for the expansion
of neighbouring HSCs in vivo. However, there is a need to explore alternative
MSCs source due to the pain and risk of infection in harvesting fresh BM-MSCs
and its variability to donor age etc. Though UCB-MSCs have been isolated 231-234 ,
some groups have failed or obtained very low MSCs number in UCB 225,226,235. In
fact, Bieback et al only manage to isolate 29 MSC-like colonies in 17 out of 59
processed cord blood and their optimal cell growth is only reached as late as 20
days in culture 234.
On the other hand, another MSC-like cells like hWJSCs that can be isolated from
the Wharton's jelly portion of discarded umbilical cord in abundance is an
attractive source for allogeneic or autologous stromal support for HSCs ex vivo
expansion. Using protocol previously described, the derivation efficiency of
hWJSCs was 100% and 4-5 x 106 hWJSCs/cm of the umbilical cord can be
consistently isolated 3,4. Such MSCs numbers with serial culture are very much
higher than what is available in bone marrow or UCB.
Phase contrast images and SEM images showed that in the presence of
hWJSCs or hWJSC-CM, the HSCs began to put out pseudopodia-like outgrowth
to help them migrate towards the surface of the stromal hWJSCs niche, to attach
and proliferate. Such outgrowths have been previously described as "fleet fleet"
236 or uropods 223. Direct contact of HSCs with MSCs have been shown to affect
migratory behavior and gene expression profiles of CD133+ HSCs during ex vivo
expansion 223. It was hypotheisized that specific stem cell niches within the
stromal cell monolayers played a role in HSCs migration and proliferation and the
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MSCs surface was the predominant site for HSCs proliferation while the
compartments beneath the MSCs layer mimicked the stem cell niche 224. In
addition, the immunocytochemistry staining of hWJSCs in this chapter indicate
that similar to BM-MSCs, hWJSCs also expresses molecules like CXCR4, CD44,
CD146, CD29, VCAM-1, MMP-2, MMP-9, hyaluronan, laminin, Stro-1 that is
required for HSCs migration and homing.
hWJSCs have been shown to secrete a wide variety of factors of the interleukin
family, glycosaminoglycans (GAGs), hyaluronic acid (HA), cell membrane
proteins, cell adhesion molecules, cadherins and growth factors 7,112. The results
of the proteomic analysis in this chapter were consistent with these observations.
The members of the interleukins family specifically IL-6 and IL-8 and the growth
factors (SCF, HGF) were secreted at extremely high level and may be important
for CD34+ cells ex vivo expansion. IL-6 has been reposted to stimulate
hematopoiesis 237 and IL-8 enhances proliferation 238. SCF and HGF were shown
to be effective in their maintenance 239. hWJSCs also secreted high levels of HA
and GAGs which are the building blocks of the extracellular matrix 14.
Interestingly, it was recently shown that when heparan sulfate was administered
alone to CD34+ cells it helped to expand and maintain blood lineages in vitro 240.
While others reported the use of bone marrow stromal conditioned medium
supplemented with IL-3 and MIP-1a are required for expansion of long-term
culture-initiating cells and CFC 241, hWJSC-CM is naturally rich in these specific
agents and other additional useful interleukins, growth factors to bring about an
even greater desirable effects.
The logistical limitations using BM-MSCs from a family member of the patient as
stromal support for ex vivo expansion of HSCs included (1) the appropriate family
member not being available for donation and (2) the long time taken to not only
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generate sufficent BM-MSCs but also to carry out co-culture expansion to provide
sufficient HSCs since the disease progression was rapid in some leukemic
patients 220. The availability of "off-the-shelf" GMP compliant allogeneic MSCs for
immediate use to alleviate this logistic problem have been recommended. The
results of this chapter supported these suggestions and hWJSCs could be an
alternative "off-the-shelf” allogeneic MSCs source. Moreover, hWJSCs in general
are considered hypoimmunogenic 46.
The results of the present study also demonstrated that autologous hWJSCs
harvested from the same umbilical cord can also provide a useful source for
stromal support for cord blood HSCs expansion. The feasibility to store
autologous hWJSCs have immense benefits as it has also been demonstrated
that the major histocompatibility complex (MHC) restriction exists between HSCs
and stromal cells both in vitro and in vivo 242,243. Significant reductions in both
cobblestone colonies of murine HSCs and bone marrow engraftments were
observed with MHC-mismatched stromal cells as compared to MHC-matched
stromal cells in vitro and in vivo respectively 242,243. Likewise, there is also
preferential expansion of UCB CD34+ cells when co-cultured with MHC-matched
amnion-derived MSCs 244. As the harvesting of hWJSCs only take a few hours 3,4,
it is possible to freeze and store UCB-HSCs and hWJSCs from the same
umbilical cord on the same day in a dual chamber blood collection bag. When the
HSCs are needed, the hWJSCs could be thawed and used for HSCs expansion
of HSCs if the number were inadequate. Moreover, co-transplantation of
hWJSCs with UCB CD34+ cells could accelerate hematopoietic recovery in
NOD/SCID mice even when limited numbers of UCB CD34+ cells were infused
112. As such, the use of autologous hWJSCs cell source together with cord blood
HSCs would to help improve the HSC tranplantation engraftment efficiencies
greatly, and therefore we propose to co-bank hWJSCs with their corresponding
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cord blood stem cells in the cord blood bank. This approach will avoid the need
for discarding precious HSCs samples that are low in numbers as it is practiced
by cord blood banks today.
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6.1 Introduction
Since the introduction of bone marrow hematopoietic stem cells (HSCs)
transplantation, HSCs have been used in the treatment of hematopoietic
diseases such as leukemia, lymphoma, thalassemia and autoimmune disorders.
HSC transplantation has also been shown to produce promising results for the
treatment of chronic liver failure and acquired immunodeficiency syndrome 95,96.
HSCs can be obtained from many different sources such as bone marrow (BM),
peripheral blood (PB) and umbilical cord blood (UCB). HSCs isolated from the
UCB have several advantages for transplantation therapy compared to the BM
and PB 103-105. They are easily collected and stored in cord blood banks, have
lesser risk of graft versus host disease (GVHD) in transplant recipients due to
their immune naivety and require less stringent criteria for donor-recipient
matching. Additionally they have high proliferation rates, autocrine production of
hematopoietic factors and longer telomere lengths due to their younger
chronological age.
However, a major limitation to their use in transplantation is the low cell numbers
collected in a single UCB unit. The typical yield of HSCs from a single freeze-
thawed UCB unit is about 1.0 x 107 cells 109. This number is far from enough than
the recommended cell numbers range of 2.5 to 5 x 106 CD34+ cells/kg for a
successful engraftment 245,246. As such, single unit UCB-derived HSC
transplantation is often a challenge for the treatment of adults 109. Two of the
strategies for successful transplantation in adult humans are (i) the use of double
UCB unit transplantation and (ii) ex vivo expansion of the single UCB unit.
However, double UCB transplantation has been associated with delayed
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engraftment and elevated engraftment failure and usually one UCB unit ultimately
predominates over the other 220. Since there is a threshold dose below which
cord blood transplantation recipients have engraftment failure, the ex vivo
expansion of HSC numbers from single UCB units for the treatment of adults is a
more plausible approach to successful transplantation therapy. Thus, attempts
were made to increase HSC numbers in single UCB units. One such method is
the refinement of existing cryopreservation protocols so as to increase freeze-
thaw survival cell numbers.
For most types of cells, slow programmed freezing gives optimum freeze-thaw
survival results compared to rapid or ultra-rapid methods because of the slow ice
crystal formation helping in its preservation. However, existing slow freezing
protocols for HSCs are far from ideal as there is significant cell death and loss of
CD34+ cell populations after freeze-thaw 247. This is because the slow freezing
process results in nutrient deprivation, cellular dehydration, stress changes to
structure, and physiology of HSCs and these effects compromise the post-thaw
survival rate of stem cells 248.  Cryoinjury-induced apoptosis has also been
reported as one of the main reasons for the loss of viability after cryopreservation
249. Post-thaw apoptosis of CD34+ cells has also been shown to affect the
recovery of viable CD34+ cells required for transplantation therapy 250,251. It has
been reported that the post-thaw apoptosis of CD34+ cells was mediated by the
mitochondria and activated caspase 3 activity 252. Previous studies used catalase
and trehalose additives to provide cryoprotection by preventing apoptotic cell
death 253. The ROCK inhibitor Y-27632 was shown to enhance post-thaw survival
and recovery of human embryonic stem cells and induced pluripotent stem cells
254,255, human mesenchymal stem cells (hMSCs) 249 and human umbilical cord
Wharton’s jelly stem cells (hWJSCs) 256. However, it was shown to impair the
survival, recovery and expansion of cryopreserved CD34+ cells 247. Currently,
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novel methods are being explored to improve the freeze-thaw viability and
numbers of cryopreserved UCB-HSCs 105. An optimal protocol for
cryopreservation of HSCs that could overcome cryopreservation-induced
damage needs to be developed to support HSC transplantation 257.
Chapter 5 showed that the secretions in the culture medium conditioned by
hWJSCs over 24h had potent molecules that had strong anticancer effects and
also supported the expansion of HSCs ex vivo 8. When UCB-HSCs were
exposed to hWJSC conditioned medium (hWJSC-CM) they were motile
immediately, put out pseudopodia-like projections and underwent proliferation.
With increase culture time, augmentation of CD34+ cell numbers and colony
forming units resulted and eventually generated all the lineages of normal
hematopoiesis 8. A proteomic analysis of the hWJSC-CM showed high
concentrations of several families of important agents such as interleukins,
growth factors, glycosaminoglycans and cell adhesion molecules which were
attributed the spontaneous activity and expansion of the HSCs to 8. Given the
potent actions and potential therapeutic value of the agents in hWJSC-CM, the
aim of this chapter is to explore whether the incorporation of hWJSC-CM as a
supplement in freezing and thawing media in cryopreservation protocols and in
post-thaw culture would enhance freeze-thaw survival and subsequent increase
of CD34+ cell numbers.
6.2 Material and Methods
6.2.1 Cell Culture
Human Wharton's jelly stem cells (hWJSCs)
After informed patient consent and approval from the Institutional Domain
Specific Review Board (DSRB), hWJSC lines were developed from human
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umbilical cords. hWJSCs were cultured in hWJSC medium comprising of 80%
DMEM, 20% fetal bovine serum (FBS) (Biochrom, Berlin, Germany),  1% non-
essential amino acids, 2 mM L-glutamine, 0.1 mM β-mercaptoethanol, 1%
insulin-transferrin-selenium, antibiotic/antimycotic mixture (Invitrogen Life
Technologies, Carlsbad, CA) and 16 ng/ml basic fibroblast growth factor
(Millipore Bioscience, Temecula, CA).
Cord Blood CD34+ cells
Approval for purchase and use of commercial cord blood CD34+ cells (HSCs)
(StemCell Technologies Vancouver, BC, Canada) was granted by the National
University of Singapore Institutional Review Board (NUS-IRB). The cell lines were
thawed and expanded in StemSpan SFEM medium (StemCell Technologies)
supplemented with 2mM L-glutamine, 1% antibiotic/antimyotic mixture (Invitrogen
Life Technologies) and cytokines cocktail CC110 for 3 days before use for
freeze-thaw survival experiments (StemCell Technologies).
6.2.2 Preparation of hWJSC conditioned medium (hWJSC-CM)
The preparation of hWJSC-CM was carried out as previously described 8,9,57.
Briefly, early passages of hWJSCs (3P to 5P) were first cultured in hWJSC
medium until 70% confluency. The medium was then replaced with basal
StemSpan SFEM (StemSpan Technologies) supplemented with 1%
antibiotic/antimyotic mixture (Invitrogen). After 24h, the medium (hWJSC-CM)
was collected, filtered through a 0.22M filter (Millipore) and stored at -80oC until
use.




Freezing of cord blood CD34+ cells
The expanded cord blood CD34+ cells were divided into 2 equal groups. Cells in
the control group (Group A) were frozen in Freezing Medium (Control) (FMC)
comprising of 50% StemSpan SFEM (StemCell Technologies Vancouver,  BC)
supplemented with 2 mM L-glutamine, 1% antibiotic/antimyotic mixture
(Invitrogen Life Technologies), 40% FBS (HyClone Thermo Fisher Scientific,
Rochester, NY) and 10% DMSO (Sinopharm Chemical Reagent Co.Ltd,
Shanghai, China). Cells in the experimental group (Group B) were frozen in 24h-
50% hWJSC-CM supplemented with 2 mM L- glutamine, 1% antibiotic/antimyotic
mixture (Invitrogen Life Technologies, Carlsbad, CA), 40% FBS (HyClone
Thermo Scientific) and 10% DMSO (Sinopharm Chemical Reagent Co Ltd). Both
groups of cells were frozen using slow programmed freezing in a controlled rate
freezing machine (Kryo10 Series II) from room temperature at a freezing rate of -
1oC per minute to -120oC as previously described 258. The cryovials were
removed at -120oC and plunged into liquid nitrogen (-1960C) in a tank for at least
2 weeks before analysis.
Thawing of cord blood CD34+ cells
Frozen CD34+ cells from Groups A and B were thawed rapidly within 1-2 min in a
37oC water bath and added to thawing medium [IMDM (Invitrogen Life
Technologies) supplemented with 20% FBS (HyClone Thermo Fisher Scientific),
2 mM L-glutamine, 1% antibiotic/antimyotic mixture (Invitrogen Life Technologies)]
and centrifuged.  The cell pellets from each of Groups A and B were divided into
2 Subgroups, with each Subgroup having Experimental and Control arms.
Subgroup 1: 0 h post- thaw analysis (Analysis done immediately after thawing)
(Experimental arm: hWJSC-CM; Control arm: control).
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Subgroup 2: 72 h post-thaw analysis (Analysis done 72 hours after thawing).
Thawed cells grown for 72 h in 24h-50% hWJSC-CM supplemented with 20%
FBS (HyClone Thermo Fisher Scientific, 2mM L-glutamine and 1%
antibiotic/antimyotic mixture (Invitrogen Life Technologies) in the Experimental
group while in the Control group, thawed cells grown for 72 h in basal StemSpan
SFEM supplemented with 20% FBS (HyClone Thermo Fisher Scientific), 2mM L-
glutamine and 1% antibiotic/antimyotic mixture (Invitrogen Life Technologies).
The cells were then analyzed for cell morphology, cell proliferation assay, CD34+
cell analysis, CFU assay, Annexin V-FITC/PI assay, Live/Dead® Viability assay
and cell cycle assay.
6.2.4 Experimental Analysis Test
Cell Morphology
Cell pellets from Experimental and Control arms from both subgroups were
placed in their respective media and the cell morphology imaged with Olympus
IX70 Inverted fluorescence microscope (Olympus Corporation, Tokyo, Japan).
Cell viability (MTT assay)
The cells from Experimental and Control groups collected, washed once with
PBS (-), centrifuged at 300 x g and then re-suspended in 100 L growth media.
10 µl [3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide] (MTT, 0.5
mg/ml) (Duchefa Biochemie B.V., Haarlem, Netherlands) was added to the
medium for each sample and the tubes were incubated overnight at 37oC in 5%
CO2. The cell suspension was then centrifuged at 1,500 x g for 5 min, medium
decanted and 100 µl of DMSO reagent (Sinopharm Chemical Reagent Co.Ltd)
added to the cell pellet. The cells were dispensed into 96-well assay plates
(NUNC, Rochester, NY) and incubated in the dark at 37oC for 10 min.
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Absorbance at 570 nm against a reference wavelength of 630 nm was measured
using a spectrophotometer microplate reader (mQuant; BioTek, Winooski, VT,
USA).
CD34+ cells
The cells pellet from Experimental and Control groups were collected and
blocked with 10% normal goat serum (NGS) to prevent non-specific binding. The
cells were then incubated with primary anti human CD34 antibodies (1:100)
(Biolegends, San Diego, USA) for 30 min followed by secondary goat anti-mouse
IgG (H+L) Alexa Fluor 488 antibodies (Invitrogen Life Technologies) for 30 min in
the dark. The cells were washed with PBS, resuspended in 10% NGS, filtered
with a 40 m strainer and analyzed with CyAnTM ADP analyzer (Beckman Coulter,
Fullerton, CA, USA).
Colony Forming Unit (CFU)
Cell pellets from Experimental and Control arms were re-suspended in 1 mL of
IMDM medium supplemented with 20% FBS, L-glutamine and
antibiotic/antimycotic mixture. 50l of the cell suspension from each group was
seeded into each well of a 24-well plate containing 0.5 mL in MethoCultR H4435
medium (StemCell Technologies). The 24-wells plates were incubated at 37oC in
a 5% CO2 in air atmosphere for 12 days. Colonies (CFU) that were formed after
12 days were classified based on morphology as described by the Atlas of
Hematopoietic Colonies from Cord Blood. The CFU colonies were imaged using
an inverted phase contrast microscope (Nikon Instruments, Tokyo, Japan). The
CFU colonies were later quantified using the CytoSelectTM Hematopoietic Colony
Forming assay (Cell Biolabs, Inc., San Diego, CA). Briefly, the cells were
collected and resuspended in 250 L IMDM medium supplemented with 20%
Chapter 6: hWJSC-CM Enhances Cord Blood CD34+ Cells Freeze Thaw
Survival
128
FBS, L-glutamine and antibiotic/antimycotic mixture (Invitrogen Life
Technologies). 50l of 4X Lysis Buffer/CyQuant® GR dye solution (1:75 dilution)
was then added to each sample, mixed, and incubated for 30 min at room
temperature. 100 l of the mixture was added to each well in the 96 well plate
and readings were taken with a 485 nm/535 nm filter set using TECAN GENios
(TECAN Austria GmBH, Salzburg, Austria).
Annexin V/PI assay
The cell pellet from Experimental and Control groups were collected, washed
once with PBS (-), centrifuged and then resuspended with 500 L of 1X Annexin
V binding buffer (BioVision, Inc., Mountain View, CA). The cells were then
stained with 1 L of Annexin V- FITC (BioVision) and counterstained with 1L of
propidium iodide (PI, Invitrogen), at room temperature for 15 min, filtered with a
40 m nylon strainer and analyzed using a CyAnTM ADP analyzer (Beckman
Coulter, Fullerton, CA, USA).
Live/Dead cell assay
The live/dead cell assay was performed on the cell pellets from Experimental and
Control groups using the Live/Dead® Viability/Cytotoxicity Kit for mammalian
cells (Invitrogen). A working solution of component A (included in the kit) was first
made by adding 1 l of component A into 79 l of DMSO (Sinopharm Chemical
Reagent Co.Ltd). 1 µL of this component A working solution and 2 µL of
component B (supplied in the kit) were added to 500 µl of PBS (-) to make the
staining solution.
The cells were later collected, washed once with PBS (-), centrifuged and
resuspended in 500 µl of staining solution and then incubated for 15 min in the
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dark. The cell suspension was filtered with a 40 µm nylon strainer and analyzed
using a CyAnTM ADP analyzer (Beckman).
Cell cycle analysis
The cell pellets from the Experimental and Control groups were collected,
washed once with PBS (-), then fixed in cold 70% ethanol at -20oC overnight. The
cells were later washed with PBS (-) once before adding 20 g/mL PI, 100 µg/mL
RNase A (AppliChem GmbH, Garmstadt, Germany) to each sample and then
incubated for 15 min at 37oC in 5% CO2. The cell suspension was then filtered
using a 40 µm nylon strainer to remove any cell clumps before analysis using a
CyAnTM ADP analyser (Beckman).
6.2.5 Statistical Analysis
All results were expressed as mean (fold change) ± SEM and statistical
signiﬁcance between the groups was calculated using the one way ANOVA or
two-tailed Student’s t-test (SPSS Statistic v 17.0 software package) (SPSS, Inc,
IL).  The p-value of <0.05 was considered as statistically significant.
6.3 Results
6.3.1 Cell Morphology
No distinct morphological differences were observed in the UCB CD34+ cells
between the Control and Experimental groups with cells in both groups showing
their characteristic spherical shape and size immediately after thawing [Fig. 31(a,
b)]. There are more cellular debris was observed after 72 h culture in the Control
compared to the Experimental group [Fig. 31(c-f)].
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6.3.2 Cell Viability and CD34+ analysis
Cord blood CD34+ cells had significant greater cell viability in hWJSC-CM
compared to controls immediately after thawing. The cell viability rates increased
by 2.08 ± 0.3 fold (Fig. 32A) in samples frozen in hWJSC-CM immediately after
thawing. Cord blood CD34+ cells then had significantly greater cell viability of
CD34+ cells were observed when they were frozen in hWJSC-CM and cultured
after thawing for 72 h in hWJSC-CM compared to controls. The cell viability rates
increased by 2.28 ± 0.17 fold (normalized to control) (Fig. 32B) in samples frozen
in hWJSC-CM and cultured in hWJSC-CM after thawing. Cord blood CD34+ cells
showed higher percentages of CD34+ in hWJSC-CM compared to the controls
immediately after thawing. The percentages of CD34+ for control and hWJSC-
CM were 94.84 ± 2.42% and 96.63 ± 1.43% respectively (Fig. 32C) immediately
Figure 31 Morphology of CD34+
(a, b): Morphology of CD34+ cells frozen in hWJSC-CM, thawed and analysed
immediately (0 h post-thaw). Note the thawed CD34+ cells that were frozen in
hWJSC-CM having similar healthy circular morphology as controls. (c-f): Morphology
of CD34+ cells frozen in hWJSC-CM, thawed and then grown in hWJSC-CM for 72
h (72 h post-thaw). (c, d): Note low and high magnification of healthy CD34+ cells
(arrows) (e, f): Controls showing greater cell death (cell debris) (arrows). Scale bar: 100
m.
Chapter 6: hWJSC-CM Enhances Cord Blood CD34+ Cells Freeze Thaw
Survival
131
after thawing. Cord blood CD34+ cells then showed significantly greater
percentages of CD34+ cells when they were frozen in hWJSC-CM and cultured
after thawing for 72 h in hWJSC-CM compared to controls. The percentages of
CD34+ for control and hWJSC-CM were 65.23 ± 1.69% and 77.57 ± 0.54% (Fig.
32D) 72 h after thawing.
Figure 32 Cell viability rate of CD34+ cells frozen in hWJSC-CM, thawed and grown in
hWJSC-CM for 72h.
(a): Note greater fold increases (normalised to respective controls) of CD34+ cells frozen
in hWJSC-CM, thawed and analysed immediately (0 h post-thaw) and; (b): Note greater
fold increases of CD34+ cells after thawing and growing in hWJSC-CM for 72 h (72 h post-
thaw). (c): Higher percentaged of CD34+ cells were observed when CD34+ were frozen in
hWJSC-CM, thawed and analysed immediately (0 h post-thaw); and (d) Higher
percentage of CD34+ cells were observed when CD34+cells were frozen in hWJSC-CM,
thawed and grown in hWJSC-CM for 72. Values are mean ± SEM of 3 different
experiments. Asterisk (*): p<0.05.
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6.3.3 Colony Forming Unit (CFU) Assay
Cord blood CD34+ cells from all groups displayed typical GEMM CFU
morphology as described by the Atlas of Hematopoietic Colonies from Cord
Blood [Fig 33 (A-D)]. When the CFU colonies were quantified using the
CytoSelectTM Hematopoietic Colony Forming assay, cells that were frozen in
hWJSC-CM produced more CFUs compared to controls (1.07 ± 0.02)
immediately after thawing (Fig. 33E). Cord blood CD34+ cells had produced
more CFUs when they were frozen in hWJSC-CM and cultured after thawing for
72 h in hWJSC-CM compared to the controls. The CFU unit increased 1.6 ± 0.17
fold (normalized to control) (Fig. 33F) in samples frozen in hWJSC-CM and
cultured in hWJSC-CM after thawing.
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6.3.4 Annexin V-FITC/PI Assay
Cord blood CD34+ cells had lower percentages of Annexin V+ cells in hWJSC-
CM compared to controls immediately after thawing. The percentages of Annexin
V+ for control and hWJSC-CM were 15.36 ± 0.59% and 14.00 ± 0.95%
respectively (Fig. 34A) immediately after thawing. Likewise cord blood CD34+
had lower percentages of PI+ cells in hWJSC-CM compared to the controls
immediately after thawing. The percentages of PI+ for control and hWJSC-CM
Figure 33 CFU assay of CD34+ cells frozen in hWJSC-CM, thawed and grown in
hWJSC-CM for 72 h.
(a): CD34+ cells frozen in hWJSC-CM, thawed and grown on methylcellulose for 12 days
showed typical GEMM colonies, (b): Parallel controls showed similar GEMM colonies.
(c): Similar GEMM colonies were observed for CD34+ cells frozen in hWJSC-CM, thawed
and then grown in hWJSC-CM for 72 h. (d): Parallel controls showed similar GEMM
colonies. (e): Greater number of colonies (normalised to controls) were observed when
CD34+ cells were frozen in hWJSC-CM, thawed and grown on methylcellulose; and (f):
Greater number of colonies (normalised to controls) were observed when CD34+ cells
were frozen in hWJSC-CM, thawed, grown in hWJSC-CM for 72 h and then grown on
methylcellulose. Values are mean ± SEM of 3 different experiments.
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were 11.45 ± 0.23% and 11.45 ± 0.23% receptectively (Fig. 34B) immediately
after thawing.
Cord blood CD34+ cells then had significantly lower percentages of Annexin V+
and PI+ cells when they were frozen in hWJSC-CM and cultured after thawing for
72 h in hWJSC-CM compared to the controls. The mean ± SEM percentages for
Annexin V+ for control and hWJSC-CM were 18.92 ± 0.1% and 8.68 ± 0.57%
(Fig. 34C) respectively 72 h after thawing. The mean ± SEM percentages for PI+
cells for control and hWJSC-CM were 12.39 ± 0.35% and 7.19 ± 0.34%
respectively (Fig. 34D) 72 h after thawing.
Figure 34 Annexin V/PI assay of CD34+ cells frozen in hWJSC-CM, thawed and
grown in hWJSC-CM for 72 h.
(a): Lower percentages of apoptotic cells (Annexin V+) were observed when CD34+ cells
were frozen in hWJSC-CM, thawed and analysed immediately (0 h post-thaw). (b): Lower
percentages of necrotic cells (PI+) were observed when CD34+ cells were frozen in
hWJSC-CM, thawed and analysed immediately (0 h post-thaw). (c): Lower percentages of
apoptotic cells (Annexin V+) were observed when CD34+ cells were frozen in hWJSC-CM,
thawed and grown in hWJSC-CM for 72 h (72 h post-thaw). (d): Lower percentages of
necrotic cells (PI+) were observed when CD34+ cells were frozen in hWJSC-CM, thawed
and grown in hWJSC-CM for 72 h (72 h post-thaw). Values are mean ± SEM of 3 samples
with 3 different experiments. Asterisk (*): p<0.05.
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6.3.5 Live/Dead and Cell Cycle Assay
Cord blood CD34+ cells showed greater percentages of live cells in hWJSC-CM
compared to the controls immediately after thawing. The percentages of live cells
for control and hWJSC-CM were 81.2 ± 0.58% and 83.07 ± 1.73% respectively
(Fig. 35A) immediately after thawing. Similarly, cord blood CD34+ showed lower
percentages of dead cells in hWJSC-CM compared to controls immediately after
thawing. The percentages of dead cells for control and hWJSC-CM were 17.07 ±
1.93% and 16.18 ± 1.34% respectively (Fig. 35B) immediately after thawing.
Cord blood CD34+ cells then had higher percentages of live cells when they were
frozen in hWJSC-CM and cultured after thawing for 72 h in hWJSC-CM
compared to controls. The mean ± SEM percentages for live cells for control and
hWJSC-CM were 68.05 ± 0.84% and 74.75 ± 3.43% (Fig. 35C) respectively 72 h
after thawing.
Likewise cord blood CD34+ had lower percentages of dead cells when they were
frozen in hWJSC-CM and cultured after thawing for 72 h in hWJSC-CM
compared to controls. The mean ± SEM percentages for dead cells for control
and hWJSC-CM were 22.02 ± 0.49% and 20.05 ± 2.1% respectively (Fig. 35D)
72 h after thawing.
Cell cycle analysis had lesser percentage of cord blood CD34+ cells with
fragmented DNA (Sub-G1 phase) in samples frozen in hWJSC-CM compared to
the controls. The percentages of sub-G1 for control and hWJSC-CM were 4.47 ±
1.89% and 3.24 ± 0.63% respectively (Fig. 35E) immediately after thawing. In
addition, cord blood CD34+ had significantly lower percentages of cells with
fragmented DNA dead when they were frozen in hWJSC-CM and cultured after
thawing for 72 h in hWJSC-CM compared to controls. The mean ± SEM
percentages for sub-G1 cells for control and hWJSC-CM were 10.65 ± 0.27%
and 3.10 ± 0.69% respectively (Fig. 35F) 72 h after thawing.
Chapter 6: hWJSC-CM Enhances Cord Blood CD34+ Cells Freeze Thaw
Survival
136
Figure 35 Live/Dead viability and cell cycle analysis of CD34+ cells frozen in
hWJSC-CM, thawed and grown in hWJSC-CM for 72 h.
(a): Higher percentages of live cells were observed when CD34+ cells were frozen in
hWJSC-CM, thawed and analysed immediately (0 h post-thaw). (b): Lower percentages of
dead cells were observed when CD34+ cells were frozen in hWJSC-CM thawed and
analysed immediately (0 h post-thaw).(c): Higher percentages of live cells were observed
when CD34+ cells were frozen in hWJSC-CM, thawed and grown in hWJSC-CM for 72 h
(72 h post-thaw). (d): Lower percentages of dead cells were observed when CD34+ cells
were frozen in hWJSC-CM, thawed and grown in hWJSC-CM for 72 h (72 h post-thaw).
(e): Lower percentages of cells with fragmented DNA (sub G1 phase) were observed
when CD34+ cells were frozen in hWJSC-CM, thawed and analysed immediately (0 h
post-thaw); and (f): Lower percentages of cells with fragmented DNA (sub G1 phase)
were observed when CD34+ cells were frozen in hWJSC-CM, thawed and grown in
hWJSC-CM for 72 h (72 h post-thaw). Values are mean ± SEM of 3 different experiments.
Asterisk (*): p<0.05.




hWJSCs are mesenchymal stem cells (MSCs) that can be harvested painlessly in
large numbers from discarded umbilical cords without ethical constraints and
served as an attractive alternative to bone marrow MSCs for cell based therapies
3,4. In vivo, MSCs served as a natural scaffold within the bone marrow for the
expansion of HSCs. They are similar to a pharmacy that dispense molecules for
the maturation and proliferation of CD34+ cells that eventually produced all the
blood lineages in the general circulation. Such expansion of CD34+ cells is
mediated via cell-to-cell attachment and migration into the niches of the MSC
scaffold or via the molecules secreted by the MSCs. hWJSCs are of the same
embryological origin as bone marrow MSCs 5, but they are different in terms of
their nature, properties and concentrations of the unique bioactive molecules they
release 259. hWJSCs appear to provide the three dimensional architecture
mimicking physiological conditions ex vivo. We reported in chapter 5 that HSCs
multiply in large numbers in vitro when in the presence of hWJSCs or hWJSC-
CM and postulated that such effects may be cell-to-cell contact mediated or via
molecules such as interleukins, growth factors, glycosaminoglycans and growth
adhesion factors released in high concentrations into hWJSC-CM 8. The present
study demonstrated that the members of these interleukin, interferon, GAGs and
cell adhesion molecule families are secreted in high concentrations by hWJSCs
and they singly or in combination may be the important players involved in
enhanced CD34+ survival and proliferation. These same agents may be playing
a role in the increased freeze-thaw survival and subsequent enhanced growth of
CD34+ cells observed in this chapter. The cell adhesion molecules in particular
may be helping to preserve the cell membrane integrity of the CD34+ cells during
the freezing process while the growth factors and interleukins may enhance
mitosis of the cells during the 72 h after freeze-thawing.
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Studies aimed at improving the cryopreservation of HSCs are focused mainly in
two areas (1) refinement of the freezing media and (2) improvement of the
freezing and storage procedures 260. DMSO at a concentration of 10% is the
conventional cryoprotectant used for the freezing of HSCs in cord blood banks.
However, clinically, DMSO has been known to be associated with significant side
effects that include nausea, vomiting and abdominal cramps in addition to other
systemic disturbances in patients receiving HSC transplantation. Therefore
reducing the concentration of DMSO or buffering its effects is of vital importance
in improved cryopreservation protocols for HSCs. Additionally, cryopreservation
using the current conventional recipes of DMSO + freezing media results in a
significant proportion of collected stem cells (20-30%) becoming non-viable due
to early irreversible apoptosis 261. Various additives were able to improve the
post-thaw recovery of CD34+ cells. Low levels of trehalose and catalase were
shown to reduce post-thaw apoptosis in murine HSCs 262. Freezing solutions
supplemented with membrane stabilisers such as taurine, ascorbic acid and α-
tocopheryl acetate also showed improved post-thaw recovery 263. These reports
confirmed that supplements in the freezing medium can help to protect CD34+
cells from the cryoinjuries of freezing and thawing. The results of the present
study using hWJSC-CM in the freezing medium showed greater post-thaw
recovery of CD34+ cells as compared to the use of such additives. This
improvement is perhaps due to a combined effect of the interleukins, GAGs,
growth factors and cell adhesion molecules present in hWJSC-CM. It was
reported that the addition of certain selected interleukins to cultures of CD34+
cells induced the expansion and differentiation of these cells 264. Hyaluronic acid
which is an important member of the GAGs family was shown to stimulate the
growth of CD34+ selected UCB cells into specifically differentiated mature
eosinophils. This process was modulated by the CD44 receptor on the progenitor
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cell population 265. Interleukin 11 stimulated the proliferation of human
hematopoietic CD34+ and CD34+CD33-DR- cells and synergized with stem cell
factor, interleukin-3, and granulocyte-macrophage colony-stimulating factor 266.
Cryopreservation results in a combination of physical and biological stresses that
damages cells leading to post-thaw apoptosis 257. CD34+ cells appear to be more
vulnerable to cryoinjury compared to other somatic cells. Cryoinjury-induced
apoptosis is one of the main reasons for the loss of viability after
cryopreservation and such post-thaw loss of viability of CD34+ cells has been
the major contributing factor that influences the cell numbers required for
successful HSC engraftment 249-251. Although the use of UCB-HSCs in
transplantation therapy has become increasingly popular, its application has
been confined to transplantation for children because of limited viable CD34+ cell
numbers 267. Previous cryopreservation studies which examined vehicle solution,
serum and protein addition, cryoprotectant and freezing curve focused only on
improving the physical parameters without taking into consideration how to
prevent these biological stresses 268. Studies from adherent stem cell populations
such as bone marrow MSCs and hWJSCs postulated that by inhibiting the p160-
Rho-associated coiled-coil kinase signaling pathway, post-thaw apoptosis could
be prevented, hence improving cell recovery and survival 256. However, the same
inhibitor failed to exhibit a similar protective effect on non-adherent UCB CD34+
cells suggesting that cell death may be occurring via a different signaling
pathway 247. The exact mechanisms as to how hWJSC-CM influences freeze-
thaw survival and expansion of CD34+ cells are still unclear. Preliminary results
from detailed proteomic and microRNA studies on hWJSC and/or hWJSC-CM
conducted previously suggested that there is a down regulation of miR-146 which
in turn resulted in an increase in prostaglandin E2 (PGE2) production
(Unpublished data). Recently, there appeared to be increasing evidence
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suggesting that PGE2 is crucial for the regulation of hematopoiesis and HSC
engraftment 269. It was reported that both mouse and human HSCs express PGE2
receptors and short term ex-vivo exposure to PGE2 enhanced the expansion,
homing and survival of HSCs 270. Hence the presence of PGE2 in the hWJSC-CM
may have also prevented cryoinjury-induced apoptosis by increasing intracellular
survivin levels.
hWJSCs and hWJSC-CM support the expansion of HSCs and hWJSC-CM also
helped to enhance CD34+ thaw-survival viability and further cell proliferation after
thawing, we proposed that cord blood banks derive and store hWJSCs at the
same time as UCB collection. An autologous supply of the same patient’s
hWJSCs will be an ideal adjuvant that can not only be used for cell based
therapies after differentiation into a desirable lineage but can also be useful for
improved freezing and expansion ex vivo. An autologous source has the added
advantage of being matched to the same patient avoiding any immunorejection
problems. Additionally, since hWJSCs have been reported to be
hypoimmunogenic 46, allogeneic sources from other donor umbilical cords could
also be stored in cord blood banks as ‘off-the-shelf’ cells for the same purpose.
Up to 4-5 x 106 live fresh hWJSCs could be obtained from 1 cm of umbilical cord
and they are highly proliferative with short population doubling times 3,4. As such,
frozen hWJSCs could be thawed and confluent monolayers established very fast
for stromal support as well as for preparation of 24 h hWJSC-CM. Storage of
hWJSCs or hWJSC-CM could be easily carried out in the second chamber of a
dual chamber blood bag (first chamber: UCB) and the freezing protocol with or
without hWJSC-CM could be the same for the contents of both chambers. To
meet this objective we also proposed that hWJSC lines and hWJSC-CM be
developed under current good manufacturing practice (cGMP) conditions that will
be safe for the patients.
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Chapter 7: General Discussion
7.1 Hypotheses
Numerous independent reports have confirmed the hWJSCs paradoxical
tumoricidal properties in vitro and in vivo on solid tumors of mammary
adenocarcinoma, ovarian carcinoma, osteosarcoma, and cholangiocarcinoma
and bladder carcinoma. hWJSCs could also provide the structural and
physiological support for self renewal, expansion and homing of HSCs as
reported by several authors. Furthermore, hWJSCs express and secrete high
level of adhesion molecules, extracellular matrix components like
glycosaminoglycans, osteopontin, MCP-1 and ICAM-1 which are inherent
constituents of the hematopoietic stem cell niche that help to regulate the
expansion and maintenance of HSCs. As such, this thesis hypothesized that
hWJSCs and/or its extracts can be used to enhance the treatment of
hematological malignancies and blood disorders. The approach to the hypothesis
was to evaluate (1) the tumoricidal effect of hWJSCs or its extracts on malignant
hematological malignancies and (2) to use hWJSCs or its extracts to enhance the
numbers and freeze thaw survival of hematopoietic stem cells (HSC) (Fig. 36).
Figure 36 Approach to the hypothesis
hWJSCs or its extracts were evaluated for their anti-tumorigenic effect on hematological
malignancies, enhancement of HSC numbers and freeze-thaw survival.
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7.2 Findings, Implications and Limitations
7.2.1 Direct anti-cancer effects of hWJSCs and hWJSC-CM
The bone marrow microenvironment which is made up of mesenchymal stem
cells (MSCs) and extracellular matrix (ECM) serves as an important
hematopoietic niche which influences the abilities of hematopoietic stem cells
(HSCs) or hematopoietic progenitor cells (HPCs) to home, engraft, self-renew
and differentiate via direct cell-cell contact and secretion of hematopoietic growth
factors. The use of aggressive chemotherapeutic agents or radiation-conditioning
regimes prior to HSC transplantation often cause damage to the bone marrow
microenvironment and have a profound influence on HSC engraftment kinetics
and the outcome of patient treatment.
This thesis uses a primitive stromal cell from the Wharton's jelly compartment of
the human umbilical cord with high expression of MSC CD markers and low level
expression of human embryonic stem cell (hESC) markers. They are
hypoimmunogenic, do not form tumor associated fibroblasts and do not induce
tumorigenesis in laboratory animals, primates and humans. Moreover, there are
numerous reports that have confirmed their tumoricidal properties both in vitro
and in vivo on solid tumors. Likewise, results from this thesis have demonstrated
for the first time that these hWJSCs have tumoricidal effects on non-solid
hematopoietic malignant cells as well. The mechanism whereby the hWJSCs
inhibit the growth of the lymphoma cells appeared to be via secretions from the
hWJSCs because hWJSC-CM have inhibited lymphoma cell growth. Exposing
lymphoma cells to a 3kDa molecular weight cut-off (MWCO) concentrate of
hWJSC-CM induced the most cell death in the cancer cells compared to other
molecular weight cut-offs. Further analysis suggested that the bioactive
molecules were larger than 3kDa as lymphoma cell viability significant decreased
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with the 3kDa hWJSC-CM concentrates fraction and not with the flow through (FT)
fraction. The results also showed a mechanism of lymphoma cell death induced
by hWJSC-CM via the oxidative stress pathway by alteration of antioxidant
enzymes. Exposing lymphoma cells to 3kDa hWJSC-CM concentrates showed
an increase in functional activity of H2O2-generating SOD enzymes and
concomitant decrease in functional activity of all three H2O2-catabolic
antioxidative enzymes (GPx, catalase and TPx). Significant increases in H2O2
levels in both lymphoma cell lines were also observed after treatment with the
3kDa MWCO concentrates. Though numerous studies previously have
suggested that the high level of intracellular H2O2 induced cancer cell death,
direct administration of H2O2 to cancer patients was never seen as an appropriate
therapeutic strategy as both the safety and effectiveness were yet to be
ascertained. The thesis suggested a method of inducing cancer cell death by
increasing intracellular H2O2 using hWJSC-CM.
In addition, most chemotherapy or radiation treatment regimens administered to
lymphoma patients often result in damage to the bone marrow, gastrointestinal
tract, heart, brain and kidney. The non-specific inhibition of growth of normal cells
by such regimens is an unwanted side effect. Previous studies also indicated that
aggressive chemotherapeutic or radiation conditioning regimens prior to HSC
transplantation often caused irreversible damage to the stromal cells in the
hematopoietic microenvironment ultimately affecting HSC engraftment and
reconstitution after transplantation. The control fibroblast and adult hBMMSCs in
this thesis were minimally affected by hWJSCs, hWJSC-CM or 3kDa MWCO
concentrates. Therefore the use of hWJSC-CM as a potential therapy for
lymphoma patients may be a safe option in the future as the hematopoietic niche
remains intact.
Lastly, the results in the thesis also indicated that all three molecular hallmarks
for ICD namely ecto-CRT/Hsp90, extracellular ATP and HMGB1 were
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significantly increased in all tested cancer cell lines exposed to 3kDa hWJSC-CM
concentrates. Moreover, earlier studies reported that hWJSCs secrete large
varieties of cytokines and factors like IL-6, IL-8, and MCP-1 that have been
known to play a role in modulating the innate immune response. Treatment of
mammary carcinoma xenograft rat model with rat WJSCs increased CD8+ T cell
infiltration in the tumor tissue. This further strengthens the hypothesis that anti-
tumorigenic treatment with hWJSCs or its conditioned medium could also mount
an immunogenic cell death response. Recent growing evidence indicates that the
patient’s immune competence is crucial in determining efficacy of
chemotherapeutic and radio-therapeutic treatments and the discoveries of
chemotherapeutic and radiotherapeutic treatment strategies that induce
immunogenic cell death in tumors have resulted in many long-term successful
therapeutic options for tumor eradication. Therefore, the upregulation of
molecular DAMPs seen in all cancer cell lines in this thesis shows that hWJSCs
or hWJSC-CM could mount a dual anti-cancer attack in (1) directly killing cancer
cells and (2) activating an immunogenic cancer cell death response which could
unlock a sequence of events leading to development of anti-tumor immunity.
Though the thesis demonstrated the tumoricidal and immunogenic cell death
potential of hWJSCs and hWJSC-CM,  one of the limitations is that the  specific
active agents present in hWJSC-CM that are responsible for its tumoricidal effect
or induction of immunogenic cell death were not extensively pursued in the thesis.
Future studies will involve in the narrowing down and determining the specific
molecules or targets in hWJSCs or hWJSC-CM that are involved. The possible
anti-tumorigenic agents in the hWJSC-CM includes the proteins, miRNAs,
mRNAs and microvesicles present. Untargeted metabolomics or proteomics
using high performance liquid chromatography and mass spectrometry could be
used to determine the moelcules and proteins within the 3kDa MWCO hWJSC-
CM concentrates. Likewise, mRNA or miRNA-PCR array could be performed to
Chapter 7: General Discussion
145
determine the miRNAs present in the 3kDa MWCO hWJSC-CM concentrates.
Furthermore, microvesicles could also be isolated and used directly to analyze
their anti-tumorigenic properties on lymphoma cells. With the results, the
immunogenic tumoricidal effects of specific agents within the 3kDa MWCO
hWJSC-CM concentrates or hWJSCs could be further evaluated by knocking
down, blocking or neutralizing the mRNA, miRNA, proteins or microvesicles in
order to narrow down the candidate active agents as future therapeutics. The
tumoricidal effects of the candidate agents could first be evaluated in a primary
patient-derived cancer cells in vitro system and subsequently evaluated in a
humanized pre-clinical in vivo animal model.
7.2.2 Increasing hematopoietic stem cell number for transplantation
Bone marrow hematopoietic stem cell (HSC) transplantation has been used for
the treatment of malignant and non-malignant hematopoietic diseases such as
leukemia, lymphoma and thalassemia. HSCs from the human umbilical cord
blood (UCB) have been successfully used for the treatment of hematopoietic
diseases in children in autologous and allogeneic settings. UCB contains HSCs
and hematopoietic progenitor cells (HPCs) that appear to have higher
proliferation rates and immunological tolerance compared to those in bone
marrow. However, one major challenge associated with the use of UCB-HSCs for
transplantation is the relatively low cell numbers available. It has been reported
that the HSC and HPC yields in UCB was adequate for the treatment of
hematopoietic diseases in children and not adults as it is estimated that for
successful engraftment, at least 2.5 x 106 CD34+ cells per kg of patient body
weight is required. However, a good UCB harvest from a single umbilical cord
generates a total of only about 10 x 106 CD34+ cells.  Moreover, preexisting slow
freezing protocols for HSCs are far from ideal as there is significant cell death
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and loss of CD34+ cell populations after freeze-thaw. Cryoinjury-induced
apoptosis has also been reported as one of the main reasons for the loss of
viability after cryopreservation. Post-thaw apoptosis of CD34+ cells has also
been shown to affect the recovery of viable CD34+ cells required for
transplantation therapy. As such, the thesis evaluated the use hWJSCs or its
extracts to increase the numbers of cord blood CD34+ cells by ex vivo expansion
and improve their freeze thaw survival of hematopoietic stem cells
In this thesis, phase contrast images and SEM images showed that in the
presence of hWJSCs or hWJSC-CM, the HSCs began to put out pseudopodia-
like outgrowth to help them migrate towards the surface of the stromal hWJSCs
niche, to attach and proliferate. In addition, secretions in the culture medium
conditioned by hWJSCs over 24-72h had potent molecules supported the
expansion of HSCs ex vivo. When UCB-HSCs were exposed to hWJSC
conditioned medium (hWJSC-CM) they immediately became motile, put out
pseudopodia-like projections and underwent proliferation. With increased culture
time, there were more CD34+ cell numbers and colony forming units which
eventually generated all the lineages of normal hematopoiesis. A proteomic
analysis of the hWJSC-CM showed high concentrations of several families of
important agents such as interleukins, growth factors, glycosaminoglycans and
cell adhesion molecules to which the spontaneous activity and expansion of the
HSCs were attributed. Moreover, adding hWJSC-CM in the freezing medium
showed greater post-thaw recovery of CD34+ cells compared to the use of such
additives.
The logistical limitations of using BM-MSCs from a family member of the patient
as stromal support for ex vivo expansion of HSCs or improvement in HSCs
freeze-thaw survival include (1) the appropriate family member not being
available for donation and (2) the long time taken to not only generate sufficient
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BM-MSCs but also to carry out co-culture expansion to provide sufficient HSCs
since the disease progression was rapid in some leukemic patients. The
availability of "off-the-shelf" GMP compliant allogeneic and hypoimmunogenic
MSCs like hWJSCs for immediate use to alleviate this logistical problem are
recommended. In addition, the thesis also demonstrated that autologous
hWJSCs harvested from the same umbilical cord can also provide a useful
source for stromal support for cord blood HSCs expansion. The feasibility to store
autologous hWJSCs have immense benefits as it has also been demonstrated
that the major histocompatibility complex (MHC) restriction existde between
HSCs and stromal cells in vitro and in vivo. As the harvesting of hWJSCs only
take a few hours, it is possible to freeze and store UCB-HSCs and hWJSCs from
the same umbilical cord on the same day in a dual chamber blood collection bag.
When the HSCs are needed, the hWJSCs could be thawed and used for HSCs
expansion of HSCs if the number were inadequate. As such, the use of
autologous hWJSCs cell source together with cord blood HSCs would help
improve the HSC transplantation engraftment efficiencies, and therefore this
thesis proposes to co-bank hWJSCs with their corresponding cord blood stem
cells in the cord blood bank. This approach will avoid the need for discarding
precious HSC samples that are low in numbers as is practiced by cord blood
banks today.
However, one limitation to the thesis was that all evaluations of the expanded
cord blood CD34+ cells were performed using in vitro assays and no evaluations
were done using the in vivo HSCs repopulating mouse model. Therefore, it is still
not known whether CD34+ cells expanded after autologous or allogeneic hWJSC
stromal support or after enhancement in freeze-thaw protocol are adequate to
bring about improvement in engraftment in vivo. As it is paramount to evaluate in
vivo engraftment in the animal model to confirm the enhancement in  CD34+ cells
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HSCs repopulating capabilties using hWJSCs or hWJSC-CM, future studies need
to be centered in proving the improved functional engrafment outcome of the
cord blood CD34+ HSCs after hWJSCs co-culture or hWJSC-CM supplement  in
an in vivo animal model. The expanded CD34+ HSCs could be transplanted into
sub-lethally irradiated NOD-SCID IL2Rg null mice via the tail vein and the positive
positive engraftment of the human cells (at least 0.1% of CD45+ cells) in the
bone marrow will be analysed twelve weeks after the transplantation. In addition,
the presence of primitive and differentiated human HSCs markers like CD34,
CD45, CD13, CD19 and CD3  in the mice bone marrow, spleen and peripheral
blood could be evaluated .
7.3 Conclusion
The results from this thesis demonstrated that hWJSCs or hWJSC extracts
(namely hWJSC-CM) can be derived from commonly discarded umbilical cord
and used as a direct anti-tumorigenic agent on lymphoma cells or used as
supplements in increasing cord blood HSCs numbers by ex vivo expansion or
improving their freeze-thaw survival rates. However, further studies will include
experiments to determinate the tumorigenic active agents within hWJSCs or
hWJSC-CM, the evaluation of the anti-tumorigenic effect on patient-derived
lymphoma cells and in an in vivo experimental model. Likewise, an in vivo
experimental system is needed to evaluate the cord blood HSCs that have been
expanded ex vivo using hWJSCs/hWJSC-CM or freeze in hWJSC-CM.
Nevertheless, the findings in the thesis would encourage the storage of
commonly discarded hWJSCs in public cord blood banks and these cells could
subsequently be used to help improve the efficiency in the management of




1 Bongso, A. & Fong, C. Y. The therapeutic potential, challenges and future
clinical directions of stem cells from the Wharton's jelly of the human
umbilical cord. Stem cell reviews 9, 226-240, doi:10.1007/s12015-012-
9418-z (2013).
2 McElreavey, K. D., Irvine, A. I., Ennis, K. T. & McLean, W. H. Isolation,
culture and characterisation of fibroblast-like cells derived from the
Wharton's jelly portion of human umbilical cord. Biochemical Society
transactions 19, 29S (1991).
3 Fong, C. Y., Richards, M., Manasi, N., Biswas, A. & Bongso, A.
Comparative growth behaviour and characterization of stem cells from
human Wharton's jelly. Reproductive biomedicine online 15, 708-718
(2007).
4 Fong, C. Y. et al. Derivation efficiency, cell proliferation, freeze-thaw
survival, stem-cell properties and differentiation of human Wharton's jelly
stem cells. Reproductive biomedicine online 21, 391-401,
doi:10.1016/j.rbmo.2010.04.010 (2010).
5 Wang, X. Y. et al. Identification of mesenchymal stem cells in aorta-
gonad-mesonephros and yolk sac of human embryos. Blood 111, 2436-
2443, doi:10.1182/blood-2007-07-099333 (2008).
6 Taghizadeh, R. R., Cetrulo, K. J. & Cetrulo, C. L. Wharton's Jelly stem
cells: future clinical applications. Placenta 32 Suppl 4, S311-315,
doi:10.1016/j.placenta.2011.06.010 (2011).
7 Angelucci, S. et al. Proteome analysis of human Wharton's jelly cells
during in vitro expansion. Proteome science 8, 18, doi:10.1186/1477-
5956-8-18 (2010).
8 Fong, C. Y. et al. Human umbilical cord Wharton's jelly stem cells and its
conditioned medium support hematopoietic stem cell expansion ex vivo.
Journal of cellular biochemistry 113, 658-668, doi:10.1002/jcb.23395
(2012).
9 Gauthaman, K. et al. Human umbilical cord Wharton's jelly stem cell
(hWJSC) extracts inhibit cancer cell growth in vitro. Journal of cellular
biochemistry 113, 2027-2039, doi:10.1002/jcb.24073 (2012).
10 Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal
stromal cells. The International Society for Cellular Therapy position
statement. Cytotherapy 8, 315-317, doi:10.1080/14653240600855905
(2006).
11 Wang, H. S. et al. Mesenchymal stem cells in the Wharton's jelly of the




12 Troyer, D. L. & Weiss, M. L. Wharton's jelly-derived cells are a primitive
stromal cell population. Stem cells 26, 591-599,
doi:10.1634/stemcells.2007-0439 (2008).
13 Gauthaman, K. et al. Osteogenic differentiation of human Wharton's jelly
stem cells on nanofibrous substrates in vitro. Tissue engineering. Part A
17, 71-81, doi:10.1089/ten.TEA.2010.0224 (2011).
14 Fong, C. Y. et al. Human umbilical cord Wharton's jelly stem cells
undergo enhanced chondrogenic differentiation when grown on
nanofibrous scaffolds and in a sequential two-stage culture medium
environment. Stem cell reviews 8, 195-209, doi:10.1007/s12015-011-
9289-8 (2012).
15 Fong, C. Y. et al. Human Wharton's jelly stem cells have unique
transcriptome profiles compared to human embryonic stem cells and
other mesenchymal stem cells. Stem cell reviews 7, 1-16,
doi:10.1007/s12015-010-9166-x (2011).
16 Carlin, R., Davis, D., Weiss, M., Schultz, B. & Troyer, D. Expression of
early transcription factors Oct-4, Sox-2 and Nanog by porcine umbilical
cord (PUC) matrix cells. Reproductive biology and endocrinology : RB&E
4, 8, doi:10.1186/1477-7827-4-8 (2006).
17 Nekanti, U. et al. Long-term expansion and pluripotent marker array
analysis of Wharton's jelly-derived mesenchymal stem cells. Stem cells
and development 19, 117-130, doi:10.1089/scd.2009.0177 (2010).
18 Hoynowski, S. M. et al. Characterization and differentiation of equine
umbilical cord-derived matrix cells. Biochemical and biophysical research
communications 362, 347-353, doi:10.1016/j.bbrc.2007.07.182 (2007).
19 Chao, Y. H. et al. Cotransplantation of umbilical cord MSCs to enhance
engraftment of hematopoietic stem cells in patients with severe aplastic
anemia. Bone marrow transplantation 46, 1391-1392,
doi:10.1038/bmt.2010.305 (2011).
20 Hu, J. et al. Long term effects of the implantation of Wharton's jelly-
derived mesenchymal stem cells from the umbilical cord for newly-onset
type 1 diabetes mellitus. Endocrine journal 60, 347-357 (2013).
21 Dalous, J., Larghero, J. & Baud, O. Transplantation of umbilical cord-
derived mesenchymal stem cells as a novel strategy to protect the central
nervous system: technical aspects, preclinical studies, and clinical
perspectives. Pediatric research 71, 482-490, doi:10.1038/pr.2011.67
(2012).
22 Chen, H. et al. Human umbilical cord Wharton's jelly stem cells: immune
property genes assay and effect of transplantation on the immune cells of




23 Wu, K. H. et al. Cotransplantation of umbilical cord-derived mesenchymal
stem cells promote hematopoietic engraftment in cord blood
transplantation: a pilot study. Transplantation 95, 773-777,
doi:10.1097/TP.0b013e31827a93dd (2013).
24 Ma, L. et al. Immunosuppressive function of mesenchymal stem cells from
human umbilical cord matrix in immune thrombocytopenia patients.
Thrombosis and haemostasis 107, 937-950, doi:10.1160/TH11-08-0596
(2012).
25 Wu, K. H. et al. Effective treatment of severe steroid-resistant acute graft-
versus-host disease with umbilical cord-derived mesenchymal stem cells.
Transplantation 91, 1412-1416, doi:10.1097/TP.0b013e31821aba18
(2011).
26 Fan, C. G., Zhang, Q. J. & Zhou, J. R. Therapeutic potentials of
mesenchymal stem cells derived from human umbilical cord. Stem cell
reviews 7, 195-207, doi:10.1007/s12015-010-9168-8 (2011).
27 Mitchell, K. E. et al. Matrix cells from Wharton's jelly form neurons and
glia. Stem cells 21, 50-60, doi:10.1634/stemcells.21-1-50 (2003).
28 Fu, Y. S. et al. Conversion of human umbilical cord mesenchymal stem
cells in Wharton's jelly to dopaminergic neurons in vitro: potential
therapeutic application for Parkinsonism. Stem cells 24, 115-124,
doi:10.1634/stemcells.2005-0053 (2006).
29 Matsuse, D. et al. Human umbilical cord-derived mesenchymal stromal
cells differentiate into functional Schwann cells that sustain peripheral
nerve regeneration. Journal of neuropathology and experimental
neurology 69, 973-985, doi:10.1097/NEN.0b013e3181eff6dc (2010).
30 Peng, J. et al. Human umbilical cord Wharton's jelly-derived
mesenchymal stem cells differentiate into a Schwann-cell phenotype and
promote neurite outgrowth in vitro. Brain research bulletin 84, 235-243,
doi:10.1016/j.brainresbull.2010.12.013 (2011).
31 Xu, Q. et al. In vitro and in vivo magnetic resonance tracking of Sinerem-
labeled human umbilical mesenchymal stromal cell-derived Schwann cells.
Cellular and molecular neurobiology 31, 365-375, doi:10.1007/s10571-
010-9628-3 (2011).
32 Weiss, M. L. et al. Human umbilical cord matrix stem cells: preliminary
characterization and effect of transplantation in a rodent model of
Parkinson's disease. Stem cells 24, 781-792, doi:10.1634/stemcells.2005-
0330 (2006).
33 Koh, S. H. et al. Implantation of human umbilical cord-derived
mesenchymal stem cells as a neuroprotective therapy for ischemic stroke




34 Ding, D. C. et al. Enhancement of neuroplasticity through upregulation of
beta1-integrin in human umbilical cord-derived stromal cell implanted
stroke model. Neurobiology of disease 27, 339-353,
doi:10.1016/j.nbd.2007.06.010 (2007).
35 Yang, C. C. et al. Transplantation of human umbilical mesenchymal stem
cells from Wharton's jelly after complete transection of the rat spinal cord.
PloS one 3, e3336, doi:10.1371/journal.pone.0003336 (2008).
36 Dongmei, H. et al. Clinical analysis of the treatment of spinocerebellar
ataxia and multiple system atrophy-cerebellar type with umbilical cord
mesenchymal stromal cells. Cytotherapy 13, 913-917,
doi:10.3109/14653249.2011.579958 (2011).
37 Lv, Y. T. et al. Transplantation of human cord blood mononuclear cells
and umbilical cord-derived mesenchymal stem cells in autism. Journal of
translational medicine 11, 196, doi:10.1186/1479-5876-11-196 (2013).
38 Chao, K. C., Chao, K. F., Fu, Y. S. & Liu, S. H. Islet-like clusters derived
from mesenchymal stem cells in Wharton's Jelly of the human umbilical
cord for transplantation to control type 1 diabetes. PloS one 3, e1451,
doi:10.1371/journal.pone.0001451 (2008).
39 Anzalone, R. et al. New emerging potentials for human Wharton's jelly
mesenchymal stem cells: immunological features and hepatocyte-like
differentiative capacity. Stem cells and development 19, 423-438,
doi:10.1089/scd.2009.0299 (2010).
40 Campard, D., Lysy, P. A., Najimi, M. & Sokal, E. M. Native umbilical cord
matrix stem cells express hepatic markers and differentiate into
hepatocyte-like cells. Gastroenterology 134, 833-848,
doi:10.1053/j.gastro.2007.12.024 (2008).
41 Zhang, Y. N., Lie, P. C. & Wei, X. Differentiation of mesenchymal stromal
cells derived from umbilical cord Wharton's jelly into hepatocyte-like cells.
Cytotherapy 11, 548-558, doi:10.1080/14653240903051533 (2009).
42 Zhao, Q. et al. Differentiation of human umbilical cord mesenchymal
stromal cells into low immunogenic hepatocyte-like cells. Cytotherapy 11,
414-426, doi:10.1080/14653240902849754 (2009).
43 Tsai, P. C. et al. The therapeutic potential of human umbilical
mesenchymal stem cells from Wharton's jelly in the treatment of rat liver
fibrosis. Liver transplantation : official publication of the American
Association for the Study of Liver Diseases and the International Liver
Transplantation Society 15, 484-495, doi:10.1002/lt.21715 (2009).
44 Shi, M. et al. Human mesenchymal stem cell transfusion is safe and
improves liver function in acute-on-chronic liver failure patients. Stem cells
translational medicine 1, 725-731, doi:10.5966/sctm.2012-0034 (2012).
45 Zhang, Z. et al. Human umbilical cord mesenchymal stem cells improve
liver function and ascites in decompensated liver cirrhosis patients.




46 Weiss, M. L. et al. Immune properties of human umbilical cord Wharton's
jelly-derived cells. Stem cells 26, 2865-2874, doi:10.1634/stemcells.2007-
1028 (2008).
47 Prasanna, S. J., Gopalakrishnan, D., Shankar, S. R. & Vasandan, A. B.
Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune
properties of human bone marrow and Wharton jelly mesenchymal stem
cells differentially. PloS one 5, e9016, doi:10.1371/journal.pone.0009016
(2010).
48 La Rocca, G. et al. Isolation and characterization of Oct-4+/HLA-G+
mesenchymal stem cells from human umbilical cord matrix: differentiation
potential and detection of new markers. Histochemistry and cell biology
131, 267-282, doi:10.1007/s00418-008-0519-3 (2009).
49 Tipnis, S., Viswanathan, C. & Majumdar, A. S. Immunosuppressive
properties of human umbilical cord-derived mesenchymal stem cells: role
of B7-H1 and IDO. Immunology and cell biology 88, 795-806,
doi:10.1038/icb.2010.47 (2010).
50 Kikuchi-Taura, A. et al. Human umbilical cord provides a significant
source of unexpanded mesenchymal stromal cells. Cytotherapy 14, 441-
450, doi:10.3109/14653249.2012.658911 (2012).
51 Rachakatla, R. S., Marini, F., Weiss, M. L., Tamura, M. & Troyer, D.
Development of human umbilical cord matrix stem cell-based gene
therapy for experimental lung tumors. Cancer gene therapy 14, 828-835,
doi:10.1038/sj.cgt.7701077 (2007).
52 Ayuzawa, R. et al. Naive human umbilical cord matrix derived stem cells
significantly attenuate growth of human breast cancer cells in vitro and in
vivo. Cancer letters 280, 31-37, doi:10.1016/j.canlet.2009.02.011 (2009).
53 Ganta, C. et al. Rat umbilical cord stem cells completely abolish rat
mammary carcinomas with no evidence of metastasis or recurrence 100
days post-tumor cell inoculation. Cancer research 69, 1815-1820,
doi:10.1158/0008-5472.CAN-08-2750 (2009).
54 Matsuzuka, T. et al. Human umbilical cord matrix-derived stem cells
expressing interferon-beta gene significantly attenuate bronchioloalveolar
carcinoma xenografts in SCID mice. Lung cancer 70, 28-36,
doi:10.1016/j.lungcan.2010.01.003 (2010).
55 Maurya, D. K. et al. Therapy with un-engineered naive rat umbilical cord
matrix stem cells markedly inhibits growth of murine lung adenocarcinoma.
BMC cancer 10, 590, doi:10.1186/1471-2407-10-590 (2010).
56 Chao, K. C., Yang, H. T. & Chen, M. W. Human umbilical cord
mesenchymal stem cells suppress breast cancer tumourigenesis through
direct cell-cell contact and internalization. Journal of cellular and




57 Gauthaman, K. et al. Human Wharton's jelly stem cell conditioned
medium and cell-free lysate inhibit human osteosarcoma and mammary
carcinoma cell growth in vitro and in xenograft mice. Journal of cellular
biochemistry 114, 366-377, doi:10.1002/jcb.24367 (2013).
58 Kawabata, A. et al. Naive rat umbilical cord matrix stem cells significantly
attenuate mammary tumor growth through modulation of endogenous
immune responses. Cytotherapy 15, 586-597,
doi:10.1016/j.jcyt.2013.01.006 (2013).
59 Liu, J., Han, G., Liu, H. & Qin, C. Suppression of cholangiocarcinoma cell
growth by human umbilical cord mesenchymal stem cells: a possible role
of Wnt and Akt signaling. PloS one 8, e62844,
doi:10.1371/journal.pone.0062844 (2013).
60 Ma, Y., Hao, X., Zhang, S. & Zhang, J. The in vitro and in vivo effects of
human umbilical cord mesenchymal stem cells on the growth of breast
cancer cells. Breast cancer research and treatment 133, 473-485,
doi:10.1007/s10549-011-1774-x (2012).
61 Wu, S., Ju, G. Q., Du, T., Zhu, Y. J. & Liu, G. H. Microvesicles derived
from human umbilical cord Wharton's jelly mesenchymal stem cells
attenuate bladder tumor cell growth in vitro and in vivo. PloS one 8,
e61366, doi:10.1371/journal.pone.0061366 (2013).
62 De Coppi, P. et al. Isolation of amniotic stem cell lines with potential for
therapy. Nature biotechnology 25, 100-106, doi:10.1038/nbt1274 (2007).
63 Bongso, A., Fong, C. Y., Ng, S. C. & Ratnam, S. Isolation and culture of
inner cell mass cells from human blastocysts. Human reproduction 9,
2110-2117 (1994).
64 Thomson, J. A. et al. Embryonic stem cell lines derived from human
blastocysts. Science 282, 1145-1147 (1998).
65 Bunnell, B. A., Flaat, M., Gagliardi, C., Patel, B. & Ripoll, C. Adipose-
derived stem cells: isolation, expansion and differentiation. Methods 45,
115-120, doi:10.1016/j.ymeth.2008.03.006 (2008).
66 Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal
stem cells. Science 284, 143-147 (1999).
67 Walenda, T. et al. Co-culture with mesenchymal stromal cells increases
proliferation and maintenance of haematopoietic progenitor cells. Journal
of cellular and molecular medicine 14, 337-350, doi:10.1111/j.1582-
4934.2009.00776.x (2010).
68 Laurent, L. C. et al. Dynamic changes in the copy number of pluripotency
and cell proliferation genes in human ESCs and iPSCs during
reprogramming and time in culture. Cell stem cell 8, 106-118,
doi:10.1016/j.stem.2010.12.003 (2011).
69 Ben-David, U. & Benvenisty, N. The tumorigenicity of human embryonic




70 Fong, C. Y., Gauthaman, K. & Bongso, A. Teratomas from pluripotent
stem cells: A clinical hurdle. Journal of cellular biochemistry 111, 769-781,
doi:10.1002/jcb.22775 (2010).
71 Fujikawa, T. et al. Teratoma formation leads to failure of treatment for
type I diabetes using embryonic stem cell-derived insulin-producing cells.
The American journal of pathology 166, 1781-1791, doi:10.1016/S0002-
9440(10)62488-1 (2005).
72 Cao, F. et al. In vivo visualization of embryonic stem cell survival,
proliferation, and migration after cardiac delivery. Circulation 113, 1005-
1014, doi:10.1161/CIRCULATIONAHA.105.588954 (2006).
73 Gauthaman, K. et al. Extra-embryonic human Wharton's jelly stem cells
do not induce tumorigenesis, unlike human embryonic stem cells.
Reproductive biomedicine online 24, 235-246,
doi:10.1016/j.rbmo.2011.10.007 (2012).
74 Wang, Y. et al. A toxicity study of multiple-administration human umbilical
cord mesenchymal stem cells in cynomolgus monkeys. Stem cells and
development 21, 1401-1408, doi:10.1089/scd.2011.0441 (2012).
75 Houghton, J. et al. Gastric cancer originating from bone marrow-derived
cells. Science 306, 1568-1571, doi:10.1126/science.1099513 (2004).
76 Tolar, J. et al. Sarcoma derived from cultured mesenchymal stem cells.
Stem cells 25, 371-379, doi:10.1634/stemcells.2005-0620 (2007).
77 Amariglio, N. et al. Donor-derived brain tumor following neural stem cell
transplantation in an ataxia telangiectasia patient. PLoS medicine 6,
e1000029, doi:10.1371/journal.pmed.1000029 (2009).
78 Zhu, W. et al. Mesenchymal stem cells derived from bone marrow favor
tumor cell growth in vivo. Experimental and molecular pathology 80, 267-
274, doi:10.1016/j.yexmp.2005.07.004 (2006).
79 Yu, J. M., Jun, E. S., Bae, Y. C. & Jung, J. S. Mesenchymal stem cells
derived from human adipose tissues favor tumor cell growth in vivo. Stem
cells and development 17, 463-473, doi:10.1089/scd.2007.0181 (2008).
80 Cardone, A., Tolino, A., Zarcone, R., Borruto Caracciolo, G. & Tartaglia, E.
Prognostic value of desmoplastic reaction and lymphocytic infiltration in
the management of breast cancer. Panminerva medica 39, 174-177
(1997).
81 Bissell, M. J. & Radisky, D. Putting tumours in context. Nature reviews.
Cancer 1, 46-54, doi:10.1038/35094059 (2001).
82 Blankenstein, T. The role of tumor stroma in the interaction between




83 Mishra, P. J. et al. Carcinoma-associated fibroblast-like differentiation of
human mesenchymal stem cells. Cancer research 68, 4331-4339,
doi:10.1158/0008-5472.CAN-08-0943 (2008).
84 Karnoub, A. E. et al. Mesenchymal stem cells within tumour stroma
promote breast cancer metastasis. Nature 449, 557-563,
doi:10.1038/nature06188 (2007).
85 Spaeth, E. L. et al. Mesenchymal stem cell transition to tumor-associated
fibroblasts contributes to fibrovascular network expansion and tumor
progression. PloS one 4, e4992, doi:10.1371/journal.pone.0004992
(2009).
86 Jodele, S. et al. The contribution of bone marrow-derived cells to the
tumor vasculature in neuroblastoma is matrix metalloproteinase-9
dependent. Cancer research 65, 3200-3208, doi:10.1158/0008-
5472.CAN-04-3770 (2005).
87 Paunescu, V. et al. Tumour-associated fibroblasts and mesenchymal
stem cells: more similarities than differences. Journal of cellular and
molecular medicine 15, 635-646, doi:10.1111/j.1582-4934.2010.01044.x
(2011).
88 Subramanian, A. et al. Human umbilical cord Wharton's jelly
mesenchymal stem cells do not transform to tumor-associated fibroblasts
in the presence of breast and ovarian cancer cells unlike bone marrow
mesenchymal stem cells. Journal of cellular biochemistry 113, 1886-1895,
doi:10.1002/jcb.24057 (2012).
89 Zhao, T., Zhang, Z. N., Rong, Z. & Xu, Y. Immunogenicity of induced
pluripotent stem cells. Nature 474, 212-215, doi:10.1038/nature10135
(2011).
90 Guha, P., Morgan, J. W., Mostoslavsky, G., Rodrigues, N. P. & Boyd, A. S.
Lack of immune response to differentiated cells derived from syngeneic
induced pluripotent stem cells. Cell stem cell 12, 407-412,
doi:10.1016/j.stem.2013.01.006 (2013).
91 Medicetty, S., Bledsoe, A. R., Fahrenholtz, C. B., Troyer, D. & Weiss, M. L.
Transplantation of pig stem cells into rat brain: proliferation during the first
8 weeks. Experimental neurology 190, 32-41,
doi:10.1016/j.expneurol.2004.06.023 (2004).
92 Di Nicola, M. et al. Human bone marrow stromal cells suppress T-
lymphocyte proliferation induced by cellular or nonspecific mitogenic
stimuli. Blood 99, 3838-3843 (2002).
93 Aggarwal, S. & Pittenger, M. F. Human mesenchymal stem cells modulate
allogeneic immune cell responses. Blood 105, 1815-1822,
doi:10.1182/blood-2004-04-1559 (2005).
94 Najar, M. et al. Mesenchymal stromal cells promote or suppress the
proliferation of T lymphocytes from cord blood and peripheral blood: the




95 Salama, H. et al. Autologous hematopoietic stem cell transplantation in 48
patients with end-stage chronic liver diseases. Cell transplantation 19,
1475-1486, doi:10.3727/096368910X514314 (2010).
96 Krishnan, A. & Forman, S. J. Hematopoietic stem cell transplantation for
AIDS-related malignancies. Current opinion in oncology 22, 456-460,
doi:10.1097/CCO.0b013e32833d2cf0 (2010).
97 Wengler, G. S. et al. In-utero transplantation of parental CD34
haematopoietic progenitor cells in a patient with X-linked severe
combined immunodeficiency (SCIDXI). Lancet 348, 1484-1487 (1996).
98 Flake, A. W. et al. Treatment of X-linked severe combined
immunodeficiency by in utero transplantation of paternal bone marrow.
The New England journal of medicine 335, 1806-1810,
doi:10.1056/NEJM199612123352404 (1996).
99 Becker, P. S. et al. Spontaneous splenic rupture following administration
of granulocyte colony-stimulating factor (G-CSF): occurrence in an
allogeneic donor of peripheral blood stem cells. Biology of blood and
marrow transplantation : journal of the American Society for Blood and
Marrow Transplantation 3, 45-49 (1997).
100 Falzetti, F., Aversa, F., Minelli, O. & Tabilio, A. Spontaneous rupture of
spleen during peripheral blood stem-cell mobilisation in a healthy donor.
Lancet 353, 555, doi:10.1016/S0140-6736(99)00268-8 (1999).
101 Nuamah, N. M., Goker, H., Kilic, Y. A., Dagmoura, H. & Cakmak, A.
Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-
blood stem cell following the administration of granulocyte colony-
stimulating factor (g-csf). A case report and review of the literature.
Haematologica 91, ECR08 (2006).
102 Adler, B. K. et al. Fatal sickle cell crisis after granulocyte colony-
stimulating factor administration. Blood 97, 3313-3314 (2001).
103 Gluckman, E. et al. Outcome of cord-blood transplantation from related
and unrelated donors. Eurocord Transplant Group and the European
Blood and Marrow Transplantation Group. The New England journal of
medicine 337, 373-381, doi:10.1056/NEJM199708073370602 (1997).
104 Gluckman, E. & Rocha, V. Cord blood transplantation: state of the art.
Haematologica 94, 451-454, doi:10.3324/haematol.2009.005694 (2009).
105 Broxmeyer, H. E. Insights into the biology of cord blood stem/progenitor
cells. Cell proliferation 44 Suppl 1, 55-59, doi:10.1111/j.1365-
2184.2010.00728.x (2011).
106 Rocha, V. & Broxmeyer, H. E. New approaches for improving engraftment
after cord blood transplantation. Biology of blood and marrow
transplantation : journal of the American Society for Blood and Marrow
Transplantation 16, S126-132, doi:10.1016/j.bbmt.2009.11.001 (2010).
Chapter 8: Bibliography
158
107 Ramirez, P., Brunstein, C. G., Miller, B., Defor, T. & Weisdorf, D. Delayed
platelet recovery after allogeneic transplantation: a predictor of increased
treatment-related mortality and poorer survival. Bone marrow
transplantation 46, 981-986, doi:10.1038/bmt.2010.218 (2011).
108 Solh, M., Brunstein, C., Morgan, S. & Weisdorf, D. Platelet and red blood
cell utilization and transfusion independence in umbilical cord blood and
allogeneic peripheral blood hematopoietic cell transplants. Biology of
blood and marrow transplantation : journal of the American Society for
Blood and Marrow Transplantation 17, 710-716,
doi:10.1016/j.bbmt.2010.08.017 (2011).
109 Zhang, Y., Chai, C., Jiang, X. S., Teoh, S. H. & Leong, K. W. Co-culture of
umbilical cord blood CD34+ cells with human mesenchymal stem cells.
Tissue engineering 12, 2161-2170, doi:10.1089/ten.2006.12.2161 (2006).
110 Bakhshi, T. et al. Mesenchymal stem cells from the Wharton's jelly of
umbilical cord segments provide stromal support for the maintenance of
cord blood hematopoietic stem cells during long-term ex vivo culture.
Transfusion 48, 2638-2644, doi:10.1111/j.1537-2995.2008.01926.x
(2008).
111 Lu, L. L. et al. Isolation and characterization of human umbilical cord
mesenchymal stem cells with hematopoiesis-supportive function and
other potentials. Haematologica 91, 1017-1026 (2006).
112 Friedman, R. et al. Umbilical cord mesenchymal stem cells: adjuvants for
human cell transplantation. Biology of blood and marrow transplantation :
journal of the American Society for Blood and Marrow Transplantation 13,
1477-1486, doi:10.1016/j.bbmt.2007.08.048 (2007).
113 Koc, O. N. et al. Rapid hematopoietic recovery after coinfusion of
autologous-blood stem cells and culture-expanded marrow mesenchymal
stem cells in advanced breast cancer patients receiving high-dose
chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 18, 307-316 (2000).
114 Noort, W. A. et al. Mesenchymal stem cells promote engraftment of
human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice.
Experimental hematology 30, 870-878 (2002).
115 Angelopoulou, M. et al. Cotransplantation of human mesenchymal stem
cells enhances human myelopoiesis and megakaryocytopoiesis in
NOD/SCID mice. Experimental hematology 31, 413-420 (2003).
116 Lazarus, H. M. et al. Cotransplantation of HLA-identical sibling culture-
expanded mesenchymal stem cells and hematopoietic stem cells in
hematologic malignancy patients. Biology of blood and marrow
transplantation : journal of the American Society for Blood and Marrow
Transplantation 11, 389-398, doi:10.1016/j.bbmt.2005.02.001 (2005).
117 Le Blanc, K. et al. Transplantation of mesenchymal stem cells to enhance




118 Baron, F. et al. Cotransplantation of mesenchymal stem cells might
prevent death from graft-versus-host disease (GVHD) without abrogating
graft-versus-tumor effects after HLA-mismatched allogeneic
transplantation following nonmyeloablative conditioning. Biology of blood
and marrow transplantation : journal of the American Society for Blood
and Marrow Transplantation 16, 838-847, doi:10.1016/j.bbmt.2010.01.011
(2010).
119 Carrancio, S. et al. Bone marrow mesenchymal stem cells for improving
hematopoietic function: an in vitro and in vivo model. Part 2: Effect on
bone marrow microenvironment. PloS one 6, e26241,
doi:10.1371/journal.pone.0026241 (2011).
120 Bartsch, K. et al. Mesenchymal stem cells remain host-derived
independent of the source of the stem-cell graft and conditioning regimen
used. Transplantation 87, 217-221, doi:10.1097/TP.0b013e3181938998
(2009).
121 Muguruma, Y. et al. Reconstitution of the functional human hematopoietic
microenvironment derived from human mesenchymal stem cells in the
murine bone marrow compartment. Blood 107, 1878-1887,
doi:10.1182/blood-2005-06-2211 (2006).
122 Karp, J. M. & Leng Teo, G. S. Mesenchymal stem cell homing: the devil is
in the details. Cell stem cell 4, 206-216, doi:10.1016/j.stem.2009.02.001
(2009).
123 Villaron, E. M. et al. Mesenchymal stem cells are present in peripheral
blood and can engraft after allogeneic hematopoietic stem cell
transplantation. Haematologica 89, 1421-1427 (2004).
124 Horvat-Karajz, K. et al. In vitro effect of carboplatin, cytarabine, paclitaxel,
vincristine, and low-power laser irradiation on murine mesenchymal stem
cells. Lasers in surgery and medicine 41, 463-469, doi:10.1002/lsm.20791
(2009).
125 Spyridonidis, A. et al. Reduced intensity conditioning compared to
standard conditioning preserves the in vitro growth capacity of bone
marrow stroma, which remains of host origin. Stem cells and development
14, 213-222, doi:10.1089/scd.2005.14.213 (2005).
126 Kemp, K. et al. Chemotherapy-induced mesenchymal stem cell damage
in patients with hematological malignancy. Annals of hematology 89, 701-
713, doi:10.1007/s00277-009-0896-2 (2010).
127 Liu, Y. et al. Reconstruction of hematopoietic inductive microenvironment
after transplantation of VCAM-1-modified human umbilical cord blood
stromal cells. PloS one 7, e31741, doi:10.1371/journal.pone.0031741
(2012).
128 Di, G. H. et al. Human umbilical cord mesenchymal stromal cells mitigate
chemotherapy-associated tissue injury in a pre-clinical mouse model.
Cytotherapy 14, 412-422, doi:10.3109/14653249.2011.646044 (2012).
Chapter 8: Bibliography
160
129 Wu, K. H. et al. Human Application of Ex-Vivo Expanded Umbilical Cord-
Derived Mesenchymal Stem Cells: Enhance Hematopoiesis after Cord
Blood Transplantation. Cell transplantation,
doi:10.3727/096368913X663523 (2013).
130 O'Flaherty, E., Sparrow, R. & Szer, J. Bone marrow stromal function from
patients after bone marrow transplantation. Bone marrow transplantation
15, 207-212 (1995).
131 Guest, I. & Uetrecht, J. Drugs toxic to the bone marrow that target the
stromal cells. Immunopharmacology 46, 103-112 (2000).
132 Tauchmanova, L. et al. High prevalence of endocrine dysfunction in long-
term survivors after allogeneic bone marrow transplantation for
hematologic diseases. Cancer 95, 1076-1084, doi:10.1002/cncr.10773
(2002).
133 Tauchmanova, L. et al. Long-lasting bone damage detected by dual-
energy x-ray absorptiometry, phalangeal osteosonogrammetry, and in
vitro growth of marrow stromal cells after allogeneic stem cell
transplantation. The Journal of clinical endocrinology and metabolism 87,
5058-5065 (2002).
134 Lo Celso, C., Wu, J. W. & Lin, C. P. In vivo imaging of hematopoietic stem
cells and their microenvironment. Journal of biophotonics 2, 619-631,
doi:10.1002/jbio.200910072 (2009).
135 Gillette, J. M. & Lippincott-Schwartz, J. Hematopoietic progenitor cells
regulate their niche microenvironment through a novel mechanism of cell-
cell communication. Communicative & integrative biology 2, 305-307
(2009).
136 Rubinstein, P. et al. Outcomes among 562 recipients of placental-blood
transplants from unrelated donors. The New England journal of medicine
339, 1565-1577, doi:10.1056/NEJM199811263392201 (1998).
137 Laughlin, M. J. et al. Hematopoietic engraftment and survival in adult
recipients of umbilical-cord blood from unrelated donors. The New
England journal of medicine 344, 1815-1822,
doi:10.1056/NEJM200106143442402 (2001).
138 Fritz, V. & Jorgensen, C. Mesenchymal stem cells: an emerging tool for
cancer targeting and therapy. Current stem cell research & therapy 3, 32-
42 (2008).
139 Prockop, D. J. Repair of tissues by adult stem/progenitor cells (MSCs):
controversies, myths, and changing paradigms. Molecular therapy : the
journal of the American Society of Gene Therapy 17, 939-946,
doi:10.1038/mt.2009.62 (2009).
140 Wong, R. S. Mesenchymal stem cells: angels or demons? Journal of




141 Maestroni, G. J., Hertens, E. & Galli, P. Factor(s) from nonmacrophage
bone marrow stromal cells inhibit Lewis lung carcinoma and B16
melanoma growth in mice. Cellular and molecular life sciences : CMLS 55,
663-667 (1999).
142 Ohlsson, L. B., Varas, L., Kjellman, C., Edvardsen, K. & Lindvall, M.
Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo
and in vitro in gelatin matrix. Experimental and molecular pathology 75,
248-255 (2003).
143 Khakoo, A. Y. et al. Human mesenchymal stem cells exert potent
antitumorigenic effects in a model of Kaposi's sarcoma. The Journal of
experimental medicine 203, 1235-1247, doi:10.1084/jem.20051921
(2006).
144 Zhang, T. et al. Bone marrow-derived mesenchymal stem cells promote
growth and angiogenesis of breast and prostate tumors. Stem cell
research & therapy 4, 70, doi:10.1186/scrt221 (2013).
145 Secchiero, P. et al. Human bone marrow mesenchymal stem cells display
anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's
lymphoma xenografts. PloS one 5, e11140,
doi:10.1371/journal.pone.0011140 (2010).
146 Fonseka, M., Ramasamy, R., Yip, W. K., Tan, B. C. & Seow, H. F. Human
Umbilical Cord Blood-Derived Mesenchymal Stem Cells (hUCB-MSC)
Inhibits the Proliferation of K562 (Human Erythromyeloblastoid Leukemic
Cell Line). Cell biology international, doi:10.1042/CBI20110595 (2012).
147 Yang, H. T. & Chao, K. C. Foetal defence against cancer: a hypothesis.
Journal of cellular and molecular medicine 17, 1096-1098,
doi:10.1111/jcmm.12095 (2013).
148 Alexander, A. et al. Metastatic melanoma in pregnancy: risk of
transplacental metastases in the infant. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 21, 2179-2186,
doi:10.1200/JCO.2003.12.149 (2003).
149 Dildy, G. A., 3rd, Moise, K. J., Jr., Carpenter, R. J., Jr. & Klima, T.
Maternal malignancy metastatic to the products of conception: a review.
Obstetrical & gynecological survey 44, 535-540 (1989).
150 Jackisch, C. et al. Lung cancer during pregnancy involving the products of
conception and a review of the literature. Archives of gynecology and
obstetrics 268, 69-77, doi:10.1007/s00404-002-0356-x (2003).
151 Liu, J. & Guo, L. Intraplacental choriocarcinoma in a term placenta with
both maternal and infantile metastases: a case report and review of the
literature. Gynecologic oncology 103, 1147-1151,
doi:10.1016/j.ygyno.2006.08.007 (2006).
152 Potter, J. F. & Schoeneman, M. Metastasis of maternal cancer to the
placenta and fetus. Cancer 25, 380-388 (1970).
Chapter 8: Bibliography
162
153 Henry, F., Bretaudeau, L., Barbieux, I., Meflah, K. & Gregoire, M.
Induction of antigen presentation by macrophages after phagocytosis of
tumour apoptotic cells. Research in immunology 149, 673-679 (1998).
154 Barker, R. N. et al. Antigen presentation by macrophages is enhanced by
the uptake of necrotic, but not apoptotic, cells. Clinical and experimental
immunology 127, 220-225 (2002).
155 Takemura, G. & Fujiwara, H. Doxorubicin-induced cardiomyopathy from
the cardiotoxic mechanisms to management. Progress in cardiovascular
diseases 49, 330-352, doi:10.1016/j.pcad.2006.10.002 (2007).
156 Takimoto, C. H. et al. Severe neurotoxicity following 5-fluorouracil-based
chemotherapy in a patient with dihydropyrimidine dehydrogenase
deficiency. Clinical cancer research : an official journal of the American
Association for Cancer Research 2, 477-481 (1996).
157 Vogelzang, N. J. Nephrotoxicity from chemotherapy: prevention and
management. Oncology 5, 97-102, 105; disc 105, 109-111 (1991).
158 Chamberlin, W., Barone, J., Kedo, A. & Fried, W. Lack of recovery of
murine hematopoietic stromal cells after irradiation-induced damage.
Blood 44, 385-392 (1974).
159 Galotto, M. et al. Stromal damage as consequence of high-dose
chemo/radiotherapy in bone marrow transplant recipients. Experimental
hematology 27, 1460-1466 (1999).
160 Gibson, L. F. et al. Disruption of bone marrow stromal cell function by
etoposide. Biology of blood and marrow transplantation : journal of the
American Society for Blood and Marrow Transplantation 3, 122-132
(1997).
161 Wolf, N. S. Dissecting the hematopoietic microenvironment. V: limitations
of repair following damage to the hematopoietic support stroma.
Experimental hematology 10, 108-118 (1982).
162 Lee, S. H. et al. Co-transplantation of third-party umbilical cord blood-
derived MSCs promotes engraftment in children undergoing unrelated
umbilical cord blood transplantation. Bone marrow transplantation 48,
1040-1045, doi:10.1038/bmt.2013.7 (2013).
163 Lopez-Lazaro, M. Dual role of hydrogen peroxide in cancer: possible
relevance to cancer chemoprevention and therapy. Cancer letters 252, 1-
8, doi:10.1016/j.canlet.2006.10.029 (2007).
164 Davicino, R., Manuele, M. G., Turner, S., Ferraro, G. & Anesini, C.
Antiproliferative activity of Larrea divaricata Cav. on lymphoma cell line:




165 Polytarchou, C., Hatziapostolou, M. & Papadimitriou, E. Hydrogen
peroxide stimulates proliferation and migration of human prostate cancer
cells through activation of activator protein-1 and up-regulation of the
heparin affin regulatory peptide gene. The Journal of biological chemistry
280, 40428-40435, doi:10.1074/jbc.M505120200 (2005).
166 Park, S., You, X. & Imlay, J. A. Substantial DNA damage from
submicromolar intracellular hydrogen peroxide detected in Hpx- mutants
of Escherichia coli. Proceedings of the National Academy of Sciences of
the United States of America 102, 9317-9322,
doi:10.1073/pnas.0502051102 (2005).
167 Hunt, C. R. et al. Genomic instability and catalase gene amplification
induced by chronic exposure to oxidative stress. Cancer research 58,
3986-3992 (1998).
168 del Bello, B., Paolicchi, A., Comporti, M., Pompella, A. & Maellaro, E.
Hydrogen peroxide produced during gamma-glutamyl transpeptidase
activity is involved in prevention of apoptosis and maintainance of
proliferation in U937 cells. FASEB journal : official publication of the
Federation of American Societies for Experimental Biology 13, 69-79
(1999).
169 Qian, Y. et al. Hydrogen peroxide formation and actin filament
reorganization by Cdc42 are essential for ethanol-induced in vitro
angiogenesis. The Journal of biological chemistry 278, 16189-16197,
doi:10.1074/jbc.M207517200 (2003).
170 Ahmad, K. A., Iskandar, K. B., Hirpara, J. L., Clement, M. V. & Pervaiz, S.
Hydrogen peroxide-mediated cytosolic acidification is a signal for
mitochondrial translocation of Bax during drug-induced apoptosis of tumor
cells. Cancer research 64, 7867-7878, doi:10.1158/0008-5472.CAN-04-
0648 (2004).
171 Hirpara, J. L., Clement, M. V. & Pervaiz, S. Intracellular acidification
triggered by mitochondrial-derived hydrogen peroxide is an effector
mechanism for drug-induced apoptosis in tumor cells. The Journal of
biological chemistry 276, 514-521, doi:10.1074/jbc.M004687200 (2001).
172 Lin, H. D., Fong, C. Y., Biswas, A., Choolani, M. & Bongso, A. Human
Wharton's Jelly Stem Cells, its Conditioned Medium and Cell-Free Lysate
Inhibit the Growth of Human Lymphoma Cells. Stem cell reviews,
doi:10.1007/s12015-014-9514-3 (2014).
173 Oberley, L. W. Anticancer therapy by overexpression of superoxide
dismutase. Antioxidants & redox signaling 3, 461-472,
doi:10.1089/15230860152409095 (2001).
174 Bakan, N. et al. Glutathione peroxidase, glutathione reductase, Cu-Zn
superoxide dismutase activities, glutathione, nitric oxide, and
malondialdehyde concentrations in serum of patients with chronic
lymphocytic leukemia. Clinica chimica acta; international journal of clinical
chemistry 338, 143-149 (2003).
Chapter 8: Bibliography
164
175 Bewick, M., Coutie, W. & Tudhope, G. R. Superoxide dismutase,
glutathione peroxidase and catalase in the red cells of patients with
malignant lymphoma. British journal of haematology 65, 347-350 (1987).
176 Jaramillo, M. C., Frye, J. B., Crapo, J. D., Briehl, M. M. & Tome, M. E.
Increased manganese superoxide dismutase expression or treatment with
manganese porphyrin potentiates dexamethasone-induced apoptosis in
lymphoma cells. Cancer research 69, 5450-5457, doi:10.1158/0008-
5472.CAN-08-4031 (2009).
177 Rodriguez, A. M., Carrico, P. M., Mazurkiewicz, J. E. & Melendez, J. A.
Mitochondrial or cytosolic catalase reverses the MnSOD-dependent
inhibition of proliferation by enhancing respiratory chain activity, net ATP
production, and decreasing the steady state levels of H(2)O(2). Free
radical biology & medicine 29, 801-813 (2000).
178 Li, S., Yan, T., Yang, J. Q., Oberley, T. D. & Oberley, L. W. The role of
cellular glutathione peroxidase redox regulation in the suppression of
tumor cell growth by manganese superoxide dismutase. Cancer research
60, 3927-3939 (2000).
179 Jeffree, G. M. Hydrogen peroxide and cancer. Nature 182, 892 (1958).
180 Nathan, C. F. & Cohn, Z. A. Antitumor effects of hydrogen peroxide in vivo.
The Journal of experimental medicine 154, 1539-1553 (1981).
181 Questionable methods of cancer management: hydrogen peroxide and
other 'hyperoxygenation' therapies. CA: a cancer journal for clinicians 43,
47-56 (1993).
182 Chen, Q. et al. Pharmacologic ascorbic acid concentrations selectively kill
cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues.
Proceedings of the National Academy of Sciences of the United States of
America 102, 13604-13609, doi:10.1073/pnas.0506390102 (2005).
183 Padayatty, S. J. et al. Intravenously administered vitamin C as cancer
therapy: three cases. CMAJ : Canadian Medical Association journal =
journal de l'Association medicale canadienne 174, 937-942,
doi:10.1503/cmaj.050346 (2006).
184 Tome, M. E., Jaramillo, M. C. & Briehl, M. M. Hydrogen peroxide signaling
is required for glucocorticoid-induced apoptosis in lymphoma cells. Free
radical biology & medicine 51, 2048-2059,
doi:10.1016/j.freeradbiomed.2011.09.002 (2011).
185 Poh, T. W. & Pervaiz, S. LY294002 and LY303511 sensitize tumor cells to
drug-induced apoptosis via intracellular hydrogen peroxide production
independent of the phosphoinositide 3-kinase-Akt pathway. Cancer
research 65, 6264-6274, doi:10.1158/0008-5472.CAN-05-0152 (2005).
186 MacMillan-Crow, L. A. & Crow, J. P. Does more MnSOD mean more




187 Bracci, L., Schiavoni, G., Sistigu, A. & Belardelli, F. Immune-based
mechanisms of cytotoxic chemotherapy: implications for the design of
novel and rationale-based combined treatments against cancer. Cell
death and differentiation 21, 15-25, doi:10.1038/cdd.2013.67 (2014).
188 Inoue, H. & Tani, K. Multimodal immunogenic cancer cell death as a
consequence of anticancer cytotoxic treatments. Cell death and
differentiation 21, 39-49, doi:10.1038/cdd.2013.84 (2014).
189 Martins, I. et al. Molecular mechanisms of ATP secretion during
immunogenic cell death. Cell death and differentiation 21, 79-91,
doi:10.1038/cdd.2013.75 (2014).
190 Garg, A. D., Martin, S., Golab, J. & Agostinis, P. Danger signalling during
cancer cell death: origins, plasticity and regulation. Cell death and
differentiation 21, 26-38, doi:10.1038/cdd.2013.48 (2014).
191 Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune
system to anticancer chemotherapy and radiotherapy. Nature medicine 13,
1050-1059, doi:10.1038/nm1622 (2007).
192 Fukunaga, A. et al. CD8+ tumor-infiltrating lymphocytes together with
CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the
prognosis of patients with pancreatic adenocarcinoma. Pancreas 28, e26-
31 (2004).
193 Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial
ovarian cancer. The New England journal of medicine 348, 203-213,
doi:10.1056/NEJMoa020177 (2003).
194 Sato, E. et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a
high CD8+/regulatory T cell ratio are associated with favorable prognosis
in ovarian cancer. Proceedings of the National Academy of Sciences of
the United States of America 102, 18538-18543,
doi:10.1073/pnas.0509182102 (2005).
195 Tomsova, M., Melichar, B., Sedlakova, I. & Steiner, I. Prognostic
significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
Gynecologic oncology 108, 415-420, doi:10.1016/j.ygyno.2007.10.016
(2008).
196 Kono, K., Mimura, K. & Kiessling, R. Immunogenic tumor cell death
induced by chemoradiotherapy: molecular mechanisms and a clinical
translation. Cell death & disease 4, e688, doi:10.1038/cddis.2013.207
(2013).
197 Igney, F. H. & Krammer, P. H. Death and anti-death: tumour resistance to
apoptosis. Nature reviews. Cancer 2, 277-288, doi:10.1038/nrc776 (2002).
198 Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease.
Science 267, 1456-1462 (1995).
199 Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death




200 Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of
cancer cell death. Nature medicine 13, 54-61, doi:10.1038/nm1523 (2007).
201 Tesniere, A. et al. Immunogenic death of colon cancer cells treated with
oxaliplatin. Oncogene 29, 482-491, doi:10.1038/onc.2009.356 (2010).
202 Zitvogel, L. et al. Immunogenic tumor cell death for optimal anticancer
therapy: the calreticulin exposure pathway. Clinical cancer research : an
official journal of the American Association for Cancer Research 16, 3100-
3104, doi:10.1158/1078-0432.CCR-09-2891 (2010).
203 Sukkurwala, A. Q. et al. Immunogenic calreticulin exposure occurs
through a phylogenetically conserved stress pathway involving the
chemokine CXCL8. Cell death and differentiation 21, 59-68,
doi:10.1038/cdd.2013.73 (2014).
204 Zappasodi, R. et al. Improved clinical outcome in indolent B-cell
lymphoma patients vaccinated with autologous tumor cells experiencing
immunogenic death. Cancer research 70, 9062-9072, doi:10.1158/0008-
5472.CAN-10-1825 (2010).
205 Chao, M. P. et al. Calreticulin is the dominant pro-phagocytic signal on
multiple human cancers and is counterbalanced by CD47. Science
translational medicine 2, 63ra94, doi:10.1126/scitranslmed.3001375
(2010).
206 Fucikova, J. et al. Human tumor cells killed by anthracyclines induce a
tumor-specific immune response. Cancer research 71, 4821-4833,
doi:10.1158/0008-5472.CAN-11-0950 (2011).
207 Spisek, R. et al. Bortezomib enhances dendritic cell (DC)-mediated
induction of immunity to human myeloma via exposure of cell surface heat
shock protein 90 on dying tumor cells: therapeutic implications. Blood 109,
4839-4845, doi:10.1182/blood-2006-10-054221 (2007).
208 Spisek, R. & Dhodapkar, M. V. Towards a better way to die with
chemotherapy: role of heat shock protein exposure on dying tumor cells.
Cell cycle 6, 1962-1965 (2007).
209 Buttiglieri, S., Galetto, A., Forno, S., De Andrea, M. & Matera, L. Influence
of drug-induced apoptotic death on processing and presentation of tumor
antigens by dendritic cells. International journal of cancer. Journal
international du cancer 106, 516-520, doi:10.1002/ijc.11243 (2003).
210 Galetto, A. et al. Drug- and cell-mediated antitumor cytotoxicities
modulate cross-presentation of tumor antigens by myeloid dendritic cells.
Anti-cancer drugs 14, 833-843,
doi:10.1097/01.cad.0000097711.69687.64 (2003).
211 Ma, Y. et al. Anticancer chemotherapy-induced intratumoral recruitment




212 Ayna, G. et al. ATP release from dying autophagic cells and their
phagocytosis are crucial for inflammasome activation in macrophages.
PloS one 7, e40069, doi:10.1371/journal.pone.0040069 (2012).
213 Zitvogel, L., Kepp, O., Galluzzi, L. & Kroemer, G. Inflammasomes in
carcinogenesis and anticancer immune responses. Nature immunology
13, 343-351, doi:10.1038/ni.2224 (2012).
214 Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic
cells induces IL-1beta-dependent adaptive immunity against tumors.
Nature medicine 15, 1170-1178, doi:10.1038/nm.2028 (2009).
215 Michaud, M. et al. Autophagy-dependent anticancer immune responses
induced by chemotherapeutic agents in mice. Science 334, 1573-1577,
doi:10.1126/science.1208347 (2011).
216 Ko, A. et al. Autophagy inhibition radiosensitizes in vitro, yet reduces
radioresponses in vivo due to deficient immunogenic signalling. Cell death
and differentiation 21, 92-99, doi:10.1038/cdd.2013.124 (2014).
217 Mandapathil, M. et al. Generation and accumulation of
immunosuppressive adenosine by human CD4+CD25highFOXP3+
regulatory T cells. The Journal of biological chemistry 285, 7176-7186,
doi:10.1074/jbc.M109.047423 (2010).
218 Bell, C. W., Jiang, W., Reich, C. F., 3rd & Pisetsky, D. S. The extracellular
release of HMGB1 during apoptotic cell death. American journal of
physiology. Cell physiology 291, C1318-1325,
doi:10.1152/ajpcell.00616.2005 (2006).
219 Suzuki, Y. et al. Immunogenic tumor cell death induced by
chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Cancer research 72, 3967-3976, doi:10.1158/0008-5472.CAN-12-0851
(2012).
220 Robinson, S. N. et al. Mesenchymal stem cells in ex vivo cord blood
expansion. Best practice & research. Clinical haematology 24, 83-92,
doi:10.1016/j.beha.2010.11.001 (2011).
221 Rocha, V. et al. Graft-versus-host disease in children who have received
a cord-blood or bone marrow transplant from an HLA-identical sibling.
Eurocord and International Bone Marrow Transplant Registry Working
Committee on Alternative Donor and Stem Cell Sources. The New
England journal of medicine 342, 1846-1854,
doi:10.1056/NEJM200006223422501 (2000).
222 Paulin, T. Importance of bone marrow cell dose in bone marrow
transplantation. Clinical transplantation 6, 48-54 (1992).
223 Alakel, N. et al. Direct contact with mesenchymal stromal cells affects
migratory behavior and gene expression profile of CD133+ hematopoietic




224 Jing, D. et al. Hematopoietic stem cells in co-culture with mesenchymal
stromal cells--modeling the niche compartments in vitro. Haematologica
95, 542-550, doi:10.3324/haematol.2009.010736 (2010).
225 Mareschi, K. et al. Isolation of human mesenchymal stem cells: bone
marrow versus umbilical cord blood. Haematologica 86, 1099-1100 (2001).
226 Wexler, S. A. et al. Adult bone marrow is a rich source of human
mesenchymal 'stem' cells but umbilical cord and mobilized adult blood are
not. British journal of haematology 121, 368-374 (2003).
227 Musina, R. A., Bekchanova, E. S., Belyavskii, A. V., Grinenko, T. S. &
Sukhikh, G. T. Umbilical cord blood mesenchymal stem cells. Bulletin of
experimental biology and medicine 143, 127-131 (2007).
228 Breems, D. A. et al. Stroma-contact prevents loss of hematopoietic stem
cell quality during ex vivo expansion of CD34+ mobilized peripheral blood
stem cells. Blood 91, 111-117 (1998).
229 Balduini, A., Braun, S. E., Cornetta, K., Lyman, S. & Broxmeyer, H. E.
Comparative effects of retroviral-mediated gene transfer into primary
human stromal cells of Flt3-ligand, interleukin 3 and GM-CSF on
production of cord blood progenitor cells in long-term culture. Stem cells
16 Suppl 1, 37-49, doi:10.1002/stem.5530160807 (1998).
230 Nishioka, K. et al. Immortalization of bone marrow-derived human
mesenchymal stem cells by removable simian virus 40T antigen gene:
analysis of the ability to support expansion of cord blood hematopoietic
progenitor cells. International journal of oncology 23, 925-932 (2003).
231 Erices, A., Conget, P. & Minguell, J. J. Mesenchymal progenitor cells in
human umbilical cord blood. British journal of haematology 109, 235-242
(2000).
232 Goodwin, H. S. et al. Multilineage differentiation activity by cells isolated
from umbilical cord blood: expression of bone, fat, and neural markers.
Biology of blood and marrow transplantation : journal of the American
Society for Blood and Marrow Transplantation 7, 581-588 (2001).
233 Lee, O. K. et al. Isolation of multipotent mesenchymal stem cells from
umbilical cord blood. Blood 103, 1669-1675, doi:10.1182/blood-2003-05-
1670 (2004).
234 Bieback, K., Kern, S., Kluter, H. & Eichler, H. Critical parameters for the
isolation of mesenchymal stem cells from umbilical cord blood. Stem cells
22, 625-634, doi:10.1634/stemcells.22-4-625 (2004).
235 Romanov, Y. A., Svintsitskaya, V. A. & Smirnov, V. N. Searching for
alternative sources of postnatal human mesenchymal stem cells:
candidate MSC-like cells from umbilical cord. Stem cells 21, 105-110,
doi:10.1634/stemcells.21-1-105 (2003).
236 Frimberger, A. E. et al. The fleet feet of haematopoietic stem cells: rapid




237 Patchen, M. L., MacVittie, T. J., Williams, J. L., Schwartz, G. N. & Souza,
L. M. Administration of interleukin-6 stimulates multilineage hematopoiesis
and accelerates recovery from radiation-induced hematopoietic
depression. Blood 77, 472-480 (1991).
238 Corre, I., Pineau, D. & Hermouet, S. Interleukin-8: an autocrine/paracrine
growth factor for human hematopoietic progenitors acting in synergy with
colony stimulating factor-1 to promote monocyte-macrophage growth and
differentiation. Experimental hematology 27, 28-36 (1999).
239 Weimar, I. S. et al. Hepatocyte growth factor/scatter factor (HGF/SF)
affects proliferation and migration of myeloid leukemic cells. Leukemia 12,
1195-1203 (1998).
240 Bramono, D. S., Rider, D. A., Murali, S., Nurcombe, V. & Cool, S. M. The
effect of human bone marrow stroma-derived heparan sulfate on the ex
vivo expansion of human cord blood hematopoietic stem cells.
Pharmaceutical research 28, 1385-1394, doi:10.1007/s11095-010-0352-y
(2011).
241 Bhatia, R. et al. A clinically suitable ex vivo expansion culture system for
LTC-IC and CFC using stroma-conditioned medium. Experimental
hematology 25, 980-991 (1997).
242 Hashimoto, F., Sugiura, K., Inoue, K. & Ikehara, S. Major
histocompatibility complex restriction between hematopoietic stem cells
and stromal cells in vivo. Blood 89, 49-54 (1997).
243 Sugiura, K. et al. Major histocompatibility complex restriction between
hematopoietic stem cells and stromal cells in vitro. Stem cells 19, 46-58,
doi:10.1634/stemcells.19-1-46 (2001).
244 Mizokami, T. et al. Preferential expansion of human umbilical cord blood-
derived CD34-positive cells on major histocompatibility complex-matched
amnion-derived mesenchymal stem cells. Haematologica 94, 618-628,
doi:10.3324/haematol.2008.004705 (2009).
245 Rebulla, P. Cord blood banking 2002: 112,010 of 7,914,773 chances.
Transfusion 42, 1246-1248 (2002).
246 Berz, D., McCormack, E. M., Winer, E. S., Colvin, G. A. & Quesenberry, P.
J. Cryopreservation of hematopoietic stem cells. American journal of
hematology 82, 463-472, doi:10.1002/ajh.20707 (2007).
247 Bueno, C., Montes, R. & Menendez, P. The ROCK inhibitor Y-27632
negatively affects the expansion/survival of both fresh and cryopreserved
cord blood-derived CD34+ hematopoietic progenitor cells: Y-27632
negatively affects the expansion/survival of CD34+HSPCs. Stem cell
reviews 6, 215-223, doi:10.1007/s12015-010-9118-5 (2010).
248 Welch, W. J., Kang, H. S., Beckmann, R. P. & Mizzen, L. A. Response of
mammalian cells to metabolic stress; changes in cell physiology and
structure/function of stress proteins. Current topics in microbiology and
immunology 167, 31-55 (1991).
Chapter 8: Bibliography
170
249 Heng, B. C. Effect of Rho-associated kinase (ROCK) inhibitor Y-27632 on
the post-thaw viability of cryopreserved human bone marrow-derived
mesenchymal stem cells. Tissue & cell 41, 376-380,
doi:10.1016/j.tice.2009.01.004 (2009).
250 de Boer, F. et al. Early apoptosis largely accounts for functional
impairment of CD34+ cells in frozen-thawed stem cell grafts. Journal of
hematotherapy & stem cell research 11, 951-963,
doi:10.1089/152581602321080619 (2002).
251 de Boer, F. et al. Extensive early apoptosis in frozen-thawed CD34-
positive stem cells decreases threshold doses for haematological
recovery after autologous peripheral blood progenitor cell transplantation.
Bone marrow transplantation 29, 249-255, doi:10.1038/sj.bmt.1703357
(2002).
252 Stroh, C. et al. The role of caspases in cryoinjury: caspase inhibition
strongly improves the recovery of cryopreserved hematopoietic and other
cells. FASEB journal : official publication of the Federation of American
Societies for Experimental Biology 16, 1651-1653, doi:10.1096/fj.02-
0034fje (2002).
253 Sasnoor, L. M., Kale, V. P. & Limaye, L. S. Prevention of apoptosis as a
possible mechanism behind improved cryoprotection of hematopoietic
cells by catalase and trehalose. Transplantation 80, 1251-1260 (2005).
254 Baharvand, H., Salekdeh, G. H., Taei, A. & Mollamohammadi, S. An
efficient and easy-to-use cryopreservation protocol for human ES and iPS
cells. Nature protocols 5, 588-594, doi:10.1038/nprot.2009.247 (2010).
255 Gauthaman, K., Fong, C. Y. & Bongso, A. Effect of ROCK inhibitor Y-
27632 on normal and variant human embryonic stem cells (hESCs) in
vitro: its benefits in hESC expansion. Stem cell reviews 6, 86-95,
doi:10.1007/s12015-009-9107-8 (2010).
256 Gauthaman, K., Fong, C. Y., Subramanian, A., Biswas, A. & Bongso, A.
ROCK inhibitor Y-27632 increases thaw-survival rates and preserves
stemness and differentiation potential of human Wharton's jelly stem cells
after cryopreservation. Stem cell reviews 6, 665-676, doi:10.1007/s12015-
010-9184-8 (2010).
257 Fleming, K. K. & Hubel, A. Cryopreservation of hematopoietic and non-
hematopoietic stem cells. Transfusion and apheresis science : official
journal of the World Apheresis Association : official journal of the
European Society for Haemapheresis 34, 309-315,
doi:10.1016/j.transci.2005.11.012 (2006).
258 Hayakawa, J. et al. 5% dimethyl sulfoxide (DMSO) and pentastarch
improves cryopreservation of cord blood cells over 10% DMSO.
Transfusion 50, 2158-2166, doi:10.1111/j.1537-2995.2010.02684.x
(2010).
259 Huang, Y. C., Parolini, O., La Rocca, G. & Deng, L. Umbilical cord versus
bone marrow-derived mesenchymal stromal cells. Stem cells and
development 21, 2900-2903, doi:10.1089/scd.2012.0216 (2012).
Chapter 8: Bibliography
171
260 Hanna, J. & Hubel, A. Preservation of stem cells. Organogenesis 5, 134-
137 (2009).
261 Al-Anazi, K. A. Autologous Hematopoietic Stem Cell Transplantation for
Multiple Myeloma without Cryopreservation. Bone marrow research 2012,
917361, doi:10.1155/2012/917361 (2012).
262 Sasnoor, L. M., Kale, V. P. & Limaye, L. S. Supplementation of
conventional freezing medium with a combination of catalase and
trehalose results in better protection of surface molecules and
functionality of hematopoietic cells. Journal of hematotherapy & stem cell
research 12, 553-564, doi:10.1089/152581603322448268 (2003).
263 Limaye, L. S. & Kale, V. P. Cryopreservation of human hematopoietic
cells with membrane stabilizers and bioantioxidants as additives in the
conventional freezing medium. Journal of hematotherapy & stem cell
research 10, 709-718, doi:10.1089/152581601753193931 (2001).
264 Garin, M. I., Apperley, J. F. & Melo, J. V. Ex vivo expansion and
characterisation of CD34+ cells derived from chronic myeloid leukaemia
bone marrow and peripheral blood, and from normal bone marrow and
mobilised peripheral blood. European journal of haematology 64, 85-92
(2000).
265 Hamann, K. J., Dowling, T. L., Neeley, S. P., Grant, J. A. & Leff, A. R.
Hyaluronic acid enhances cell proliferation during eosinopoiesis through
the CD44 surface antigen. Journal of immunology 154, 4073-4080 (1995).
266 Lemoli, R. M. et al. Interleukin-11 stimulates the proliferation of human
hematopoietic CD34+ and CD34+CD33-DR- cells and synergizes with
stem cell factor, interleukin-3, and granulocyte-macrophage colony-
stimulating factor. Experimental hematology 21, 1668-1672 (1993).
267 Sasnoor, L. M., Kale, V. P. & Limaye, L. S. A combination of catalase and
trehalose as additives to conventional freezing medium results in
improved cryoprotection of human hematopoietic cells with reference to in
vitro migration and adhesion properties. Transfusion 45, 622-633,
doi:10.1111/j.0041-1132.2005.04288.x (2005).
268 Clarke, D. M., Yadock, D. J., Nicoud, I. B., Mathew, A. J. & Heimfeld, S.
Improved post-thaw recovery of peripheral blood stem/progenitor cells
using a novel intracellular-like cryopreservation solution. Cytotherapy 11,
472-479, doi:10.1080/14653240902887242 (2009).
269 Durand, E. M. & Zon, L. I. Newly emerging roles for prostaglandin E2
regulation of hematopoiesis and hematopoietic stem cell engraftment.
Current opinion in hematology 17, 308-312,
doi:10.1097/MOH.0b013e32833a888c (2010).
270 Hoggatt, J., Singh, P., Sampath, J. & Pelus, L. M. Prostaglandin E2
enhances hematopoietic stem cell homing, survival, and proliferation.
Blood 113, 5444-5455, doi:10.1182/blood-2009-01-201335 (2009).
Chapter 8: Bibliography
172
